

CITATION REPORT

List of articles citing

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC

DOI: 10.1093/eurheartj/ehw128

European Heart Journal, 2016, 37, 2129-2200.

Source: <https://exaly.com/paper-pdf/64021809/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2234	Importance of poly(ADP-ribose) polymerases in the regulation of DNA-dependent processes. 2005 , 62, 731-8		42
2233	Alpha-crystallin: an ATP-independent complete molecular chaperone toward sorbitol dehydrogenase. 2005 , 62, 599-605		13
2232	Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. 2005 , 62, 1025-37		245
2231	Right ventricular dysfunction as predictor of longer hospital stay in patients with acute decompensated heart failure: a prospective study in Indonesian population. 2016 , 14, 25		5
2230	Nursing input to clinical guidelines. 2016 , 11, 577-577		
2229	Primary Prevention of Sudden Cardiac Death in Patients with Heart Failure: How Effective is Current Pharmacologic Therapy?. 2016 , 5,		0
2228	Chagas Heart Failure in Patients from Latin America. 2016 , 2, 90-94		4
2227	-Depression in Patients with Heart Failure: Is Enough Being Done?. 2016 , 2, 110-112		23
2226	Monitoring hemostasis parameters in left ventricular assist device recipients - a preliminary report. 2016 , 13, 224-228		1
2225	Effects of Active Components of Fuzi and Gancao Compatibility on Bax, Bcl-2, and Caspase-3 in Chronic Heart Failure Rats. 2016 , 2016, 7686045		13
2224	Galectin-3 Reflects Mitral Annular Plane Systolic Excursion Being Assessed by Cardiovascular Magnetic Resonance Imaging. 2016 , 2016, 7402784		3
2223	The Differential Diagnosis of Dyspnea. 2016 , 113, 834-845		48
2222	Upregulation of Soluble HLA-G in Chronic Left Ventricular Systolic Dysfunction. 2016 , 2016, 8417190		6
2221	Advances in the management of heart failure: the role of ivabradine. 2016 , 12, 453-470		16
2220	The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure. 2016 , 2, 115-122		21
2219	Nutritional Deficiency in Patients with Heart Failure. 2016 , 8,		48
2218	Myocarditis in Paediatric Patients: Unveiling the Progression to Dilated Cardiomyopathy and Heart Failure. 2016 , 3,		6

2217	Management of Patients with Atrial Fibrillation: Focus on Treatment Options. 2016 , 9, 1450		1
2216	[Development and Effects of a Heart Health Diary for Self-Care Enhancement of Patients with Heart Failure]. 2016 , 46, 881-893		8
2215	Harnessing Cardiac Energetics in the Treatment of Heart Failure. 2016 , 01, 036-044		
2214	Case 6 / 2016 - Heart Failure in a 23-Year-Old Male with a History of Illicit Drug Use. 2016 , 107, 590-599		1
2213	Telerehabilitation in heart failure patients: The evidence and the pitfalls. 2016 , 220, 408-13		46
2212	Patiromer: The First Potassium Binder Approved in Over 50 Years. 2016 , 24, 316-323		6
2211	Sacubitril/valsartan for chronic heart failure: its future potential. 2016 , 27, 26-34		2
2210	Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review. 2016 , 3, e000449		12
2209	Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. 2016 , 69, 1119-1125		5
2208	One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. 2016 , 9,		78
2207	New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis. 2016 , 13, 267-272		5
2206	Mitochondrial Therapies in Heart Failure. 2017 , 243, 491-514		13
2205	Multipoint Pacing versus conventional ICD in Patients with a Narrow QRS complex (MPP Narrow QRS trial): study protocol for a pilot randomized controlled trial. 2016 , 17, 572		4
2204	ICD-Therapie: Primär- und Sekundärprävention. 2016 , 45, 406-411		
2203	Catheter-based and surgical interventions in cardiac and aortic conditions. <i>European Heart Journal</i> , 2016 , 37, 3421-3424		9.5
2202	Current Approach to Heart Failure. 2016 ,		
2201	Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. <i>European Heart Journal</i> , 2017 , 38, 648-660	9.5	113
2200	Myocardial Revascularization in Heart Failure. 2016 , 229-241		

2199	The Kidney and Electrolytes Imbalances in Heart Failure. 2016 , 549-571		
2198	Understanding acute heart failure: pathophysiology and diagnosis. 2016 , 18, G11-G18		25
2197	Cardiac sympathetic activity in chronic heart failure: cardiac I-MIBG scintigraphy to improve patient selection for ICD implantation. 2016 , 24, 701-708		10
2196	Heart failure: an historical perspective. 2016 , 18, G3-G10		10
2195	The bumpy road to drug development for acute heart failure. 2016 , 18, G19-G32		16
2194	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. <i>European Heart Journal</i> , 2017 , 38, 2869-2873	9.5	64
2193	Improvements of central respiratory events, Cheyne-Stokes respiration and oxygenation in patients hospitalized for acute decompensated heart failure. 2016 , 27-28, 15-19		12
2192	Nationale Versorgungsleitlinie (NVL) Chronische KHK. 2016 , 13, 50-68		
2191	The Three-Decade Long Journey in Heart Failure Drug Development. 2017 , 243, 1-14		6
2190	Prevalence, Incidence and Lifetime Risk of Heart Failure. 2016 , 3-13		0
2189	Practical multidisciplinary approaches to heart failure management for improved patient outcome. 2016 , 18, G43-G52		8
2188	Cardiac rehabilitation in Portugal: The situation in 2013-2014. 2016 , 35, 669-671		2
2187	Comentarios a la guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. 2016 , 69, 1119-1125		15
2186	Cardiac rehabilitation in Portugal: The situation in 2013-2014. 2016 , 35, 669-671		1
2185	Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. 2016 , 68, 1474-1475		2
2184	Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. <i>European Heart Journal</i> , 2016 , 37, 2096	9.5	5
2183	Cardiac resynchronization therapy: results, challenges and perspectives for the future. 2016 , 50, 282-292		3
2182	Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. 2016 , 194, 1319-1336		115

2181	From heart failure to transplantation: genes, miRNAs, and biomarkers. <i>European Heart Journal</i> , 2016 , 37, 2561-3	9.5	2
2180	[The wearable cardioverter/defibrillator : Temporary protection from sudden cardiac death]. 2016 , 57, 864-70		0
2179	Do we really need novel echocardiographic modalities to confirm the superiority of the intact His-Purkinje conduction system over pacing modes?. 2016 , 57, 178-180		0
2178	Asistencia mecánica circulatoria como puente al trasplante. 2016 , 23, 41-48		0
2177	Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes. 2016 , 38, 2265-2276		53
2176	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. 2016 , 50, e1-e88		589
2175	Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus. 2016 , 38, 2248-2264.e5		33
2174	[Optimization of the management of acute heart failure. New concept of fast-track]. 2016 , 65, 330-333		
2173	Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. Prepared by the Czech Society of Cardiology. 2016 , 58, e530-e568		27
2172	Comparison of echocardiographic parameters between pre-clinical and clinical advanced diastolic dysfunction patients. 2016 , 224, 165-169		5
2171	Echo and natriuretic peptide guided therapy improves outcome and reduces worsening renal function in systolic heart failure: An observational study of 1137 outpatients. 2016 , 224, 416-423		20
2170	Multiple hormone deficiency syndrome in heart failure with preserved ejection fraction. 2016 , 225, 1-3		32
2169	Returning to Work: A Forgotten Aspect of Rehabilitation for Heart Failure. 2016 , 134, 1010-1012		3
2168	Takotsubo: a Japanese contribution to cardiology. <i>European Heart Journal</i> , 2016 , 37, 2803-2805	9.5	2
2167	New modalities assessing left and right ventricular function: How they apply to myocardial infarction. 2016 , 57, 143-144		2
2166	Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?. 2016 , 40, 379-381		1
2165	Myocardial late gadolinium enhancement is associated with clinical presentation in Duchenne muscular dystrophy carriers. 2016 , 18, 61		17
2164	Epidemiology of Heart Failure. 2017 , 243, 15-33		40

2163	Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure. <i>European Heart Journal</i> , 2017 , 38, 373-375	9.5	11
2162	The Room Where It Happens: A Skeptic's Analysis of the New Heart Failure Guidelines. 2016 , 22, 726-30		8
2161	The Impact of Diabetes and Comorbidities on the Outcome of Heart Failure Patients Treated With Cardiac Resynchronization Therapy: Implications for Patient Management. 2016 , 9,		1
2160	Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry. <i>European Heart Journal</i> , 2016 , 37, 3141-3153	9.5	97
2159	Pharmacology of heart failure: From basic science to novel therapies. 2016 , 166, 136-49		12
2158	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. 2016 , 134, 752-72		631
2157	Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. 2016 , 375, 1221-30		876
2156	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016 , 37, 2893-2962	9.5	4465
2155	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. 2016 , 18, 1609-1678		1293
2154	Heart failure and kidney dysfunction: epidemiology, mechanisms and management. 2016 , 12, 610-23		227
2153	Symptoms in Smokers with Preserved Pulmonary Function. 2016 , 375, 897		5
2152	Does ivabradine balance dobutamine effects in cardiogenic shock? A promising new strategy. 2016 , 218, 73-7		4
2151	Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience. 2016 , 223, 781-784		7
2150	Organization and implementation of a cardio-oncology program. 2016 , 35, 485-494		4
2149	Survival, quality of life and impact of right heart failure in patients with acute cardiogenic shock treated with ECMO. 2016 , 45, 409-15		11
2148	What constitutes optimal neurohumoral antagonism in chronic heart failure?. 2016 , 102, 1922-1932		2
2147	Patients with HFpEF and HFrEF have different clinical characteristics but similar prognosis: a retrospective cohort study. 2016 , 16, 232		48
2146	Optimized management of heart failure patients aged 80 years or more improves outcomes versus usual care: The HF80 randomized trial. 2016 , 109, 667-678		3

2145	Management of suspected acute heart failure dyspnea in the emergency department: results from the French prospective multicenter DeFSSICA survey. 2016 , 24, 112		18
2144	Usefulness of Iron Deficiency Correction in Management of Patients With Heart Failure [from the Registry Analysis of Iron Deficiency-Heart Failure (RAID-HF) Registry]. 2016 , 118, 1875-1880		23
2143	The C of CHADS: Historical perspective and clinical applications for anticoagulation in patients with non valvular atrial fibrillation and congestive heart failure. 2016 , 224, 431-436		3
2142	Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives. 2016 , 224, 366-375		19
2141	Breaking news in heart failure: ESC Guidelines 2016, non-steroidal mineralocorticoid receptor antagonist, and alternate site CRT pacing. <i>European Heart Journal</i> , 2016 , 37, 2085-7	9.5	
2140	Heart Failure With a Better Ejection Fraction: Why Should We Care?. 2016 , 9,		2
2139	Ivabradine. 2017 , 243, 167-175		1
2138	Exercise training effects on elderly and middle-age patients with chronic heart failure after acute decompensation: A randomized, controlled trial. 2016 , 225, 313-323		22
2137	[Implantable sensors for outpatient assessment of ventricular filling pressure in advanced heart failure : Which telemonitoring design is optimal?]. 2016 , 27, 371-377		
2136	Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial. <i>European Heart Journal</i> , 2017 , 38, 720-726	9.5	17
2135	[The new ESC Guidelines for acute and chronic heart failure 2016]. 2016 , 41, 655-663		16
2134	Focus on the Novel Cardiovascular Drug LZC696: From Evidence to Clinical Consideration. 2016 , 30, 623-633		6
2133	Nutritional status and its effects on muscle wasting in patients with chronic heart failure: insights from Studies Investigating Co-morbidities Aggravating Heart Failure. 2016 , 128, 497-504		27
2132	Heart Failure with Preserved Ejection Fraction. 2016 , 375, 1868-1877		267
2131	Non-vitamin K antagonist oral anticoagulants and heart failure. 2016 , 109, 641-650		10
2130	Time for correct diagnosis and categorisation of heart failure in primary care. 2016 , 66, 554-555		14
2129	Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. 2016 , 68, 2217-2228		157
2128	eHealth in cardiovascular medicine: A clinical update. 2016 , 23, 5-12		35

2127	Muscle wasting in heart failure : The role of nutrition. 2016 , 128, 455-465	18
2126	Atrial remodeling in obesity and hypertension-What can we learn from the ECG?. 2016 , 24, 2448	
2125	Obstructive Ventilatory Disorder in Heart Failure-Caused by the Heart or the Lung?. 2016 , 13, 310-318	2
2124	Myokarditis-Update. 2016 , 10, 311-330	3
2123	[National disease management guidelines (NVL) for chronic CAD : What is new, what is particularly important?]. 2016 , 41, 537-60	1
2122	Angiotensin-Neprilysin Inhibition as a Paradigm for All?. 2016 , 18, 115	9
2121	Can Adiponectin Help us to Target Diastolic Dysfunction?. 2016 , 30, 635-644	13
2120	Coronary artery disease prevalence and outcome in patients hospitalized with acute heart failure: an observational report from seven Middle Eastern countries. 2016 , 44, 242-251	1
2119	How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program. 2016 , 18, 122	19
2118	Sacubitril/valsartan in heart failure: latest evidence and place in therapy. 2016 , 7, 278-290	21
2117	New guidelines from the European Society of Cardiology. 2016 , 27, 51-54	3
2116	Hartfalen: onderschatte sluipmoordenaar. 2016 , 22, 30-35	1
2115	Cumulative subgroup analysis to reduce waste in clinical research for individualised medicine. 2016 , 14, 197	9
2114	[Seeking Ariadne's thread in the labyrinth of guidelines]. 2016 , 41, 653-654	
2113	Lungenhochdruck bei Linksherzerkrankungen. 2016 , 19, 198-203	1
2112	It is important to distinguish between HFrEF and HFpEF when interpreting these data. 2016 , 102, 1934	1
2111	Development of guidance on the timeliness in response to acute kidney injury warning stage test results for adults in primary care: an appropriateness ratings evaluation. 2016 , 6, e012865	5
2110	Cardiomyopathies: definition, diagnosis, causes, and genetics. <i>European Heart Journal</i> , 2016 , 37, 1779-829.5	2

2109	Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs. 2017 , 226, 136-140	8
2108	[Dementia and comorbid conditions]. 2017 , 58, 105-116	2
2107	Antidiabetic agents and cardiovascular outcomes in patients with heart diseases. 2017 , 33, 985-992	7
2106	Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach. 2017 , 10,	56
2105	The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future. 2017 , 93, 29-37	31
2104	[Cardiogenic shock]. 2017 , 42, 1-2	
2103	[Levosimendan-no effect on multiorgan failure in septic shock]. 2017 , 112, 254-257	
2102	La fracción de eyección intermedia no permite estratificar el riesgo de los pacientes hospitalizados por insuficiencia cardiaca. 2017 , 70, 338-346	34
2101	The safety of sacubitril-valsartan for the treatment of chronic heart failure. 2017 , 16, 257-263	5
2100	Inverse remodelling of K2P3.1 K ⁺ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy. <i>European Heart Journal</i> , 2017 , 38, 1764-1774	9.5 55
2099	Echocardiographic Determinants of One-Year All-Cause Mortality in Patients With Chronic Heart Failure Complicated by Significant Functional Tricuspid Regurgitation. 2017 , 23, 434-443	5
2098	Discrepancies in the U.S. and European guidelines involving the implantable cardioverter-defibrillator and cardiac resynchronization therapy: Need for a single shared international publication. 2017 , 14, 474-475	1
2097	The Heart Failure Association Congress confirms itself as the largest European Society of Cardiology sub-speciality congress. 2017 , 3, 5-6	1
2096	Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. <i>European Heart Journal</i> , 2017 , 38, 2095-2099	9.5 27
2095	Mechanical dyssynchrony in heart failure: Still a valid concept for optimizing treatment?. 2017 , 110, 60-68	12
2094	Frequency and prognostic impact of mid-expiratory flow reduction in stable patients six months after hospitalisation for heart failure with reduced ejection fraction. 2017 , 227, 727-733	2
2093	Development of a clinical applicable graphical user interface to automatically detect exercise oscillatory ventilation: The VODEX-tool. 2017 , 240, 291-296	3
2092	New guidelines, new recommendations! But what is really new? A pragmatic interpretation of the 2016 European guidelines for the management of chronic heart failure. 2017 , 110, 1-6	2

2091	Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction. 2017 , 101, 481-490	17
2090	Carvedilol: a review of its use in the management of heart failure. 2017 , 33, 147-152	3
2089	Prognostic Implications of Serum Albumin Levels in Patients With Acute Coronary Syndromes. 2017 , 119, 951-958	53
2088	Predictive capacity of a multimarker strategy to determine short-term mortality in patients attending a hospital emergency Department for acute heart failure. BIO-EAHFE study. 2017 , 466, 22-30	10
2087	Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer. 2017 , 135, 1388-1396	114
2086	Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. 2017 , 16, 18	34
2085	Proceedings of Ranimation 2017, the French Intensive Care Society International Congress. 2017 , 7,	3
2084	Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy. 2017 , 5, 99-106	49
2083	High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction. 2017 , 135, 839-849	205
2082	Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis. 2017 , 10,	109
2081	Cardiac resynchronization therapy before and after MitraClip implantation: An advantageous upgrading to reduce mitral regurgitation. 2017 , 18, 26-29	
2080	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. 2017 , 5, 391-402	42
2079	Understanding the Epidemiology of Heart Failure to Improve Management Practices: An Asia-Pacific Perspective. 2017 , 23, 327-339	43
2078	Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis. 2017 , 35, e12253	8
2077	ECMO in cardiac arrest and cardiogenic shock. 2017 , 42, 27-44	78
2076	Cardio-Onco-Hematología en la práctica clínica. Documento de consenso y recomendaciones. 2017 , 70, 474-486	58
2075	Inflammatory biomarkers and effect of exercise on functional capacity in patients with heart failure: Insights from a randomized clinical trial. 2017 , 24, 808-817	20
2074	Fracción de eyección del ventrículo izquierdo de pacientes con insuficiencia cardíaca aguda: ¿un marcador útil?. 2017 , 70, 318-319	1

2073	[Current impact of cardiac implantable electronic devices]. 2017 , 42, 151-161	1
2072	Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival. 2017 , 235, 162-168	27
2071	Choc cardiogħique sħve : quel rħime thħapeutique mħdicamenteux optimal ? Intħħ de lħssociation vasopresseursħotropes avec effet vasodilatateur. 2017 , 26, 111	
2070	The Optimize Heart Failure Care Program: Initial lessons from global implementation. 2017 , 236, 340-344	18
2069	Positive airway pressure therapy in heart failure patients: Long-term effects on lung function. 2017 , 238, 41-46	3
2068	Effects of Upgrade Versus De Novo Cardiac Resynchronization Therapy on Clinical Response and Long-Term Survival: Results from a Multicenter Study. 2017 , 10, e004471	21
2067	Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data. 2017 , 10,	55
2066	Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials. 2017 , 106, 501-513	24
2065	Study Design and Rationale of "A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing Mldazolam Versus MORphine in Acute Pulmonary Edema": MIMO Trial. 2017 , 31, 209-213	11
2064	Spironolactone-potion or poison?. 2017 , 55, 13	
2063	Sleep-Disordered Breathing and Arrhythmia in Heart Failure Patients. 2017 , 12, 229-241	13
2062	Nutritional Status in Advanced Heart Failure and Heart Transplant Patients. 2017 , 70, 626-628	2
2061	Validation of Noninvasive Measurement of Cardiac Output Using Inert Gas Rebreathing in a Cohort of Patients With Heart Failure and Reduced Ejection Fraction. 2017 , 10,	14
2060	Anemia is a mortality prognostic factor in patients initially hospitalized for acute heart failure. 2017 , 12, 749-756	19
2059	Blood pressure dynamics during exercise rehabilitation in heart failure patients. 2017 , 24, 818-824	1
2058	Role of the Pharmacist for Improving Self-care and Outcomes in Heart Failure. 2017 , 14, 78-86	17
2057	Genetics and genomics of dilated cardiomyopathy and systolic heart failure. 2017 , 9, 20	78
2056	Imaging of the Cardiac Sympathetic Nervous System Has Potential Value in the Evaluation of Patients with Heart Failure with Preserved Ejection Fraction. 2017 , 58, 781-783	2

2055	Diuretic Strategies in Acute Decompensated Heart Failure. 2017 , 14, 127-133	8
2054	Heart Failure with Preserved Ejection Fraction. 2017 , 376, 897	30
2053	Long-Term Experience with First-Generation Implantable Neurostimulation Device in Central Sleep Apnea Treatment. 2017 , 40, 498-503	17
2052	Heart failure in the elderly: ten peculiar management considerations. 2017 , 22, 219-228	11
2051	Association between nondipper pulse rate and measures of cardiac overload: The J-HOP Study. 2017 , 19, 402-409	11
2050	Genetic determinants of myocardial dysfunction. 2017 , 54, 1-10	4
2049	Intracardiac impedance after cardiac resynchronization therapy is a novel predictor for worsening of heart failure. 2017 , 32, 926-931	4
2048	[Diabetology as an interdisciplinary challenge]. 2017 , 58, 329-335	2
2047	Reliability, construct validity and determinants of 6-minute walk test performance in patients with chronic heart failure. 2017 , 240, 285-290	44
2046	Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure. 2017 , 10, 517-534	2
2045	Can Functional Testing for Ischemia and Viability Guide Revascularization?. 2017 , 10, 354-364	13
2044	Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. 2017 , 5, 287-296	71
2043	Relationship among body mass index, NT-proBNP, and mortality in decompensated chronic heart failure. 2017 , 46, 172-177	3
2042	Emerging Cardiac Imaging Modalities for the Early Detection of Cardiotoxicity Due to Anticancer Therapies. 2017 , 70, 487-495	8
2041	Natriuretic Peptides in Older Patients With Heart Failure: A Look Into the Seeds of Time. 2017 , 65, 691-692	
2040	Management of young competitive athletes with cardiovascular conditions. 2017 , 103, 463-473	15
2039	MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure. 2017 , 7, 40696	30
2038	Estimating Left Ventricular Filling Pressure by Echocardiography. 2017 , 69, 1937-1948	200

2037	Entresto (Sacubitril/Valsartan): Angiotensin Receptor Neprilysin Inhibition for Treating Heart Failure. 2017 , 5, 47-55	
2036	Anemia at Hospital Admission and Its Relation to Outcomes in Patients With Heart Failure (from the Polish Cohort of 2 European Society of Cardiology Heart Failure Registries). 2017 , 119, 2021-2029	11
2035	[Diabetes and heart failure : Update 2017]. 2017 , 42, 329-340	0
2034	Cardiac surgery 2016 reviewed. 2017 , 106, 851-867	15
2033	Long-term treatment with ivabradine over 12months in patients with chronic heart failure in clinical practice: Effect on symptoms, quality of life and hospitalizations. 2017 , 240, 258-264	11
2032	Stress Perfusion CMR in Patients With Known and Suspected CAD: Prognostic Value and Optimal Ischemic Threshold for Revascularization. 2017 , 10, 526-537	72
2031	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. 2017 , 376, 1956-1964	185
2030	Pheochromocytoma Crisis in the ICU: A French Multicenter Cohort Study With Emphasis on Rescue Extracorporeal Membrane Oxygenation. 2017 , 45, e657-e665	29
2029	Morphine Use in the ED and Outcomes of Patients With Acute Heart Failure: A Propensity Score-Matching Analysis Based on the EAHFE Registry. 2017 , 152, 821-832	32
2028	Herzinsuffizienz-Guidelines der ESC [Was ist neu und klinisch relevant?]. 2017 , 6, 122-128	
2027	Pharmacological and Non-pharmacological Treatment for Decompensated Heart Failure: What Is New?. 2017 , 14, 147-157	5
2026	Echocardiographic pulmonary artery pressure estimation and heart failure rehospitalization burden in patients with acute heart failure. 2017 , 241, 407-410	12
2025	Current Role of Blood and Urine Biomarkers in the Clinical Care of Adults with Congenital Heart Disease. 2017 , 19, 50	9
2024	Cardiac magnetic resonance imaging in heart failure: where the alphabet begins!. 2017 , 22, 385-399	17
2023	Digoxin versus placebo, no intervention, or other medical interventions for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. 2017 , 6, 71	5
2022	Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. 2017 , 106, 711-721	24
2021	Is There a Role for Ivabradine in the Contemporary Management of Patients with Chronic Heart Failure in Academic and Community Heart Failure Clinics in Canada?. 2017 , 34, 1340-1348	5
2020	Is there a role for lifestyle changes in cardiovascular prevention? What, when and how?. 2017 , 26, 2-15	22

2019	The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure. 2017 , 22, 731-739	14
2018	Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression - design and rationale of the STAAB cohort study. 2017 , 24, 468-479	19
2017	Pulmonary hypertension due to left heart disease. 2017 , 110, 420-431	7
2016	Importance of combined left atrial size and estimated pulmonary pressure for clinical outcome in patients presenting with heart failure with preserved ejection fraction. 2017 , 18, 629-635	26
2015	Outcomes of Minimally Invasive Temporary Right Ventricular Assist Device Support for Acute Right Ventricular Failure During Minimally Invasive Left Ventricular Assist Device Implantation. 2017 , 63, 546-550	10
2014	Prevalence and Predictors of Early Heart Failure With Preserved Ejection Fraction in Patients With Paroxysmal Atrial Fibrillation. 2017 , 23, 558-562	17
2013	Novel insight into arrhythmogenic remodeling: a target for reversal. 2017 , 40, 632-634	
2012	Measuring Pulmonary Artery Pressures in Heart Failure: A New Useful Diagnostic Tool?. 2017 , 135, 1518-1521	4
2011	Palliative care in heart failure: facts and numbers. 2017 , 4, 81-87	51
2010	The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: A digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology. 2017 , 24, 1017-1031	84
2009	The lived experience of caregivers of persons with heart failure: A phenomenological study. 2017 , 16, 638-645	22
2008	Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily. <i>European Heart Journal</i> , 2017 , 38, 2279-2286	9.5 101
2007	Acute pulmonary oedema. 2017 , 305-310	
2006	Impact of prealbumin on mortality and hospital readmission in patients with acute heart failure. 2017 , 43, 36-41	16
2005	Palliative Care in Heart Failure: What Triggers Specialist Consultation?. 2017 , 60, 215-225	16
2004	Impact of pro-atrial natriuretic peptide in atrial fibrillation and stroke. 2017 , 24, 1239-1241	0
2003	Does Evidence Drive Fluid Volume Restriction in Chronic Heart Failure?. 2017 , 52, 261-267	1
2002	Cardiac resynchronization therapy in ischemic and non-ischemic cardiomyopathy. 2017 , 33, 410-416	15

2001	Cardiac resynchronization therapy in the real world: need to focus on implant rates, patient selection, co-morbidities, type of devices, and complications. <i>European Heart Journal</i> , 2017 , 38, 2129-2131 ^{9.5}	4
2000	Sacubitril-Valsartan for Heart Failure: From Devil's Advocate to Evidence-Based Medicine. 2017 , 24, e109-e110	4
1999	Extra corporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS): rationale and design of the multicenter randomized trial. 2017 , 19 Suppl 2, 124-127	33
1998	PET imaging in heart failure: the role of new tracers. 2017 , 22, 501-511	8
1997	Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research. 2017 , 69, 2428-2445	50
1996	Performance of AHEAD Score in an Asian Cohort of Acute Heart Failure With Either Preserved or Reduced Left Ventricular Systolic Function. 2017 , 6,	16
1995	Cardiac rehabilitation in cardiac valve surgery patients: Beyond cost-effectiveness. 2017 , 24, 1145-1147	2
1994	Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). 2017 , 120, 98-105	9
1993	Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G). 2017 , 29, 19-22	0
1992	Reply: Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction. 2017 , 69, 2352-2353	1
1991	HeartWare-HVAD for end-stage heart failure: a review of clinical experiences with 50 patients. 2017 , 14, 423-437	2
1990	Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC). <i>European Heart Journal</i> , 2017 , 38, 2683-2690	9.5 47
1989	Prognostic impact of diastolic dysfunction in systolic heart failure-A cross-project analysis from the German Competence Network Heart Failure. 2017 , 40, 667-673	12
1988	Epidemiology of heart failure with preserved ejection fraction. 2017 , 14, 591-602	459
1987	Role of Ivabradine in the Treatment of Heart Failure: Comments on the ESC 2016 Guidelines. 2017 , 70, 612-613	
1986	[Genetic diagnostics for cardiomyopathies]. 2017 , 142, 657-664	0
1985	Short-term mechanical circulatory support as a bridge to durable left ventricular assist device implantation in refractory cardiogenic shock: a systematic review and meta-analysis. 2017 , 52, 14-25	77
1984	Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study. 2017 , 6,	27

1983	Targets for Heart Failure With Preserved Ejection Fraction. 2017 , 102, 228-237		12
1982	[Cardiac support and replacement systems]. 2017 , 112, 417-425		0
1981	Cardiogenic shock management: Still a challenge and a need for large-registry data. 2017 , 110, 433-438		7
1980	Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions. 2017 , 120, 267-273		19
1979	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017 , 38, 2364-2373	9.5	72
1978	The ICM research agenda on extracorporeal life support. 2017 , 43, 1306-1318		61
1977	Whom are we treating with adaptive servo-ventilation? A clinical post hoc analysis. 2017 , 106, 702-710		18
1976	Prognostic Implications of Mid-Range Left Ventricular Ejection Fraction on Patients Presenting With ST-Segment Elevation Myocardial Infarction. 2017 , 120, 186-190		15
1975	Is heart failure with midrange ejection fraction similar to preserved ejection fraction? In favor. 2017 , 217, 296-298		
1974	Expert consensus document: Echocardiography and lung ultrasonography for the assessment and management of acute heart failure. 2017 , 14, 427-440		84
1973	The future of atrial fibrillation management: integrated care and stratified therapy. 2017 , 390, 1873-1887		81
1972	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. 2017 , 23, 628-651		378
1971	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. 2017 , 136, e137-e161		1503
1970	Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative. 2017 , 106, 722-733		7
1969	Inhibition of Late Sodium Current as an Innovative Antiarrhythmic Strategy. 2017 , 14, 179-186		11
1968	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. 2017 , 70, 776-803		1064
1967	True Anemia-Red Blood Cell Volume Deficit-in Heart Failure: A Systematic Review. 2017 , 10,		14
1966	Prognostic impact of anemia and iron-deficiency anemia in a contemporary cohort of patients undergoing transcatheter aortic valve implantation. 2017 , 244, 93-99		24

1965	Endothelial Senescence Contributes to Heart Failure With Preserved Ejection Fraction in an Aging Mouse Model. 2017 , 10,	77
1964	Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study. 2017 , 10,	104
1963	Cuidado paliativo en falla cardiaca. 2017 , 24, 286-296	0
1962	Uniform data collection in routine clinical practice in cardiovascular patients for optimal care, quality control and research: The Utrecht Cardiovascular Cohort. 2017 , 24, 840-847	7
1961	[Practical aspects of pacemaker indications]. 2017 , 159, 54-61	
1960	Acute Heart Failure: One Syndrome or Many?. 2017 , 69, 3040-3041	4
1959	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. 2017 , 5, 507-517	49
1958	The Notch Ligands DLL1 and Periostin Are Associated with Symptom Severity and Diastolic Function in Dilated Cardiomyopathy. 2017 , 10, 401-410	12
1957	Early in-hospital variation of red blood cell distribution width predicts mortality in patients with acute heart failure. 2017 , 243, 306-310	14
1956	Efecto de los inotrópicos sobre la mortalidad en falla cardiaca aguda. Metaanálisis en red de ensayos clínicos. 2017 , 24, 468-479	1
1955	Lung ultrasonography: a practical guide for cardiologists. 2017 , 18, 501-509	3
1954	Is there a place for a dual angiotensin receptor-neprilysin inhibitor in the treatment of hypertension?. 2017 , 35, 726-728	
1953	Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials. 2017 , 17, 150	23
1952	[Update: Cardiovascular Sleep Medicine]. 2017 , 142, 912-923	0
1951	Implantable cardioverter defibrillator use for primary prevention in ischaemic and non-ischaemic heart disease-indications in the post-DANISH trial era: results of the European Heart Rhythm Association survey. 2017 , 19, 660-664	39
1950	Prediction of Waitlist Mortality in Adult Heart Transplant Candidates: The Candidate Risk Score. 2017 , 101, 2175-2182	25
1949	Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers. 2017 , 22, 434-446	22
1948	Alcoholic cardiomyopathy: What is known and what is not known. 2017 , 43, 1-5	46

1947	Who needs secondary prevention?. 2017 , 24, 8-13	5
1946	The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV: A Survey From the European Society of Cardiology. 2017 , 40, 1233-1240	57
1945	Risk factors for chronic heart failure: obesity, renal dysfunction, arteriovenous fistulas, and amyloid deposition. <i>European Heart Journal</i> , 2017 , 38, 1857-1860	9.5 3
1944	[Recommendations for education in ultrasound in medical intensive care and emergency medicine: position paper of DGIIN, DEGUM and DGK]. 2017 , 112, 314-319	15
1943	Safe Hydration Volume to Prevent Contrast-induced Acute Kidney Injury and Worsening Heart Failure in Patients With Heart Failure and Preserved Ejection Fraction After Cardiac Catheterization. 2017 , 70, 168-175	3
1942	Exercise training in heart failure: which training modality works best?. 2017 , 123, 442-443	1
1941	Angiotensin Receptor-Neprilysin Inhibition. 2017 , 22, 356-364	5
1940	A qualitative meta-summary using Sandelowski and Barroso's method for integrating qualitative research to explore barriers and facilitators to self-care in heart failure patients. 2017 , 16, 662-677	11
1939	Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model. 2017 , 5, 2050312117700057	3
1938	Heart Failure. 2017 ,	4
1937	Left ventricular ejection fraction as therapeutic target: is it the ideal marker?. 2017 , 22, 641-655	13
1936	Effects of Levosimendan on Patients with Heart Failure Complicating Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials. 2017 , 17, 453-463	10
1935	Pulmonary congestion evaluated by lung ultrasound predicts decompensation in heart failure outpatients. 2017 , 240, 271-278	46
1934	Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment. 2017 , 42, 16-23	49
1933	Influence of renal dysfunction phenotype on mortality in decompensated heart failure with preserved and mid-range ejection fraction. 2017 , 243, 332-339	5
1932	Management of heart failure in the elderly. 2017 , 32, 217-223	6
1931	A real world wearable cardioverter defibrillator experience - Very high appropriate shock rate in ischemic cardiomyopathy patients at a European single-center. 2017 , 50, 603-609	8
1930	Future drug discovery in renin-angiotensin-aldosterone system intervention. 2017 , 12, 827-848	21

1929	Clinical Characteristics, Histopathological Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy. 2017 , 5, 435-445	62
1928	Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation. 2017 , 5, 466-467	1
1927	Heart Failure with Myocardial Recovery - The Patient Whose Heart Failure Has Improved: What Next?. 2017 , 60, 226-236	16
1926	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). 2017 , 19, 821-836	147
1925	Hyponatraemia and congestive heart failure refractory to diuretic treatment. Utility of tolvaptan. 2017 , 217, 398-404	
1924	Echocardiographic Assessment in Patients with Granulomatosis with Polyangiitis. 2017 , 1022, 27-33	6
1923	A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure. 2017 , 44, 31-38	34
1922	Renin-angiotensin system blockade: Finerenone. 2017 , 13 Suppl 1, S47-S53	11
1921	[Inotropic Support During Infarct-related Cardiogenic Shock]. 2017 , 142, 811-815	0
1920	Prevention of heart failure mortality and hospitalizations in SPRINT, EMPA-REG, ALLHAT and HYVET: are diuretics the clue?. 2017 , 26, 193-194	2
1919	Manual of Gynecardiology. 2017 ,	0
1918	Differential regulation of protein phosphatase 1 (PP1) isoforms in human heart failure and atrial fibrillation. 2017 , 112, 43	20
1917	Causes of death in atrial fibrillation: Challenges and opportunities. 2017 , 27, 494-503	10
1916	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. 2017 , 92, 1068-1078	168
1915	Frontiers of valvular heart disease: from aortic stenosis to the tricuspid valve and congenital anomalies. <i>European Heart Journal</i> , 2017 , 38, 611-614	9.5 2
1914	From systemic and pulmonary hypertension to heart failure: novel drugs and devices. <i>European Heart Journal</i> , 2017 , 38, 1087-1090	9.5
1913	Regional differences in health-related quality of life in elderly heart failure patients: results from the CIBIS-ELD trial. 2017 , 106, 645-655	3
1912	Do All Patients With Heart Failure Benefit From a Program for Early Follow-up After Hospital Discharge?. 2017 , 70, 624-625	

1911	The management of patients with chronic heart failure: the growing role of e-Health. 2017 , 14, 271-277	15
1910	Postoperative pulmonary complications. 2017 , 118, 317-334	365
1909	Relation of N-Terminal Pro-B-Type Natriuretic Peptide and Left Ventricular Diastolic Function to Exercise Tolerance in Patients With Significant Valvular Heart Disease and Normal Left Ventricular Systolic Function. 2017 , 119, 1846-1853	5
1908	Mortality Effect of ICD in Primary Prevention of Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. 2017 , 28, 538-543	15
1907	Rational and design of EuroCRT: an international observational study on multi-modality imaging and cardiac resynchronization therapy. 2017 , 18, 1120-1127	16
1906	Digoxin: beneficial or harmful?. 2017 , 3, 127-128	3
1905	Ivabradine: Current and Future Treatment of Heart Failure. 2017 , 121, 89-97	15
1904	Cardiac Natriuretic Peptides, Hypertension and Cardiovascular Risk. 2017 , 24, 115-126	40
1903	Corrections needed to 2016 ESC and AHA guidelines on heart failure. 2017 , 5, 325-326	6
1902	Diastolic dysfunction in hypertension. 2017 , 34, 128-139	6
1901	Reply: Routine Ischemic Work-Up for Patients With New-Onset Heart Failure. 2017 , 69, 364-365	
1900	Is heart failure with midrange ejection fraction similar to preserved ejection fraction? Against. 2017 , 217, 299-301	0
1899	Is heart failure with midrange ejection fraction similar to preserved ejection fraction? For. 2017 , 217, 296-298	0
1898	Selection of the Best of 2016 in Clinical Cardiology: Therapeutic Novelties. 2017 , 70, 123-124	
1897	Left Ventricular Ejection Fraction in Patients With Acute Heart Failure: A Limited Tool?. 2017 , 70, 318-319	
1896	Bloodstream Amyloid-beta (1-40) Peptide, Cognition, and Outcomes in Heart Failure. 2017 , 70, 924-932	7
1895	Selección de lo mejor del año 2016 en cardiología clínica. Novedades terapéuticas. 2017 , 70, 123-124	
1894	Papel de la ivabradina en el tratamiento de la insuficiencia cardiaca: comentarios a la guía ESC 2016. 2017 , 70, 612-613	

1893	Seguimiento mediante programas específicos de consulta precoz tras el alta de un episodio de insuficiencia cardiaca: ¿en todos los pacientes?. 2017 , 70, 624-625		
1892	Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction. 2017 , 243, 465-490		14
1891	Ventricular arrhythmias in patients with newly diagnosed nonischemic cardiomyopathy: Insights from the PROLONG study. 2017 , 40, 586-590		21
1890	Hypovitaminosis D in patients with heart failure: effects on functional capacity and patients' survival. 2017 , 58, 574-581		19
1889	Characteristics and outcomes of heart failure-related hospitalization in adults with congenital heart disease. 2017 , 110, 283-291		22
1888	Hämodynamisches Monitoring. 2017 , 6, 59-65		0
1887	Incidence and Prognostic Impact of Heart Failure Hospitalization During Follow-Up After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. 2017 , 119, 1729-1739		18
1886	The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going?. 2017 , 178, 67-82		2
1885	Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design. 2017 , 70, 1067-1073		2
1884	Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study. 2017 , 238, 72-78		15
1883	Psychometric Validation of the Heart Failure Caregiver Questionnaire (HF-CQ). 2017 , 10, 579-592		8
1882	Home-based telerehabilitation is not inferior to a centre-based program in patients with chronic heart failure: a randomised trial. 2017 , 63, 101-107		71
1881	Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials. <i>European Heart Journal</i> , 2017 , 38, 1738-1746	9.5	59
1880	Kallikrein-kinin system as the dominant mechanism to counteract hyperactive renin-angiotensin system. 2017 , 95, 1117-1124		12
1879	Cardiopulmonary Exercise Test as a Tool to Choose Therapy in Heart Failure. 2017 , 14, S67-S73		3
1878	Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF. 2017 , 22, 279-288		7
1877	Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. 2017 , 13, 583-592		7
1876	Length of stay and risk of very early readmission in acute heart failure. 2017 , 42, 61-66		15

1875	Utilization and in-hospital complications of cardiac resynchronization therapy: trends in the United States from 2003 to 2013. <i>European Heart Journal</i> , 2017 , 38, 2122-2128	9.5	29
1874	Major developments in the 2016 European guidelines for heart failure. 2017 , 217, 405-409		1
1873	Epidemiologic burden of hospitalisation for congestive heart failure among adults aged ≥9 years in the Philippines. 2017 , 9, 76-80		5
1872	A Case Base View of Heart Failure Predisposition Risk. 2017 , 312-323		
1871	Rac1 GTPase regulates 11βhydroxysteroid dehydrogenase type 2 and fibrotic remodeling. 2017 , 292, 7542-7553		15
1870	Comorbidity "depression" in heart failure - Potential target of patient education and self-management. 2017 , 17, 48		6
1869	Current Pharmacological Therapies in Heart Failure Patients. 2017 , 24, 107-114		15
1868	True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. 2017 , 188, 99-108		40
1867	Reply: Outcome Measures in HFpEF Trials: Should We Refocus?. 2017 , 69, 1359		
1866	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. 2017 , 103, 1339-1346		25
1865	Sudden death risk stratification in non-ischemic dilated cardiomyopathy using old and new tools: a clinical challenge. 2017 , 15, 315-325		5
1864	Remote monitoring to Improve long-term prognosis in heart failure patients with implantable cardioverter-defibrillators. 2017 , 14, 335-342		15
1863	The Effect of Frailty on 30-day Mortality Risk in Older Patients With Acute Heart Failure Attended in the Emergency Department. 2017 , 24, 298-307		29
1862	Prognostic Impact of In-Hospital and Postdischarge Heart Failure in Patients With Acute Myocardial Infarction: A Nationwide Analysis Using Data From the Cardiovascular Disease in Norway (CVDNOR) Project. 2017 , 6,		12
1861	Role and Value of Clinical Pharmacy in Heart Failure Management. 2017 , 102, 209-212		8
1860	Predicting Clinical and Echocardiographic Response After Cardiac Resynchronization Therapy With a Score Combining Clinical, Electrocardiographic, and Echocardiographic Parameters. 2017 , 119, 1797-1802		5
1859	Left ventricular assist device-related infections: a multicentric study. 2017 , 23, 748-751		37
1858	Heart Failure-Induced Brain Injury. 2017 , 69, 1609-1616		55

1857	An overview of current treatments in heart failure. 2017 , 12, 120-127	1
1856	[Current recommendations for diagnostic echocardiography in cancer patients : Is echocardiography too late or too early?]. 2017 , 42, 262-270	
1855	Bone scintigraphy for cardiac amyloidosis imaging: Past, present and future. 2017 , 41, 108-114	1
1854	Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations. 2017 , 70, 474-486	31
1853	Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. 2017 , 28, 659-665	29
1852	Outcome Measures in HFpEF Trials: Should We Refocus?. 2017 , 69, 1358-1359	
1851	Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction. 2017 , 174, 4070-4086	36
1850	Mid-range Ejection Fraction Does Not Permit Risk Stratification Among Patients Hospitalized for Heart Failure. 2017 , 70, 338-346	19
1849	Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients. 2017 , 106, 401-410	10
1848	A simple score for early risk stratification in acute heart failure. 2017 , 230, 248-254	11
1847	The Influence of Age on Hemodynamic Parameters During Rest and Exercise in Healthy Individuals. 2017 , 5, 337-346	71
1846	Evaluation of left ventricular diastolic function profile in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. 2017 , 40, 356-363	9
1845	Spirolactone. 2017 , 53, 288-292	19
1844	Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology. 2017 , 69, 501-507	22
1843	Specificity of B-Type Natriuretic Peptide Assays: Cross-Reactivity with Different BNP, NT-proBNP, and proBNP Peptides. 2017 , 63, 351-358	45
1842	The year in cardiology 2016: heart failure. <i>European Heart Journal</i> , 2017 , 38, 705-711	9.5 1
1841	Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study. 2017 , 135, 825-838	239
1840	Advanced refractory heart failure: conservative or interventional approach?. 2017 , 47, 193-194	

1839	[Left ventricular unloading in cardiogenic shock]. 2017 , 42, 18-26	4
1838	Sleep apnea: State of the art. 2017 , 27, 280-289	40
1837	Proenkephalin, Renal Dysfunction, and Prognosis in Patients With Acute Heart Failure: A GREAT Network Study. 2017 , 69, 56-69	47
1836	ICD Implantation in Patients with Nonischemic Heart Failure. 2017 , 376, 92	5
1835	An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands. 2017 , 20, 388-396	20
1834	Presenting phenotypes of acute heart failure patients in the ED: Identification and implications. 2017 , 35, 536-542	5
1833	Cardiac contractility modulation in heart failure patients: Randomized comparison of signal delivery through one vs. two ventricular leads. 2017 , 69, 326-332	12
1832	Primary care REFerral for Echocardiogram (REFER) in heart failure: a diagnostic accuracy study. 2017 , 67, e94-e102	21
1831	Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: A consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). 2017 , 18, 945-960	27
1830	The year 2015-16 in the European Heart Journal-Cardiovascular Imaging. Part II. 2017 , 18, 1322-1330	2
1829	Cardiac rejuvenation: a new hope in the presbycardia nightmare. <i>European Heart Journal</i> , 2017 , 38, 2968-2970	1
1828	Combination of Hydralazine and Isosorbide-Dinitrate in the Treatment of Patients with Heart Failure with Reduced Ejection Fraction. 2018 , 1067, 31-45	6
1827	Refining Classification of Heart Failure Based on Ejection Fraction. 2017 , 5, 808-809	16
1826	Reverse J-Curve Relationship Between On-Treatment Blood Pressure and Mortality in Patients With Heart Failure. 2017 , 5, 810-819	33
1825	Effect of long-term remote ischemic conditioning in patients with chronic ischemic heart failure. 2017 , 112, 67	36
1824	Ultrafiltration in heart failure: Finding the entrance. 2017 , 58, 281-282	1
1823	Clinical Implications of Echocardiographic Phenotypes of Patients With Diabetes Mellitus. 2017 , 70, 1704-1716	70
1822	Fibrilaci3 auricular y flter auricular. 2017 , 12, 2299-2308	

1821	Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure. 2017 , 5, 735-742	17
1820	Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. 2017 , 5, 724-734	49
1819	Acetazolamide as Add-on Diuretic Therapy in Exacerbations of Chronic Heart Failure: a Pilot Study. 2017 , 37, 1175-1181	25
1818	Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. 2017 , 70, 1875-1886	124
1817	(Re)Discovering the Neurohormonal and Hemodynamic Duality of Heart Failure. 2017 , 70, 1887-1889	6
1816	Inotropes and cardiorenal syndrome in acute heart failure ▯A retrospective comparative analysis. 2017 , 36, 619-625	3
1815	2017 ESC/EACTS Guidelines for the management of valvular heart disease. 2017 , 52, 616-664	359
1814	Cardiopulmonary exercise testing as prognostic indicators: Comparisons among heart failure patients with reduced, mid-range and preserved ejection fraction. 2017 , 24, 1979-1987	52
1813	Effect of ferric carboxymaltose on hospitalization and mortality outcomes in chronic heart failure: A meta-analysis. 2017 , 69, 736-741	5
1812	Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. 2017 , 9,	150
1811	Acute Heart Failure in the Emergency Department: What Is the Prognosis?. 2017 , 167, 744-745	
1810	Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIUR-AHF. 2017 , 4, 479-486	13
1809	Adherence to optimal heart rate control in heart failure with reduced ejection fraction: insight from a survey of heart rate in heart failure in Sweden (HR-HF study). 2017 , 106, 960-973	14
1808	Six-minute walking test and long term prognosis in patients with asymptomatic aortic valve stenosis. 2017 , 249, 334-339	4
1807	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. 2017 , 10,	37
1806	Therapeutic Targets for the Multi-system Pathophysiology of Heart Failure: Exercise Training. 2017 , 19, 87	6
1805	Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis. 2017 , 70, 1964-1976	172
1804	[Organ Interactions: Heart and Lung - Management of the Acute Right Heart Failure]. 2017 , 142, 1357-1364	1

1803	[Cardiogenic shock : Current evidence]. 2017 , 42, 795-806		2
1802	Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions. 2017 , 5, 763-771		103
1801	Left Atrial Strain: A Must or a Plus for Routine Clinical Practice?. 2017 , 10,		17
1800	Cardiac troponin T as a predictor of cardiac death in patients with left ventricular dysfunction. 2017 , 33, 463-468		6
1799	Increased risk of heart failure and atrial fibrillation in heterozygous familial hypercholesterolemia. 2017 , 266, 69-73		11
1798	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis. 2017 , 70, 2128-2136		24
1797	In-hospital use of non-steroidal anti-inflammatory drugs in patients with heart failure in academic centers in the United States. 2016 , 28, 181-188		3
1796	Treatment goals and discharge criteria for hospitalized patients with acute heart failure. 2017 , 3, 100-106		1
1795	Inotropes in acute heart failure. 2017 , 3, 107-116		7
1794	Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry. 2017 , 80, 750-757		21
1793	Combining echo and natriuretic peptides to guide heart failure care in the outpatient setting: A position paper. 2017 , 47, e12846		9
1792	A manifesto for cardiovascular imaging: addressing the human factor. 2017 , 18, 1311-1321		7
1791	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2017 , 38, 2739-2791	9.5	3615
1790	The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. <i>European Heart Journal</i> , 2017 , 38, 3308-3317	9.5	60
1789	Serum potassium in patients with chronic heart failure: once we make a U-turn where should we go?. <i>European Heart Journal</i> , 2017 , 38, 2897-2899	9.5	11
1788	Special issues in heart failure: pulmonary hypertension, deranged potassium levels, and haemodynamic profiles. <i>European Heart Journal</i> , 2017 , 38, 2857-2859	9.5	
1787	Application of Speckle-Tracking Echocardiography in an Experimental Model of Isolated Subendocardial Damage. 2017 , 30, 1239-1250.e2		17
1786	Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 2017 , 318, 713-720		236

1785	Rational and design of a randomized, double-blind, multicenter trial to evaluate the safety and tolerability of furosemide withdrawal in stable chronic outpatients with heart failure: The ReBIC-1 trial. 2017 , 194, 125-131	6
1784	It Is Time for a Wake-Up Call: How to Use the Best-In-Class Technology for the Most 'Challenging CRT Patients. 2017 , 3, 815-817	
1783	Mediterranean diet and prognosis of first-diagnosed Acute Coronary Syndrome patients according to heart failure phenotype: Hellenic Heart Failure Study. 2017 ,	8
1782	Heart failure with reduced ejection fraction. 2017 , 3, 17058	87
1781	Cardiac Imaging in Patients With Heart Failure and Preserved Ejection Fraction. 2017 , 10,	12
1780	New issues on measurement of B-type natriuretic peptides. 2017 , 56, 32-39	13
1779	[Medicinal treatment of tricuspid valve regurgitation]. 2017 , 42, 634-643	2
1778	Haemodynamic profiles of children with end-stage heart failure. <i>European Heart Journal</i> , 2017 , 38, 2900-2909	18
1777	A Blueprint for the Post Discharge Clinic Visit after an Admission for Heart Failure. 2017 , 60, 237-248	8
1776	Inotropes and cardiorenal syndrome in acute heart failure - A retrospective comparative analysis. 2017 , 36, 619-625	8
1775	Left atrial volume index in patients with heart failure and severely impaired left ventricular systolic function: the role of established echocardiographic parameters, circulating cystatin C and galectin-3. 2017 , 11, 283-295	10
1774	Iron deficiency in heart failure: Efficacy and safety of intravenous iron therapy. 2017 , 35, e12301	9
1773	Who still remains at risk of arrhythmic death at time of implantable cardioverter-defibrillator generator replacement?. 2017 , 40, 1129-1138	4
1772	Levosimendan prevents bronchoconstriction and adverse respiratory tissue mechanical changes in rabbits. 2017 , 313, L950-L956	5
1771	Evolution of Functional Mitral Regurgitation and Prognosis in Medically Managed Heart Failure Patients With Reduced Ejection Fraction. 2017 , 5, 652-659	47
1770	Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure. 2017 , 36, 655-668	14
1769	Cardiac I-MIBG scintigraphy is associated with freedom of appropriate ICD therapy in stable chronic heart failure patients. 2017 , 248, 403-408	23
1768	Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. 2017 , 5, 688-689	3

1767	Levosimendan ohne Vorteil bei Sepsis. 2017 , 142, 246-247	
1766	Pathophysiology, diagnosis and treatment of tachycardiomyopathy. 2017 , 103, 1543-1552	50
1765	Cardiac resynchronization therapy and its role in the management of heart failure. 2017 , 78, 312-319	1
1764	The Future of Biological Markers in COPD. 2017 , 53, 541-542	
1763	Subclinical Hyperthyroidism and the Cardiovascular Disease. 2017 , 49, 723-731	21
1762	Seasonal variability of NT-proBNP in Swedish primary care patients. 2017 , 34, 1473-1477	4
1761	Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. 2017 , 121, 731-748	306
1760	Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. 2017 , 136, e232-e268	618
1759	The Initial Evaluation and Management of a Patient with Heart Failure. 2017 , 19, 103	
1758	Pharmacological management of type 2 diabetes: what's new in 2017?. 2017 , 10, 1383-1394	16
1757	Prevalence and prognostic impact of anemia and iron deficiency in patients hospitalized in an internal medicine ward: The PRO-IRON study. 2017 , 99, 505-513	16
1756	How to interpret an echocardiography report (for the non-imager)?. 2017 , 103, 1733-1744	6
1755	Conduction Disturbances After Transcatheter Aortic Valve Replacement: Current Status and Future Perspectives. 2017 , 136, 1049-1069	231
1754	Clinical predictors of challenging atrioventricular node ablation procedure for rate control in patients with atrial fibrillation. 2017 , 245, 168-173	1
1753	Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure. 2017 , 36, 655-668	6
1752	Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure. 2017 , 10,	14
1751	Psychometric evaluation of the Caregiver Preparedness Scale in caregivers of adults with heart failure. 2017 , 40, 470-478	14
1750	A plea for an early ultrasound-clinical integrated approach in patients with acute heart failure. A proactive comment on the ESC Guidelines on Heart Failure 2016. 2017 , 245, 207-210	7

1749	Approaches to the Role of The Heart Team in Therapeutic Decision Making for Heart Valve Disease. 2017 , 1, 249-255	8
1748	Postmarketing Adverse Events Related to the CardioMEMS HF System. 2017 , 2, 1277-1279	33
1747	Combination drug treatment in hypertension. 2017 , 125, 266-271	24
1746	Percutaneous Closure of Left Atrial Appendage affects Mid-Term Release of MR-proANP. 2017 , 7, 9028	2
1745	The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials. 2017 , 31, 391-400	17
1744	Heat shock protein 27 acts as a predictor of prognosis in chronic heart failure patients. 2017 , 473, 127-132	10
1743	The management of diagnosed heart failure in older people in primary care. 2017 , 106, 26-30	4
1742	Heart Failure With Preserved Ejection Fraction: A Perioperative Review. 2017 , 31, 1820-1830	7
1741	Feasibility and acceptability of a patient-reported outcome intervention in chronic heart failure. 2017 , 7, 470-479	33
1740	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR [®] Research to Practice project. 2017 , 24, 1637-1645	73
1739	Impaired renal function affects clinical outcomes and management of patients with heart failure. 2017 , 4, 576-584	13
1738	[Acute and chronic heart failure]. 2017 , 42, 699-712	3
1737	Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope. 2017 , 70, 991-1004	23
1736	Biomedical time series preprocessing and expert-system based feature extraction in MULTISAB platform. 2017 ,	1
1735	Sleep-disordered breathing in heart failure: facts and numbers. 2017 , 4, 198-202	8
1734	The MOGE(S) classification for cardiomyopathies: current status and future outlook. 2017 , 22, 743-752	33
1733	Long-term management of end-stage heart failure. 2017 , 31, 153-166	15
1732	Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model. 2017 , 2, 285-296	4

- 1731 The optimum chest compression site with regard to heart failure demonstrated by computed tomography. **2017**, 35, 1899-1906 8
- 1730 Sudden cardiac death in nonischemic cardiomyopathy: Refining risk assessment. **2017**, 28, 1361-1366 8
- 1729 Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. **2017**, 20, 1260-1269 21
- 1728 Protocolo diagnóstico de la descompensación aguda de la insuficiencia cardíaca. **2017**, 12, 2131-2135
- 1727 Reply to «The value of troponin during an episode of acute heart failure in emergency department. One more reason to request it». **2017**, 217, 379
- 1726 Nuevas técnicas de imagen cardíaca en la detección precoz de cardiotoxicidad secundaria a tratamientos oncológicos. **2017**, 70, 487-495 22
- 1725 Mechanical circulatory support: harm without benefit? Fascinated by devices, cardiologists may lose common sense. *European Heart Journal*, **2017**, 38, 3535-3537 9.5 3
- 1724 Risk of stroke in congestive heart failure with and without atrial fibrillation. **2017**, 248, 182-187 31
- 1723 Persistent atrial fibrillation vs paroxysmal atrial fibrillation: differences in management. **2017**, 15, 601-618 23
- 1722 Letter by Smiseth and Nagueh et al Regarding Article, "Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study". **2017**, 136, 428-429
- 1721 The role of procalcitonin in acute heart failure patients. **2017**, 4, 203-208 18
- 1720 Tl surveillance et insuffisance cardiaque. **2017**, 2017, 6-9
- 1719 The Future of Biological Markers in COPD. **2017**, 53, 541-542 1
- 1718 Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study. **2017**, 248, 414-420 4
- 1717 Insuficiencia cardíaca aguda. **2017**, 12, 2092-2099
- 1716 Protocolo de diagnóstico y tratamiento de la anemia en el paciente con insuficiencia cardíaca. **2017**, 12, 2127-2130
- 1715 Protocolo terapéutico de la insuficiencia cardíaca aguda según el perfil del paciente. **2017**, 12, 2136-2139
- 1714 Varón de 69 años con dolor torácico y disnea. **2017**, 12, 2143.e1-2143.e4

1713	Universal response to cardiac resynchronization therapy: A challenge still to be overcome. 2017 , 36, 427-430	
1712	Mid-regional pro-adrenomedullin and ST2 in heart failure: Contributions to diagnosis and prognosis. 2017 , 36, 465-472	5
1711	Historique des études cardiovasculaires : de l'OGDPA aux dernières études. 2017 , 11, 2S15-2S26	7
1710	Insuficiencia cardíaca. Generalidades. 2017 , 12, 2085-2091	1
1709	Estado nutricional en insuficiencia cardíaca avanzada y receptores de trasplante cardíaco. 2017 , 70, 626-628	2
1708	Impact of Hyperkalemia and Worsening Renal Function on the Use of Renin Angiotensin Aldosterone System Inhibitors in Chronic Heart Failure With Reduced Ejection Fraction. 2017 , 102, 389-391	7
1707	Que retenir des dernières recommandations européennes sur l'insuffisance cardiaque ?. 2017 , 2017, 1-2	
1706	Un shunt inter-atrial pour le traitement de l'insuffisance cardiaque à fraction d'éjection préservée. 2017 , 2017, 10-13	
1705	Check-list de sortie d'hospitalisation d'un insuffisant cardiaque. 2017 , 2017, 14-17	1
1704	Intérêt de l'échographie pulmonaire en cardiologie. 2017 , 2017, 3-5	
1703	Comparison of non-traditional biomarkers, and combinations of biomarkers, for vascular risk prediction in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. 2017 , 264, 67-73	12
1702	Physician preferences for management of patients with heart failure and arrhythmia. 2017 , 3, 5-8	
1701	Protocolo diagnóstico y etiológico de la insuficiencia cardíaca. 2017 , 12, 2140-2142	
1700	Major developments in the 2016 european guidelines for heart failure. 2017 , 217, 405-409	4
1699	Hyponatraemia and congestive heart failure refractory to diuretic treatment. Utility of tolvaptan. 2017 , 217, 398-404	1
1698	Amiloide beta (1-40) en sangre, cognición y pronóstico en insuficiencia cardíaca. 2017 , 70, 924-932	6
1697	Estrategias diuréticas en insuficiencia cardíaca aguda con disfunción renal: terapia convencional frente a guiada por el antígeno carbohidrato 125. Diseño de ensayo clínico. 2017 , 70, 1067-1073	8
1696	Diagnóstico y tratamiento de la amiloidosis cardíaca por transtiretina. Progreso y esperanza. 2017 , 70, 991-1004	50

1695	An approach to improving heart failure management - A local contribution. 2017 , 36, 439-441		2
1694	Universal response to cardiac resynchronization therapy: A challenge still to be overcome. 2017 , 36, 427-430		
1693	An approach to improving heart failure management [A local contribution]. 2017 , 36, 439-441		2
1692	Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD. <i>European Heart Journal</i> , 2017 , 38, 2680-2682	9.5	45
1691	Indikationen zur invasiven Koronardiagnostik und Revaskularisation. 2017 , 11, 272-284		7
1690	Functional Mitral Regurgitation Predicts Short-Term Adverse Events in Patients With Acute Heart Failure and Reduced Left Ventricular Ejection Fraction. 2017 , 120, 1344-1348		14
1689	[Main novelties of the last set of European guidelines for the management of heart failure]. 2017 , 46, 758-765		1
1688	Myocardial Tissue Engineering for Regenerative Applications. 2017 , 19, 78		19
1687	Treatment of chronic heart failure in Germany: a retrospective database study. 2017 , 106, 923-932		17
1686	Cross-Validation of the Minnesota Living With Heart Failure Questionnaire. 2017 , 49, 513-520		10
1685	Complete recovery of fulminant peripartum cardiomyopathy on mechanical circulatory support combined with high-dose bromocriptine therapy. 2017 , 4, 641-644		12
1684	Cardiac Reverse Remodeling in Heart Failure: Is There a Role for Epidural in the Current Treatment Landscape?. 2017 , 31, 1577-1579		
1683	[ESC Guidelines 2016 - Heart Failure]. 2017 , 142, 1123-1127		4
1682	Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. <i>European Heart Journal</i> , 2017 , 38, 2879-2887	9.5	265
1681	Mechanical Circulatory Support for Decompensated Heart Failure. 2017 , 14, 365-375		6
1680	Impact of Frailty and Disability on 30-Day Mortality in Older Patients With Acute Heart Failure. 2017 , 120, 1151-1157		22
1679	Estudio retrospectivo sobre las diferencias entre insuficiencia cardíaca sistólica y diastólica en un registro de 1.000 pacientes del hospital Puerta de Hierro-Majadahonda-Madrid. Comparación con el Registro Nacional español de Insuficiencia Cardíaca (RICA). 2017 , 24, 598-601		
1678	Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. 2017 , 4, 312-318		17

1677	Haemodynamic monitoring of cardiac status using heart sounds from an implanted cardiac device. 2017 , 4, 605-613		11
1676	A Janus-headed electrolyte and 'RALES' disease'. 2017 , 4, 195-197		0
1675	Sexual function of patients with heart failure: distinct phenotypes, distinct sexual function?. 2017 , 4, 319		3
1674	A contemporary review of peripartum cardiomyopathy. 2017 , 17, 316-321		11
1673	Chronisch obstruktive Lungenerkrankung und Komorbiditäten. 2017 , 14, 325-334		1
1672	[Circulatory failure : Out- and inpatient management]. 2017 , 58, 908-915		
1671	Empfehlungen zur Ultraschallausbildung in der internistischen Intensiv- und Notfallmedizin: Positionspapier der DGIIN, DEGUM und DGK. 2017 , 11, 285-290		3
1670	Im Spannungsfeld zwischen HFpEF und den normalen Zeichen des Alterns. 2017 , 11, 262-263		
1669	First Steps Toward a Theory of Caregiver Contribution to Self-care in Heart Failure. 2017 , 32, 584-586		9
1668	Automatic positive airway pressure for treatment of obstructive sleep apnea in heart failure. 2017 , 21, 273-280		13
1667	Extracorporeal Membrane Oxygenation (ECMO) and the Critical Cardiac Patient. 2017 , 4, 218-225		28
1666	Acute Heart Failure: Definition, Classification and Epidemiology. 2017 , 14, 385-392		111
1665	The Role of Genetics in Peripartum Cardiomyopathy. 2017 , 10, 437-445		10
1664	Inpatient Monitoring of Decompensated Heart Failure: What Is Needed?. 2017 , 14, 393-397		3
1663	Associations of serum potassium levels with mortality in chronic heart failure patients. <i>European Heart Journal</i> , 2017 , 38, 2890-2896	9.5	91
1662	Prediction of major cardiac events after vascular surgery. 2017 , 66, 1826-1835.e1		20
1661	Development and validation of a risk stratification model for prediction of disability and hospitalisation in patients with heart failure: a study protocol. 2017 , 7, e014840		2
1660	Strength and aerobic exercise training in coronary artery disease; it's not 'either-or'. 2017 , 24, 1686-1691		1

1659	An update on heart failure: from experimental findings to clinical trials. <i>European Heart Journal</i> , 2017 , 38, 305-307	9.5
1658	Noninvasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus article from the European Association of Cardiovascular Imaging, the European Society of Cardiology Council on Hypertension and the European Society of Hypertension. 2017 , 35, 1727-1741	24
1657	How to take arms against central apneas in heart failure. 2017 , 15, 743-755	2
1656	Guía ESC 2017 sobre el tratamiento del infarto agudo de miocardio en pacientes con elevaci3n del segmento ST. 2017 , 70, 1082.e1-1082.e61	35
1655	A Feline HFpEF Model with Pulmonary Hypertension and Compromised Pulmonary Function. 2017 , 7, 16587	17
1654	Zelluläre Mechanismen der systolischen Herzinsuffizienz. 2017 , 46, 470-475	
1653	Tobacco smoking and electronic cigarette: two sides of the same coin?. 2017 , 58, 253-255	2
1652	Enhancing Response in the Cardiac Resynchronization Therapy Patient: The 3B Perspective-Bench, Bits, and Bedside. 2017 , 3, 1203-1219	11
1651	The heart matters in diabetes: 10-Year outcomes of peripheral artery disease. 2017 , 5, 2050312117740988	4
1650	Point-of-care testing (POCT) and evidence-based laboratory medicine (EBLM) - does it leverage any advantage in clinical decision making?. 2017 , 54, 471-494	65
1649	Sleep-disordered breathing in heart failure: The state of the art after the SERVE-HF trial. 2017 , 36, 859-867	4
1648	Abdominal Obesity Is Associated With an Increased Risk of All-Cause Mortality in Patients With HFpEF. 2017 , 70, 2739-2749	100
1647	From breathless to failure: symptom onset and diagnostic meaning in patients with heart failure-a qualitative study. 2017 , 7, e013648	12
1646	Disease management programs in heart failure: half a century of an unmet need. 2017 , 129, 861-863	2
1645	Improving kNowledge Transfer to Efficaciously RAise the level of Contemporary Treatment in Heart Failure (INTERACT-in-HF): Study protocol of a mixed methods study. 2017 , 20, 171-182	2
1644	Muscle wasting and sarcopenia in heart failure and beyond: update 2017. 2017 , 4, 492-498	111
1643	Sleep-disordered breathing in heart failure: The state of the art after the SERVE-HF trial. 2017 , 36, 859-867	2
1642	The Association between Galectin-3 and hs-CRP and the Clinical Outcome after Non-ST-Elevation Myocardial Infarction with Preexisting Atrial Fibrillation. 2017 , 7, 15106	7

1641	[Ventricular arrhythmias : What has been confirmed in therapy?]. 2017 , 58, 1272-1280	1
1640	Medikamentöse Herzinsuffizienztherapie. 2017 , 17, 31-37	
1639	Cardiac involvement in myotonic dystrophy: The role of troponins and N-terminal pro B-type natriuretic peptide. 2017 , 267, 110-115	6
1638	Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. 2017 , 70, 2476-2486	368
1637	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. 2017 , 70, 2490-2500	65
1636	Publishing in a heart failure journal-where lies the scientific interest?. 2017 , 4, 389-401	0
1635	Diuretic Treatment in Heart Failure. 2017 , 377, 1964-1975	134
1634	Diastolic Dysfunction is Common in Survivors of Pediatric Differentiated Thyroid Carcinoma. 2017 , 27, 1481-1489	6
1633	Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction. 2017 , 6,	55
1632	Effect of cardiologist care on 6-month outcomes in patients discharged with heart failure: results from an observational study based on administrative data. 2017 , 7, e018243	13
1631	Disease management programs in chronic heart failure : Position statement of the Heart Failure Working Group and the Working Group of the Cardiological Assistance and Care Personnel of the Austrian Society of Cardiology. 2017 , 129, 869-878	15
1630	Heart failure: a story of damage, fatigue and injury?. 2017 , 4, e000684	7
1629	[Pharmacotherapy in chronic Heart Failure]. 2017 , 159, 42-48	
1628	Cognitively impaired patients with heart failure may not perceive weight gain as a risk for decompensation. 2017 , 20, 115-116	
1627	Rationale and Design of Low-dose Administration of Carperitide for Acute Heart Failure (LASCAR-AHF). 2017 , 31, 551-557	4
1626	Miocardopatías (II). Formas dilatadas. 2017 , 12, 2561-2572	
1625	Resynchronization therapy in patients with atrial fibrillation: What are the results?. 2017 , 36, 695-697	
1624	Heart rate and outcomes in patients with heart failure with preserved ejection fraction: A dose-response meta-analysis. 2017 , 96, e8431	10

1623	Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes. 2017 , 31, 233-246		72
1622	Frontiers in heart failure: sodium, longitudinal strain, contractility sensor, fatal arrhythmias, and stroke. <i>European Heart Journal</i> , 2017 , 38, 693-696	9.5	
1621	Interventional Therapies for Heart Failure in Older Adults. 2017 , 13, 535-570		2
1620	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. 2017 , 5, 471-482		176
1619	Gender issues in arrhythmias: from atrial fibrillation to CRT and arrhythmogenic ventricular cardiomyopathy. <i>European Heart Journal</i> , 2017 , 38, 1443-1446	9.5	
1618	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. <i>European Heart Journal</i> , 2017 , 38, 2649-2662	9.5	88
1617	Acute heart failure and decompensated chronic heart failure. 2017 , 311-316		
1616	[New pharmacologic therapies for chronic heart failure]. 2017 , 58, 990-999		3
1615	Sind Erwachsene mit angeborenen Herzfehlern ausreichend versorgt?. 2017 , 31, 228-240		1
1614	Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. <i>European Heart Journal</i> , 2017 , 38, 3523-3537	9.5	184
1613	Is heart failure with midrange ejection fraction similar to preserved ejection fraction? Against. 2017 , 217, 299-301		
1612	Management of septic myocardial dysfunction in intensive care unit: A survey of French speaking intensivists. 2017 , 42, 107-108		
1611	Inflammation in Heart Failure: known knowns and unknown unknowns. 2017 , 18, 1225-1233		16
1610	Resolution of Cheyne-Stokes Respiration after Treatment of Heart Failure with Sacubitril/Valsartan: A First Case Report. 2017 , 137, 96-99		9
1609	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. 2017 , 136, 1374-1383		179
1608	Prise en charge de la dyspnée aiguë suspecte d'insuffisance cardiaque en urgence : un challenge diagnostique et thérapeutique. 2017 , 7, 247-257		0
1607	Management of arrhythmias: NOACs, digoxin, alcohol, light, and devices. <i>European Heart Journal</i> , 2017 , 38, 2081-2085	9.5	
1606	Reply: The Influence of Exercise Therapy on the Heart Failure Disease Pathway. 2017 , 69, 2351		

1605	Role of implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a systematic review and meta-analysis of prospective randomized clinical trials. 2017 , 49, 263-270	7
1604	Uncovering difference: a glimpse at patients with heart failure in low-income and middle-income countries. 2017 , 5, e634-e635	1
1603	Cardio-Oncology - A new subspecialty with collaboration at its heart. 2017 , 69, 556-562	9
1602	Observation of Patients Transitioned to an Oral Loop Diuretic Before Discharge and Risk of Readmission for Acute Decompensated Heart Failure. 2017 , 23, 746-752	6
1601	Elevation of plasma oncostatin M in heart failure. 2017 , 13, 219-227	10
1600	Neue Indikationen ff.die Peritonealdialyse. 2017 , 12, 6-13	
1599	Adaptive servoventilation to treat sleep-disordered breathing in cardiac patients. 2017 , 21, 82-83	8
1598	Addendum zum Positionspapier Schlafmedizin in der Kardiologie. Update 2014□ 2017 , 21, 51-52	7
1597	Kommentar zu den ESC-Leitlinien 2015 V Ventrikuläre Arrhythmien und Prävention des plötzlichen Herztodes□ 2017 , 11, 27-43	8
1596	Addendum zum Positionspapier Schlafmedizin in der Kardiologie. Update 2014□ 2017 , 11, 19-20	3
1595	Zustand nach Lungenembolie. 2017 , 11, 125-138	1
1594	Does an electronic cognitive aid have an effect on the management of severe gynaecological TURP syndrome? A prospective, randomised simulation study. 2017 , 17, 72	7
1593	Kommentar zu den Leitlinien der Europäischen Gesellschaft ff.Kardiologie (ESC) zur Diagnostik und Behandlung der akuten und chronischen Herzinsuffizienz. 2017 , 11, 183-192	9
1592	Enkeloedeem en vermoeide voeten een normaal ouderdomsverschijnsel of een teken van hartfalen?. 2017 , 25, 63-66	
1591	Selection of Patients for Initial Clinical Trials of Solid Organ Xenotransplantation. 2017 , 101, 1551-1558	43
1590	Low adiponectin is associated with diastolic dysfunction in women: a cross-sectional study from the Tromsø Study. 2017 , 17, 79	16
1589	Decreased cardiac mortality with nicorandil in patients with ischemic heart failure. 2017 , 17, 141	5
1588	Understanding heart failure; explaining telehealth - a hermeneutic systematic review. 2017 , 17, 156	69

1587	The anti-ageing molecule sirt1 mediates beneficial effects of cardiac rehabilitation. 2017 , 14, 7	28
1586	The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial. 2017 , 18, 36	2
1585	The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. 2017 , 6, 47	4
1584	Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis. 2017 , 167, 103-111	30
1583	Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball. 2017 , 19, 70	18
1582	Cardiac Resynchronization Therapy for Heart Failure. 2017 , 6, 417-426	5
1581	Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure. 2017 , 69, 393-401	11
1580	Mid-regional pro-adrenomedullin and ST2 in heart failure: Contributions to diagnosis and prognosis. 2017 , 36, 465-472	6
1579	Remote monitoring of heart failure: benefits for therapeutic decision making. 2017 , 15, 503-515	14
1578	Remote management of heart failure using implantable electronic devices. <i>European Heart Journal</i> , 2017 , 38, 2352-2360	9.5 119
1577	Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials. 2017 , 7, e016352	13
1576	Heart failure - or a failure of imagination?. 2017 , 93, 439-440	1
1575	Practical guidance on heart failure diagnosis and management in primary care: recent EPCCS recommendations. 2017 , 67, 326-327	8
1574	The effects of resistance training on muscle strength, quality of life and aerobic capacity in patients with chronic heart failure - A meta-analysis. 2017 , 227, 413-423	68
1573	Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus. 2017 , 8, 33-53	12
1572	Biomarkers in Heart Failure with Preserved Ejection Fraction: Problems and Opportunities. 2017 , 136, 228-229	2
1571	Impact of chronic obstructive pulmonary disease on clinical course after an episode of acute heart failure. EAHFE-COPD study. 2017 , 227, 450-456	14
1570	Established and novel treatment options in acute myocarditis, with or without heart failure. 2017 , 15, 25-34	15

1569	Association of chronic kidney disease with impaired left atrial reservoir function: A community-based cohort study. 2017 , 24, 392-398	11
1568	Heart Failure Care: More Than Just Heart Failure. 2017 , 23, 10-11	1
1567	Right Ventricular Dysfunction Complicates Time in Therapeutic Range in Heart Failure Patients Receiving Warfarin. 2017 , 99, 19-26	2
1566	Management of anemia in patients with congestive heart failure. 2017 , 92, 88-93	32
1565	Mechanical Support for Cardiogenic Shock: Lost in Translation?. 2017 , 69, 288-290	20
1564	Novel Biomarkers of Heart Failure. 2017 , 79, 93-152	60
1563	Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. 2017 , 3, 48-57	48
1562	The effects of adaptive servo-ventilation in the management of acute cardiogenic pulmonary edema: Definitely more than a blurb. 2017 , 69, 797-798	
1561	Targeting acetaldehyde dehydrogenase 2 (ALDH2) in heart failure-Recent insights and perspectives. 2017 , 1863, 1933-1941	22
1560	Consensus Document of the Spanish Society of Cardiology and the Spanish Society of Internal Medicine on the diagnosis and treatment of iron deficiency in heart failure. 2017 , 217, 35-45	19
1559	Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant. 2017 , 227, 863-868	8
1558	Heart Failure Therapy in 2016: SHIFTing the PARADIGM From Antiquated Therapies Toward Novel Agents. 2017 , 51, 79-82	2
1557	Mechanisms of Effort Intolerance in Patients With Heart Failure and Borderline Ejection Fraction. 2017 , 119, 416-422	7
1556	Consensus Document of the Spanish Society of Cardiology and the Spanish Society of Internal Medicine on the diagnosis and treatment of iron deficiency in heart failure. 2017 , 217, 35-45	
1555	Heart Failure: Diagnosis, Severity Estimation and Prediction of Adverse Events Through Machine Learning Techniques. 2017 , 15, 26-47	89
1554	EAHFE - TROPICA2 study. Prognostic value of troponin in patients with acute heart failure treated in Spanish hospital emergency departments. 2017 , 22, 337-344	10
1553	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. 2017 , 57, 440-451	33
1552	Devicetherapie in der Herzinsuffizienz Wie richtig einsetzen?. 2017 , 6, 129-138	

1551	The future of telemedicine for the management of heart failure patients: a Consensus Document of the Italian Association of Hospital Cardiologists (A.N.M.C.O), the Italian Society of Cardiology (S.I.C.) and the Italian Society for Telemedicine and eHealth (Digital S.I.T.). 2017 , 19, D113-D129		18
1550	An update on cardiomyopathies: immune-mediated diseases, sarcoidosis, and peripartum and hypertrophic cardiomyopathies during pregnancy. <i>European Heart Journal</i> , 2017 , 38, 2635-2638	9.5	1
1549	Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients. 2017 , 10, i25-i31		5
1548	Monitoring of nocturnal central sleep apnea in Heart failure patients using noncontact respiratory differences. 2017 , 2017, 1534-1538		1
1547	Prevalence of cardiovascular disease and evaluation of standard of care in type 2 diabetes: a nationwide study in primary care. 2017 , 6, 145-151		21
1546	Kardiale Unterstützungs- und Ersatzsysteme. 2017 , 20, 226-233		
1545	Nutzen der Palliativmedizin in der Therapie terminal herzinsuffizienter Patienten. 2017 , 6, 152-155		0
1544	Cardiac Resynchronization Therapy With Multipoint Left Ventricular Lead Pacing. 2017 , 3, 1519-1522		2
1543	Genome-Wide Association Study Implicates Atrial Natriuretic Peptide Rather Than B-Type Natriuretic Peptide in the Regulation of Blood Pressure in the General Population. 2017 , 10,		15
1542	Novel biomarkers in heart failure: How they change clinical decision?. 2017 , 58, 317-319		3
1541	Resynchronization therapy in patients with atrial fibrillation: What are the results?. 2017 , 36, 695-697		
1540	Limited role and benefit of ivabradine in the treatment of angina and heart failure with reduced ejection fraction. 2017 , 72, 664-668		1
1539	EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review. 2017 , 18, 1191-1204		34
1538	Summary of 2016 ESC guidelines on heart failure, atrial fibrillation, dyslipidaemia and cardiovascular prevention. 2017 , 72, 610-615		1
1537	Precision medicine in the management of cardiomyopathies. <i>European Heart Journal</i> , 2017 , 38, 3395-3398		5
1536	Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan. 2017 , 19, C22-C28		7
1535	Körperliche Aktivität bei Herzinsuffizienz. 2017 , 17, 43-46		
1534	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. 2017 ,		2

1533	Innovations in management of cardiac disease: drugs, treatment strategies and technology. 2017 , 119, i23-i33	7
1532	Mineralocorticoid Receptor Antagonists in High-Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease. 2017 , 6,	4
1531	Heart Transplantation in Asia. 2017 , 81, 617-621	10
1530	Flying high for heart failure: considerations for air travel. 2017 , 12, 34-39	
1529	Recent Progress Using Pluripotent Stem Cells for Cardiac Regenerative Therapy. 2017 , 81, 929-935	8
1528	Controversies in hypertension management: target blood pressure, renal nerve ablation, ARNIs, and NSAIDs medication. <i>European Heart Journal</i> , 2017 , 38, 3245-3248	9.5
1527	ESC-Leitlinie 2016 zum Management von Vorhofflimmern. 2017 , 6, 185-198	
1526	Decompensated heart failure patients: there are simple parameters that could be integrated in a machine learning process to improve our strategies. 2017 , 2, 27-27	
1525	Chronic Heart Failure Care Planning: Considerations in Older Patients. 2017 , 3, 46-51	11
1524	New Insights Into Tolvaptan Treatment and the Renin-Angiotensin-Aldosterone System. 2017 , 58, 307-309	2
1523	Entresto in heart failure. 2017 , 15, 605-611	
1522	ATRIAL FIBRILLATION AND CHRONIC HEART FAILURE: PRACTICAL ASPECTS AND DISCUSSION ISSUES OF RATIONAL PHARMACOTHERAPY. 2017 , 13, 856-862	
1521	17. Myokarditis. 2017 ,	
1520	Myxoedema in a patient with achondroplasia in rural area of Guatemala. 2017 , 2017,	1
1519	Three-Dimensional and Biomimetic Technology in Cardiac Injury After Myocardial Infarction: Effect of Acellular Devices on Ventricular Function and Cardiac Remodelling. 2017 ,	
1518	British Society for Heart Failure: 7th nurse training day. 2017 , 12, 255-256	
1517	PATIENTS WITH COMBINATION OF CHRONIC HEART FAILURE, HYPERTENSION AND HISTORY OF MYOCARDIAL INFARCTION: CLINICAL AND ANAMNESTIC CHARACTERISTICS, ADMINISTRATION OF ACE INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS, -BLOCKERS AND ADHERENCE TO THE DRUG THERAPY (DATA OF OUTPATIENT REGISTRY RECVASA). 2017 , 13, 207-212	4
1516	Characteristics, Management, and Outcomes of Acute Heart Failure in the Emergency Department: A Multicenter Registry Study with 1-year Follow-up in a Chinese Cohort in Beijing. 2017 , 130, 1894-1901	5

1515	Treating iron deficiency in chronic heart failure. 2017 , 12, 232-232	
1514	The Effects of Tai Chi Training in Patients with Heart Failure: A Systematic Review and Meta-Analysis. 2017 , 8, 989	23
1513	Managing the drug treatment of rheumatoid arthritis. 2017 , 40, 51-58	37
1512	Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy. 2017 , 18, 1470320317729919	12
1511	Global Public Health Burden of Heart Failure. 2017 , 3, 7-11	996
1510	Peripartum cardiomyopathy: challenges and solutions. 2017 , Volume 8, 31-40	1
1509	Association of left ventricular ejection fraction with contrast-induced nephropathy and mortality following coronary angiography or intervention in patients with heart failure. 2017 , 13, 887-895	14
1508	Review: In HF with preserved EF, β blockers reduced mortality; drug treatment overall did not. 2017 , 167, JC68	0
1507	Ultra-Sensitive NT-proBNP Quantification for Early Detection of Risk Factors Leading to Heart Failure. 2017 , 17,	9
1506	Heart Failure in Patients with Diabetes Mellitus. 2017 , 3, 52-55	65
1505	Der tragbare Defibrillator (WCD) IÆHRA-Review. 2017 , 6, 213-219	
1504	Zebrafish Larvae Model of Dilated Cardiomyopathy Induced by Terfenadine. 2017 , 47, 960-969	15
1503	Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework. 2017 , 4, 182	31
1502	Current Therapeutic Options for Heart Failure in Elderly Patients. 2017 , 2017, 1483873	5
1501	Oxidative Stress-Related Parthanatos of Circulating Mononuclear Leukocytes in Heart Failure. 2017 , 2017, 1249614	17
1500	Positive airway pressure for heart failure associated with central sleep apnoea. 2017 ,	1
1499	Nanotechnology-Based Cardiac Targeting and Direct Cardiac Reprogramming: The Betrothed. 2017 , 2017, 4940397	14
1498	Clinical Characteristics and Outcome of Acute Heart Failure in Korea: Results from the Korean Acute Heart Failure Registry (KorAHF). 2017 , 47, 341-353	87

1497	Heart failure and multimorbidity in Australian general practice. 2017 , 7, 44-49	8
1496	Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). 2017 , 13, 1569-1576	3
1495	Value of Telemonitoring and Telemedicine in Heart Failure Management. 2017 , 3, 116-121	54
1494	Depletion of cardiac catecholamine stores impairs cardiac norepinephrine re-uptake by downregulation of the norepinephrine transporter. 2017 , 12, e0172070	7
1493	Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure. 2017 , 12, e0179509	2
1492	Wave intensity of aortic root pressure as diagnostic marker of left ventricular systolic dysfunction. 2017 , 12, e0179938	12
1491	Persistent abnormalities in pulmonary arterial compliance after heart transplantation in patients with combined post-capillary and pre-capillary pulmonary hypertension. 2017 , 12, e0188383	8
1490	Improvement in Exercise Capacity by Exercise Training Associated With Favorable Clinical Outcomes in Advanced Heart Failure With High B-Type Natriuretic Peptide Level. 2017 , 81, 1307-1314	8
1489	Left ventricular contractile reserve by stress echocardiography as a predictor of response to cardiac resynchronization therapy in heart failure: a systematic review and meta-analysis. 2017 , 17, 223	12
1488	Complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions?. 2017 , 17, 253	
1487	Left ventricular non-compaction cardiomyopathy with coronary artery anomaly complicated by ventricular tachycardia. 2017 , 17, 263	3
1486	Quality of life questionnaire predicts poor exercise capacity only in HFpEF and not in HFrEF. 2017 , 17, 268	13
1485	Vitamin D repletion versus placebo as adjunctive treatment of heart failure patient quality of life and hormonal indices: a randomized, double-blind, placebo-controlled trial. 2017 , 17, 274	16
1484	General practitioners' awareness of depressive symptomatology is not associated with quality of life in heart failure patients - cross-sectional results of the observational RECODE-HF Study. 2017 , 18, 100	4
1483	Evolution and bad prognostic value of advanced glycation end products after acute heart failure: relation with body composition. 2017 , 16, 115	6
1482	Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). 2017 , 16, 137	9
1481	Impact of overweight on left ventricular function in type 2 diabetes mellitus. 2017 , 16, 145	17
1480	Access to medicines and diagnostic tests integral in the management of diabetes mellitus and cardiovascular diseases in Uganda: insights from the ACCODAD study. 2017 , 16, 154	13

1479	Inorganic nitrate as a treatment for acute heart failure: a protocol for a single center, randomized, double-blind, placebo-controlled pilot and feasibility study. 2017 , 15, 172	4
1478	Digitalis bei Herzinsuffizienz. 2017 , 17, 40-43	
1477	Improvement of left ventricular ejection fraction in revascularized postmyocardial patients: indication for statistical fallacy. 2017 , 10, 244	7
1476	Device-Therapie bei Herzinsuffizienz. 2017 , 17, 46-52	
1475	Progression towards Heart Failure after Myocardial Infarction Is Accompanied by a Change in the Spatial QRS-T Angle. 2017 ,	0
1474	High sensitivity troponin T and I reflect mitral annular plane systolic excursion being assessed by cardiac magnetic resonance imaging. 2017 , 22, 38	3
1473	Hartversterkers. 2017 , 23, 36-41	
1472	Sex differences in post-traumatic stress disorder in cardiovascular patients after the Great East Japan Earthquake: a report from the CHART-2 Study. 2017 , 3, 224-233	7
1471	PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY. 2017 , 13, 482-488	
1470	Biomarkers in Heart Failure. 2017 , 07,	
1469	Initial Report of the Korean Organ Transplant Registry (KOTRY): Heart Transplantation. 2017 , 47, 868-876	12
1468	Omega-3-Fettsäuren bei Herzinsuffizienz. 2017 , 66, 200-206	0
1467	Takotsubo cardiomyopathy: Pathophysiology and role of cardiac biomarkers in differential diagnosis. 2017 , 9, 723-730	27
1466	Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training. 2017 , 2017, 4865756	33
1465	Iron deficiency and iron deficiency anaemia in elderly patients with chronic heart failure. 2017 , 3,	
1464	Bedside Evaluation of Critical Dyspnea. Proposal of a Diagnostic Score for Acute Heart Failure in Emergency Setting. 2017 , 03,	
1463	Revascularization in ischemic heart failure with reduced left ventricular ejection fraction. The impact of complete revascularization. 2017 , 14, 37-42	0
1462	Toward a New Heart Failure Registry in Korea. 2017 , 47, 316-317	0

1461	Acute pulmonary oedema. 2017 , 40, 126	
1460	MODERN POSSIBILITIES OF SPECKLE TRACKING ECHOCARDIOGRAPHY IN CLINICAL PRACTICE. 2017 , 13, 248-255	14
1459	Challenges of Treating Acute Heart Failure in Patients with Chronic Obstructive Pulmonary Disease. 2017 , 3, 56-61	16
1458	Temporal Trends of Hospitalized Patients with Heart Failure in Korea. 2017 , 47, 16-24	32
1457	Awareness of physicians and pharmacists of aldosterone antagonists in heart failure and myocardial infarction in Jordan. 2017 , 15, 994	1
1456	Routine beta-blocker administration following acute myocardial infarction: why still an unsolved issue?. 2017 , 9, 4191-4194	6
1455	Fibrilaci3 auricular e insuficiencia card3aca. 2017 , 32,	
1454	Influenza vaccination to Reduce Cardiovascular Events : Time to Act. 2017 , 10, 1-2	
1453	INTEGRATION OF BIOMARKERS INTO THE PRACTICE OF TREATING PATIENTS WITH HEART FAILURE: THE ROLE OF DETERMINING THE BLOOD LEVEL OF NATRIURETIC PEPTIDES. 2017 , 13, 863-870	
1452	Insuficiencia card3aca aguda. 2017 , 32,	0
1451	Neurohormonal Blockade in Heart Failure. 2017 , 3, 19-24	27
1450	Impact on Patient Care: The 2016 European Heart Failure Guidelines. 2017 , 12, 78-79	
1449	Pulmonale Hypertonie bei Linksherzerkrankungen. 2017 , 46, 382-388	
1448	Ivabradine in the treatment of systolic heart failure - A systematic review and meta-analysis. 2017 , 9, 182-190	10
1447	Implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a meta-analysis of randomized controlled trials. 2017 , 7, 397-404	8
1446	Morphine in acute heart failure. 2017 , 9, 1851-1854	7
1445	Harmful impact of morphine use in acute heart failure. 2017 , 9, 1831-1834	3
1444	High rate of arterial complications in patients supported with extracorporeal life support for drug intoxication-induced refractory cardiogenic shock or cardiac arrest. 2017 , 9, 1988-1996	19

1443	Morphine in acute heart failure: good in relieving symptoms, bad in improving outcomes. 2017 , 9, E871-E874	4
1442	Primary prevention implantable cardioverter defibrillator in patients with reduced ejection fraction: for ischemic or non-ischemic cardiomyopathy or both?. 2017 , 9, 2749-2751	2
1441	New Classification for Heart Failure with Mildly Reduced Ejection Fraction: Greater clarity or more confusion?. 2017 , 17, e23-e26	3
1440	A critical appraisal of the morphine in the acute pulmonary edema: real or real uncertain?. 2017 , 9, 1802-1805	2
1439	Elevated soluble ST2 concentration may involve in the progression of atrial fibrillation. 2018 , 480, 138-142	13
1438	Technology Advances to Improve Response to Cardiac Resynchronization Therapy: What Clinicians Should Know. 2018 , 71, 477-484	2
1437	Cardio-oncology: the role of advanced echocardiography in cancer patients. 2018 , 16, 249-258	5
1436	COLUMNS. 2018 , 22, 12-21	1
1435	Chloroquine-induced cardiomyopathy: a reversible cause of heart failure. 2018 , 5, 372-375	26
1434	The Role of Nutritional Status in Elderly Patients with Heart Failure. 2018 , 22, 581-588	12
1433	Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2. 2018 , 12, 22-30	8
1432	Effect of Elevated C-Reactive Protein Level at Discharge on Long-Term Outcome in Patients Hospitalized for Acute Heart Failure. 2018 , 121, 961-968	7
1431	Unidimensional Longitudinal Strain: A Simple Approach for the Assessment of Longitudinal Myocardial Deformation by Echocardiography. 2018 , 31, 733-742	4
1430	Treatment of type 2 diabetes mellitus in elderly patients. 2018 , 218, 74-88	3
1429	Pathophysiological understanding of HFpEF: microRNAs as part of the puzzle. 2018 , 114, 782-793	30
1428	European Society of Cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection. <i>European Heart Journal</i> , 2018 , 39, 3353-3368 ^{9.5}	237
1427	Plasma midregional proadrenomedullin (MR-proADM) concentrations and their biological determinants in a reference population. 2018 , 56, 1161-1168	11
1426	Bone mineral density in older patients with chronic heart failure is related to NYHA classification: a retrospective study. 2018 , 9, 183-189	1

1425	[Heart failure in the general medical practice - A guide to diagnosis and therapy]. 2018 , 160, 32-38		0
1424	Echocardiographic Evaluation of Diastolic Function Is of Limited Value in the Diagnosis and Management of HFpEF. 2018 , 24, 392-396		5
1423	Novel insights in HFpEF, cardiomyopathies, and myocarditis. <i>European Heart Journal</i> , 2018 , 39, 819-822	9.5	1
1422	Synchronized Pulsatile Flow With Low Systolic Output From Venous-Arterial Extracorporeal Membrane Oxygenation Improves Myocardial Recovery After Experimental Cardiac Arrest in Pigs. 2018 , 42, 597-604		3
1421	Effects of angiotensin receptor blocker at discharge in patients with heart failure with reduced ejection fraction: Korean Acute Heart Failure (KorAHF) registry. 2018 , 257, 168-176		7
1420	High intensity interval training versus moderate intensity continuous training on exercise capacity and quality of life in patients with heart failure with reduced ejection fraction: A systematic review and meta-analysis. 2018 , 261, 134-141		62
1419	CXCL1-CXCR2 axis mediates angiotensin II-induced cardiac hypertrophy and remodelling through regulation of monocyte infiltration. <i>European Heart Journal</i> , 2018 , 39, 1818-1831	9.5	114
1418	Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design. 2018 , 5, 222-230		14
1417	Association between sleep-disordered breathing and arterial stiffness in heart failure patients with reduced or preserved ejection fraction. 2018 , 5, 284-291		9
1416	Underprescription of disease-modifying drugs in chronic heart failure: More is better?. 2018 , 254, 242-243		1
1415	Prognostic and diagnostic value of elevated serum concentration of procalcitonin in patients with suspected heart failure. A review and meta-analysis. 2018 , 23, 407-413		4
1414	Nephrologische Therapie der schweren Herzinsuffizienz. 2018 , 13, 104-110		0
1413	Ejection fraction as a statistical index of left ventricular systolic function: the first full allometric scrutiny of its appropriateness and accuracy. 2018 , 38, 976		2
1412	Left atrial dilatation in systolic heart failure: a marker of poor prognosis, not just a buffer between the left ventricle and pulmonary circulation. 2018 , 16, 155-161		9
1411	Effect of Optimizing Guideline-Directed Medical Therapy Before Discharge on Mortality and Heart Failure Readmission in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. 2018 , 121, 969-974		27
1410	Evaluation of the sST2-guided optimization of medical treatments of patients admitted for heart failure, to prevent readmission: Study protocol for a randomized controlled trial. 2018 , 66, 45-50		5
1409	Mineralocorticoid receptor antagonists for heart failure: a real-life observational study. 2018 , 5, 267-274		4
1408	Treatment of Heart Failure with Preserved Ejection Fraction. 2018 , 1067, 67-87		23

1407	Human α -AMPK Mutations. 2018 , 1732, 581-619	2
1406	Impact of the time-to-treatment concept on the outcome of acute heart failure: A pilot study. 2018 , 111, 270-275	2
1405	Post-Myocardial Infarction Heart Failure. 2018 , 6, 179-186	103
1404	Relationship between the prognostic nutritional index and long-term clinical outcomes in patients with stable coronary artery disease. 2018 , 72, 155-161	35
1403	Acute blood pressure elevation: Therapeutic approach. 2018 , 130, 180-190	10
1402	Prosarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure. 2018 , 39, 331-353	13
1401	A cohort study of cardiac resynchronization therapy in patients with chronic Chagas cardiomyopathy. 2018 , 20, 1717-1718	1
1400	Combined Angiotensin Receptor-Nephrilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure. 2018 , 7,	26
1399	A novel way to manage trastuzumab cardiotoxicity. 2018 , 81, 791-796	0
1398	Angiotensin receptor-nephrilysin inhibitor therapy in heart failure: An end that justifies the means. 2018 , 199, 176-177	
1397	Paramètres pronostiques de l'apnée cardiorespiratoire. 2018 , 2018, 8-12	
1396	Optimal Timing of Percutaneous Coronary Intervention in Patients With Non-ST-Segment Elevation Myocardial Infarction Complicated by Acute Decompensated Heart Failure (from the Korea Acute Myocardial Infarction Registry-National Institutes of Health [KAMIR-NIH]). 2018 , 121, 1285-1292	4
1395	Predicting cardiogenic pulmonary edema in heart failure patients by using an N-terminal pro-b-type natriuretic peptide (NT-pro BNP) -based score. 2018 , 480, 26-33	2
1394	Left ventricular lead implantation in cardiac resynchronization therapy (CRT): A challenging procedure. 2018 , 59, 34-35	0
1393	Sacubitril/valsartan: A novel angiotensin receptor-nephrilysin inhibitor. 2018 , 70 Suppl 1, S102-S110	8
1392	Short-term reconsultation, hospitalisation, and death rates after discharge from the emergency department in patients with acute heart failure and analysis of the associated factors. The ALTUR-ICA Study. 2018 , 150, 167-177	
1391	B-type natriuretic peptide may predict prognosis in older adults admitted with a diagnosis other than heart failure. 2018 , 28, 636-642	5
1390	Regarding the 2016 European guidelines for heart failure. 2018 , 218, 158-159	

1389	Multivessel vs. culprit-only revascularization in patients with non-ST-elevation acute coronary syndromes and multivessel coronary disease. 2018 , 37, 143-154	6
1388	Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions. 2018 , 137, 1060-1073	20
1387	Is galectin-3 a promoter of ventricular dysfunction?. 2018 , 26, 21-36	2
1386	Although Coronary Mortality Has Decreased, Rates of Cardiovascular Disease Remain High: 21 Years of Follow-Up Comparing Cohorts of Men Born in 1913 With Men Born in 1943. 2018 , 7,	10
1385	Prognostic value of N-Terminal Pro-B-Type Natriuretic Peptide in Takotsubo syndrome. 2018 , 107, 597-606	18
1384	Mortality prediction system for heart failure with orthogonal relief and dynamic radius means. 2018 , 115, 10-17	8
1383	Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator. 2018 , 71, 1897-1906	44
1382	Biomarkers for heart failure: small molecules with high clinical relevance. 2018 , 283, 530-543	58
1381	Sacubitril/Valsartan: From Clinical Trials to Real-world Experience. 2018 , 20, 45	5
1380	Nationwide Survey of Palliative Care for Patients With Heart Failure in Japan. 2018 , 82, 1336-1343	20
1379	Cardiac cachexia: addressing the challenge. 2018 , 13, 30-34	0
1378	Automatically computed ECG algorithm for the quantification of myocardial scar and the prediction of mortality. 2018 , 107, 824-835	2
1377	Influence of atrial fibrillation on the mortality of patients with heart failure with preserved ejection fraction. 2018 , 150, 376-382	
1376	Adaptive servo-ventilation to treat central sleep apnea in heart failure with reduced ejection fraction: the Bad Oeynhausen prospective ASV registry. 2018 , 107, 719-728	15
1375	Early Recognition of Heart Failure: A Call for Action. 2018 , 24, 310-312	
1374	N-terminal pro B-Type natriuretic peptide is inversely correlated with low density lipoprotein cholesterol in the very elderly. 2018 , 28, 629-635	9
1373	Machine Learning Analysis of Left Ventricular Function to Characterize Heart Failure With Preserved Ejection Fraction. 2018 , 11, e007138	57
1372	What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines. 2018 , 20, 39	21

1371	Real-world management of heart failure in the Netherlands : Improving quality of care by simple measures. 2018 , 26, 240-241		
1370	Can diaphragmatic breathing modify chest wall volumes during inspiratory loaded breathing in patients with heart failure?. 2018 , 22, 452-458		2
1369	Longitudinal evaluation of ventricular ejection fraction and NT-proBNP across heart failure subgroups. 2018 , 52, 205-210		6
1368	Long-term single-center comparison of ICD lead survival: Evidence for premature Linux lead failure. 2018 , 29, 1024-1031		8
1367	Early identification of acute heart failure at the time of presentation: do natriuretic peptides make the difference?. 2018 , 5, 309-315		6
1366	A tool for assessment of heart failure prescribing quality: A systematic review and meta-analysis. 2018 , 27, 685-694		6
1365	Creation of a restrictive atrial communication in heart failure with preserved and mid-range ejection fraction: effective palliation of left atrial hypertension and pulmonary congestion. 2018 , 107, 845-857		14
1364	The pathophysiology of myocardial infarction-induced heart failure. 2018 , 25, 277-284		36
1363	Association between heart failure with preserved ejection fraction and hypertensive retinopathy: more questions than answers!. 2018 , 32, 390-391		
1362	Novel heart failure biomarkers: why do we fail to exploit their potential?. 2018 , 55, 246-263		44
1361	Specific biomarkers of myocardial inflammation and remodeling processes as predictors of mortality in high-risk patients undergoing percutaneous mitral valve repair (MitraClip). 2018 , 41, 481-487		8
1360	The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more?. 2018 , 23, 631-639		18
1359	Potassium: an ion with dangerous airs and graces. <i>European Heart Journal</i> , 2018 , 39, 1543-1545	9.5	3
1358	Cardiac resynchronization therapy is associated with a reduction in ICD therapies as it improves ventricular function. 2018 , 41, 803-808		4
1357	Procalcitonin Monitoring as a Guide for Antimicrobial Therapy: A Review of Current Literature. 2018 , 38, 569-581		33
1356	"I was told that I would not die from heart failure": Patient perceptions of prognosis communication. 2018 , 41, 41-45		12
1355	Hypertrophic cardiomyopathy. 2018 , 150, 434-442		1
1354	[Heart Transplant and Destination Therapy - Update 2018]. 2018 , 143, 482-487		

1353	Acute HIV Infection Results in Subclinical Inflammatory Cardiomyopathy. 2018 , 218, 466-470	6
1352	Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction. 2018 , 5, 579-585	13
1351	[Mechanical circulatory support in terminal heart failure]. 2018 , 67, 326-335	2
1350	Cardiac resynchronization therapy response in heart failure patients with different subtypes of true left bundle branch block. 2018 , 52, 91-101	7
1349	Novel Insights and Treatment Strategies for Right Heart Failure. 2018 , 15, 141-155	6
1348	Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. 2018 , 126, 186-200	53
1347	Cardiovascular pharmacotherapy and real-world data. 2018 , 4, 65-66	5
1346	Exercise on-transition uncoupling of ventilatory, gas exchange and cardiac hemodynamic kinetics accompany pulmonary oxygen stores depletion to impact exercise intolerance in human heart failure. 2018 , 223, e13063	4
1345	Survival rate and predictors of mortality in patients hospitalised with heart failure: a cohort study on the data of Persian registry of cardiovascular disease (PROVE). 2018 , 94, 318-324	10
1344	Drug therapies in chronic heart failure: a focus on reduced ejection fraction. 2018 , 18, 138-145	7
1343	Sex-Specific Relations of Cardiovascular Risk Factors With Left Ventricular Diastolic Dysfunction/Heart Failure With Preserved Ejection Fraction Are Underreported: A Call for Action. 2018 , 24, 412-414	5
1342	Relationship between exercise intervention and NO pathway in patients with heart failure with preserved ejection fraction. 2018 , 23, 540-550	6
1341	Antibody-mediated rejection induced cardiogenic shock: Too late for conventional therapy. 2018 , 32, e13253	3
1340	[Atrial fibrillation as a comorbidity of heart failure]. 2018 , 59, 415-419	1
1339	Impact of heart failure and dialysis in the prognosis of diabetic patients with ischemic foot ulcers. 2018 , 11, 31-35	15
1338	Major unmet needs in the cardiovascular area. 2018 , 20, C4-C7	
1337	Genetic determinants of heart failure: facts and numbers. 2018 , 5, 211-217	15
1336	Renal Effects and Associated Outcomes During Angiotensin-Nepriylisin Inhibition in Heart Failure. 2018 , 6, 489-498	138

1335	Clinical and echocardiographic characteristics of patients in sinus rhythm, normal left ventricular function, and indeterminate diastolic function. 2018 , 35, 792-797	3
1334	Cycle length identifies obstructive sleep apnea and central sleep apnea in heart failure with reduced ejection fraction. 2018 , 22, 1093-1100	4
1333	Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. 2018 , 137, e578-e622	264
1332	Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. 2018 , 6, 353-363	56
1331	Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. 2018 , 93, 1281-1292	41
1330	Multivessel vs. culprit-only revascularization in patients with non-ST-elevation acute coronary syndromes and multivessel coronary disease. 2018 , 37, 143-154	3
1329	Mortality and Sudden Cardiac Death Risk Stratification Using the Noninvasive Combination of Wide QRS Duration and Late Gadolinium Enhancement in Idiopathic Dilated Cardiomyopathy. 2018 , 11, e006233	26
1328	A mixed methods study of Tai Chi exercise for patients with chronic heart failure aged 70 years and older. 2018 , 5, 176-185	10
1327	Incremental value of left atrial active function measured by speckle tracking echocardiography in patients with hypertrophic cardiomyopathy. 2018 , 35, 1138-1148	12
1326	Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. 2018 , 7,	79
1325	Position paper for the organization of ECMO programs for cardiac failure in adults. 2018 , 44, 717-729	162
1324	Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany. 2018 , 130, 308-316	16
1323	Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure. 2018 , 11, e004302	49
1322	Meta-Analysis Comparing Neurohumoral Antagonist Use in Patients \geq 5 Years Versus . 2018 , 121, 975-980	1
1321	Usefulness of Urinary N-Terminal Fragment of Titin to Predict Mortality in Dilated Cardiomyopathy. 2018 , 121, 1260-1265	10
1320	Validation of 2-year 123I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure. 2018 , 19, 749-756	15
1319	Effect of aerobic and resistance training on inflammatory markers in heart failure patients: systematic review and meta-analysis. 2018 , 23, 209-223	17
1318	Effect of carvedilol vs metoprolol succinate on mortality in heart failure with reduced ejection fraction. 2018 , 199, 1-6	8

1317	Addition or removal of guideline directed medical therapy in ambulatory patients with heart failure with reduced ejection fraction relative to change in symptom severity: An analysis from the PINNACLE (Practice Innovation and Clinical Excellence) Registry. 2018 , 254, 222-223	0
1316	Determinants of exercise intolerance in heart failure with preserved ejection fraction: A systematic review and meta-analysis. 2018 , 254, 224-229	7
1315	Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials. 2018 , 254, 215-221	17
1314	Predicting the future after acute myocardial infarction: A gaze into the crystal ball of gene expression profile. 2018 , 254, 47-48	1
1313	Change in Physiological Variables in the Last Two Weeks of Life: An Observational Study of Hospitalized Adults With Heart Failure. 2018 , 55, 1335-1340	3
1312	Treatment of type 2 diabetes mellitus in elderly patients. 2018 , 218, 74-88	22
1311	Selection of the Best of 2017 in Acute and Chronic Heart Failure. 2018 , 71, 298-299	
1310	Effect of Early Treatment With Ivabradine Plus Beta-blockers on Long-term Outcomes in Patients Hospitalized With Systolic Heart Failure. 2018 , 71, 1086-1088	1
1309	Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction. 2018 , 257, 188-192	23
1308	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME ² trial. <i>European Heart Journal</i> , 2018 , 39, 363-370	171
1307	Incremental prognostic value of multichamber deformation imaging and renal function status to predict adverse outcome in heart failure with reduced ejection fraction. 2018 , 35, 450-458	7
1306	The Emerging Role of Cardiac Magnetic Resonance Imaging in the Evaluation of Patients with HFpEF. 2018 , 15, 1-9	25
1305	Remote Monitoring for Chronic Disease Management: Atrial Fibrillation and Heart Failure. 2018 , 10, 43-58	2
1304	Utility of Left Atrial Expansion Index and Stroke Volume in Management of Chronic Systolic Heart Failure. 2018 , 31, 650-659.e1	9
1303	Echocardiographic risk markers of sudden death in patients with temporal lobe epilepsy. 2018 , 140, 192-197	24
1302	Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction. 2018 , 254, 203-209	9
1301	Objectively measured physical activity and cardiac biomarkers: A cross sectional population based study in older men. 2018 , 254, 322-327	1
1300	Natriuretic peptides. D'où venons-nous? Que sommes-nous? Où allons-nous?. 2018 , 254, 256-257	0

1299	Addition of Supervised Exercise Training to a Post-Hospital Disease Management Program for Patients Recently Hospitalized With Acute Heart Failure: The EJECTION-HF Randomized Phase 4 Trial. 2018 , 6, 143-152		23
1298	Guía ESC/EACTS 2017 sobre el tratamiento de las valvulopatías. 2018 , 71, 110.e1-110.e47		22
1297	[Treatment of type 2 diabetes mellitus in elderly patients]. 2018 , 53, 89-99		8
1296	Klinische Erkenntnisse zu moderner i.v.-Eisentherapie. 2018 , 47, 12-20		
1295	GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischæmic, dilated cardiomyopathy than soluble ST2. 2018 , 22, 2422-2429		16
1294	Kerala acute heart failure registry-Rationale, design and methods. 2018 , 70 Suppl 1, S118-S120		2
1293	Heart failure with preserved ejection fraction as an independent risk factor of mortality after cardiothoracic surgery. 2018 , 156, 188-193.e2		3
1292	New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors. 2018 , 32, 99-119		15
1291	Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. <i>European Heart Journal</i> , 2018 , 39, 864-873	9.5	83
1290	Hyporesponsiveness to Darbeoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbeoetin Alfa in Heart Failure): Clinical and Prognostic Associations. 2018 , 11, e004431		7
1289	[Chronic heart failure in older patients : Updated national healthcare guidelines on chronic heart failure from a geriatric perspective]. 2018 , 51, 165-168		1
1288	Noninvasive pulse contour analysis for determination of cardiac output in patients with chronic heart failure. 2018 , 107, 395-404		9
1287	Socioeconomic status and outcomes in heart failure with reduced ejection fraction. 2018 , 104, 966-967		6
1286	Optimizing Management of Heart Failure by Using Echo and Natriuretic Peptides in the Outpatient Unit. 2018 , 1067, 145-159		6
1285	Adaptive servo-ventilation and sleep quality in treatment emergent central sleep apnea and central sleep apnea in patients with heart disease and preserved ejection fraction. 2018 , 107, 421-429		13
1284	Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. <i>European Heart Journal</i> , 2018 , 39, 1770-1780	9.5	123
1283	Assessment of left ventricular dyssynchrony by three-dimensional echocardiography: Prognostic value in patients undergoing cardiac resynchronization therapy. 2018 , 29, 780-787		4
1282	Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients-a systematic review and meta-analysis. 2018 , 23, 181-190		7

1281	Preoperative platelet transfusions to reverse antiplatelet therapy for urgent non-cardiac surgery: an observational cohort study. 2018 , 16, 709-717	14
1280	Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. 2018 , 11, e004519	72
1279	Circulating Biomarkers in Heart Failure. 2018 , 1067, 89-108	12
1278	Importance of comorbidities in the treatment of primary care patients with heart failure-Baseline results of the observational RECODE-HF Study. 2018 , 35, 481-487	5
1277	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis. 2018 , 137, 286-297	102
1276	The clinical relevance of drug-drug interaction between co-trimoxazole and sacubitril/valsartan treatment in a heart failure patient: a case report and overview of mechanisms and management in clinical practice. 2018 , 107, 524-526	1
1275	Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study. 2018 , 5, 337-343	30
1274	Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism. 2018 , 10,	66
1273	Heart Failure with Preserved Ejection Fraction. 2018 , 69, 65-79	33
1272	Evolving Role of Natriuretic Peptides from Diagnostic Tool to Therapeutic Modality. 2018 , 1067, 109-131	8
1271	Pharmacological treatments for heart failure with preserved ejection fraction-a systematic review and indirect comparison. 2018 , 23, 147-156	21
1270	Combination of the best pacing configuration and atrioventricular and interventricular delays optimization in cardiac resynchronization therapy. 2018 , 41, 362-367	4
1269	Relationship of loop diuretic use with exercise intolerance in heart failure with preserved ejection fraction. 2018 , 4, 138-141	5
1268	Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors. <i>European Heart Journal</i> , 2018 , 39, 1835-1847	9.5 84
1267	Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity. 2018 , 71, 599-608	64
1266	A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets. 2018 , 258, 203-204	
1265	Heart Failure: Optimizing Recognition and Management in Outpatient Settings. 2018 , 45, 63-79	1
1264	Native T1 and ECV of Noninfarcted Myocardium and Outcome in Patients With Coronary Artery Disease. 2018 , 71, 766-778	62

1263	The Burden of Iron Deficiency in Heart Failure: Therapeutic Approach. 2018 , 71, 782-793	52
1262	The angiotensin type 2 receptor in the human adrenocortical zona glomerulosa and in aldosterone-producing adenoma: low expression and no functional role. 2018 , 132, 627-640	10
1261	Predicting new-onset HF in patients undergoing coronary or peripheral angiography: results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. 2018 , 5, 240-248	5
1260	Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. 2018 , 32, 289-299	48
1259	Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction. 2018 , 12, 1179546817751609	13
1258	Gender-related differences in heart failure with preserved ejection fraction. 2018 , 8, 1080	36
1257	Reduced stroke distance of the left ventricular outflow tract is independently associated with long-term mortality, in patients hospitalized due to heart failure. 2018 , 38, 881-888	4
1256	Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF). 2018 , 5, 344-353	14
1255	Frailty Assessment in Heart Failure: an Overview of the Multi-domain Approach. 2018 , 15, 17-23	12
1254	Hypertrophic cardiomyopathy. 2018 , 150, 434-442	4
1253	Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension. 2018 , 36, 987-994	10
1252	Long-term prognostic value of combined free triiodothyronine and late gadolinium enhancement in nonischemic dilated cardiomyopathy. 2018 , 41, 96-103	3
1251	Can available mathematical models predict serum digoxin levels in Thai patients?. 2018 , 43, 377-384	2
1250	Heart failure with improved ejection fraction: Is a newcomer in the family important?. 2018 , 25, 362-365	0
1249	Chemotherapy and echocardiographic indices in patients with non-Hodgkin lymphoma: the ONCO-ECHO study. 2017 , 35, 14	4
1248	Does presence of left ventricular contractile reserve improve response to cardiac resynchronization therapy? An updated meta-analysis. 2018 , 252, 224-228	1
1247	Implementation of smart technology to improve medication adherence in patients with cardiovascular disease: is it effective?. 2018 , 15, 119-126	22
1246	Accuracy, user-friendliness and usefulness of the Cobas h232 point-of-care test for NT-proBNP in primary care. 2018 , 71, 539-545	7

1245	Impact of Complete Revascularization on Six-Year Clinical Outcomes and Incidence of Acute Decompensated Heart Failure in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease. 2018 , 121, 544-551	2
1244	Evidence for the use of mineralocorticoid receptor antagonists in the treatment of coronary artery disease and post-angioplasty restenosis. 2017 , 107, 20-20	7
1243	The role of beta-blockers in the management of chronic obstructive pulmonary disease. 2018 , 12, 125-135	7
1242	Heart Failure With Preserved Ejection Fraction-A Systematic Review and Analysis of Perioperative Outcomes. 2018 , 32, 2423-2434	3
1241	Management of acute heart failure in adult patients with congenital heart disease. 2018 , 23, 1-14	17
1240	One-year in vitro stability of cardiac troponins and galectin-3 in different sample types. 2018 , 476, 117-122	23
1239	Increased dose of diuretics correlates with severity of heart failure and renal dysfunction and does not lead to reduction of mortality and rehospitalizations due to acute decompensation of heart failure; data from AHEAD registry. 2018 , 60, e215-e223	3
1238	Female gender and mortality risk in decompensated heart failure. 2018 , 51, 34-40	9
1237	Duration of extracorporeal membrane oxygenation support and survival in cardiovascular surgery patients. 2018 , 155, 2471-2476	23
1236	Women-specific risk factors for heart failure: A genetic approach. 2018 , 109, 104-111	3
1235	Serum vitamin D deficiency and risk of hospitalization for heart failure: Prospective results from the Moli-sani study. 2018 , 28, 298-307	16
1234	About European guidelines for heart failure 2016. 2018 , 218, 158-159	
1233	Influenza vaccination and heart failure. A priority field of improvement. 2018 , 218, 159-161	
1232	Replay to «About European guidelines for heart failure 2016». 2018 , 218, 157-158	
1231	Selection of the Best of 2017 in Clinical Cardiology. Continuum Healthcare Between Cardiology and Primary Care. 2018 , 71, 59	
1230	Alfabetizaci3n en salud y resultados de salud en pacientes muy ancianos con insuficiencia cardiaca. 2018 , 71, 178-184	7
1229	Selecci3n de lo mejor del a3o 2017 en insuficiencia cardiaca aguda y cr3nica. 2018 , 71, 298-299	2
1228	[Rehabilitation in elderly frail patients with acute heart failure. Training in REHAB-HF Pilot Study]. 2018 , 53, 63-65	0

1227	Rationale and design of the IMPACT EU-trial: improve management of heart failure with procalcitonin biomarkers in cardiology (BIC)-18. 2018 , 23, 97-103	4
1226	Impact of a 'stent for life' initiative on post-ST elevation myocardial infarction heart failure: a 15 year heart failure clinic experience. 2018 , 5, 101-105	2
1225	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). 2018 , 168, 631-638	35
1224	Assessment of potential heart donors: A statement from the French heart transplant community. 2018 , 111, 126-139	11
1223	The myocardial bright signal: The arrhythmogenic link between function and myocardial fibrosis. 2018 , 254, 258-259	
1222	Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM-HFpEF study. 2018 , 5, 95-100	24
1221	Effects of the intensity of prehospital treatment on short-term outcomes in patients with acute heart failure: the SEMICA-2 study. 2018 , 107, 347-361	23
1220	Mortality after an episode of acute heart failure in a cohort of patients with intermediate ventricular function: Global analysis and relationship with admission department. 2018 , 151, 223-230	3
1219	Quality of inclusion criteria in the registered clinical trials of heart failure with preserved ejection fraction: Is it time for a change?. 2018 , 254, 210-214	4
1218	Cardioprotective effect of influenza and pneumococcal vaccination in patients with cardiovascular diseases. 2018 , 36, 202-206	25
1217	Determinants and Prognostic Impact of Heart Failure and Left Ventricular Ejection Fraction in Acute Coronary Syndrome Settings. 2018 , 71, 820-828	5
1216	Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERTIary Cardiological cEnTer (TERCET) Registry. 2018 , 132, 204-210	13
1215	Incidence and Predictors of Postoperative Need for High-Dose Inotropic Support in Patients Undergoing Cardiac Surgery for Infective Endocarditis. 2018 , 32, 2528-2536	7
1214	Nebivolol attenuates oxidative stress and inflammation in a guinea pig model of ovalbumin-induced asthma: a possible mechanism for its favorable respiratory effects. 2018 , 96, 258-265	6
1213	Rationale and design of the comParlson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. 2018 , 198, 145-151	42
1212	Impact of nutritional indices on mortality in patients with heart failure. 2018 , 5, e000730	72
1211	Takotsubo cardiomyopathy in a young adult with transplanted heart: what happened to denervation?. 2018 , 5, 197-200	11
1210	Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. 2018 , 8, 635	133

1209	Pulsatile Hemodynamics Are Associated With Exercise Capacity in Patients With Exertional Dyspnea and Preserved Left Ventricular Ejection Fraction. 2018 , 31, 574-581		1
1208	Efficient selective screening for heart failure in elderly men and women from the community: A diagnostic individual participant data meta-analysis. 2018 , 25, 437-446		10
1207	Current use of beta-blockers in patients with coronary artery disease. 2018 , 28, 382-389		6
1206	Effectiveness of guideline-consistent heart failure drug prescriptions at hospital discharge on 1-year mortality: Results from the EPICAL2 cohort study. 2018 , 51, 53-60		6
1205	Heart failure with mid-range ejection fraction in patients admitted to internal medicine departments: Findings from the RICA Registry. 2018 , 255, 124-128		25
1204	Fulminant giant-cell myocarditis on mechanical circulatory support: Management and outcomes of a French multicentre cohort. 2018 , 253, 105-112		23
1203	Influenza vaccination and heart failure. A priority field for improvement. 2018 , 218, 159-161		
1202	Identification of capillary rarefaction using intracoronary wave intensity analysis with resultant prognostic implications for cardiac allograft patients. <i>European Heart Journal</i> , 2018 , 39, 1807-1814	9.5	10
1201	Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease. 2018 , 255, 111-117		16
1200	Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. 2018 , 31, 407-414		20
1199	Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaeamic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials. 2018 , 20, f211-f216		5
1198	Comprehensive review of cardiovascular toxicity of drugs and related agents. 2018 , 38, 1332-1403		90
1197	Optimal course of treatment in acute cardiogenic shock complicating myocardial infarction. 2018 , 16, 99-112		7
1196	Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment. 2018 , 23, 469-479		4
1195	Long-Term Survival With Implantable Cardioverter-Defibrillator in Different Symptomatic Functional Classes of Heart Failure. 2018 , 121, 615-620		8
1194	Long-Term Prognostic Significance of Plasma B-Type Natriuretic Peptide Level in Patients With Acute Heart Failure With Reduced, Mid-Range, and Preserved Ejection Fractions. 2018 , 121, 731-738		24
1193	Long-term clinical outcomes in patients with cardiogenic shock according to left ventricular function: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) programme. 2018 , 111, 678-685		5
1192	Indications and practical approach to non-invasive ventilation in acute heart failure. <i>European Heart Journal</i> , 2018 , 39, 17-25	9.5	65

1191	Heart failure subgroups: HF _r EF, HF _{mr} EF, and HF _p EF with or without mitral regurgitation. <i>European Heart Journal</i> , 2018 , 39, 1-4	9.5	15
1190	Diagnostic and therapeutic approach to the hypertensive crisis. 2018 , 150, 317-322		3
1189	Impact of the 2016 ASE/EACVI recommendations on the prevalence of diastolic dysfunction in the general population. 2018 , 19, 380-386		83
1188	Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2018 , 39, 840-849	9.5	220
1187	Aiming at the appropriate target for the treatment of pulmonary hypertension due to left heart disease. <i>European Heart Journal</i> , 2018 , 39, 1265-1268	9.5	10
1186	The year in cardiology 2017: arrhythmias and cardiac devices. <i>European Heart Journal</i> , 2018 , 39, 434-441	9.5	3
1185	Adverse impact of diabetes mellitus on left ventricular remodelling in patients with chronic primary mitral regurgitation. 2018 , 111, 487-496		4
1184	Effect of Optimization of Medical Treatment on Long-Term Survival of Patients With Heart Failure After Implantable Cardioverter Defibrillator and Cardiac Resynchronization Device Implantation (from the French National EGB Database). 2018 , 121, 725-730		6
1183	Selección de lo mejor del año 2017 en cardiología clínica. Continuidad asistencial entre cardiología y atención primaria. 2018 , 71, 59		2
1182	Heart failure with preserved ejection fraction: controversies, challenges and future directions. 2018 , 104, 377-384		53
1181	N-terminal pro-B-type natriuretic peptide for monitoring after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. 2018 , 37, 639-646		31
1180	The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin. <i>European Heart Journal</i> , 2018 , 39, 1794-1798	9.5	21
1179	Adding ivabradine to beta-blockers in chronic heart failure: Do not rest without lowering the resting heart rate sufficiently. 2018 , 70, 201-203		3
1178	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. 2018 , 265, 141-147		26
1177	Mode of initiation and clinical significance of malignant rapid ventricular arrhythmias: An observational study. 2018 , 97, e0660		1
1176	Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in heart failure with preserved ejection fraction - implications for clinical trials. 2018 , 20, 4		40
1175	Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial. 2018 , 19, 103		3
1174	Time trends in characteristics, clinical course, and outcomes of 13,791 patients with acute heart failure. 2018 , 107, 897-913		42

1173	Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting. 2018 , 18, 52	13
1172	Predictive potential of macrophage migration inhibitory factor (MIF) in patients with heart failure with preserved ejection fraction (HFpEF). 2018 , 23, 22	8
1171	Chronic heart failure - Impact of the condition on patients and the healthcare system in the Czech Republic: A retrospective cost-of-illness analysis. 2018 , 60, e224-e233	3
1170	Pulmonary Capillary Wedge Pressure Patterns During Exercise Predict Exercise Capacity and Incident Heart Failure. 2018 , 11, e004750	71
1169	ASB1 differential methylation in ischaemic cardiomyopathy: relationship with left ventricular performance in end-stage heart failure patients. 2018 , 5, 732-737	7
1168	Outcome of patients with cardiac amyloidosis admitted to an intensive care unit for acute heart failure. 2018 , 111, 582-590	13
1167	Troponins: established and novel indications in the management of cardiovascular disease. 2018 , 104, 1714-1722	7
1166	Cost-Effectiveness Benefits of a Disease Management Program:The REMADHE Trial Results. 2018 , 24, 627-637	4
1165	Long-term results of combined cardiac contractility modulation and subcutaneous defibrillator therapy in patients with heart failure and reduced ejection fraction. 2018 , 41, 518-524	8
1164	LV function validation of computer-assisted interventional system for cardiac resynchronisation therapy. 2018 , 13, 777-786	
1163	Cardiomyopathies rythmiques. 2018 , 2018, 2-9	
1162	Treatment of Cardiovascular Diseases Among Elderly Residents of Long-term Care Facilities. 2018 , 19, 428-432	8
1161	The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy: A Review and Meta-Analysis. 2018 , 11, 1274-1284	109
1160	Global Longitudinal Strain: Ready for Clinical Use and Guideline Implementation. 2018 , 71, 1958-1959	13
1159	Cardiac function during weaning failure: the role of diastolic dysfunction. 2018 , 8, 2	13
1158	Fate of Acute Heart Failure Patients With Mid-Range Ejection Fraction. 2018 , 82, 2071-2078	8
1157	Mechanical assist devices for acute cardiogenic shock. 2018 ,	1
1156	The effect of exercise training in symptomatic patients with grown-up congenital heart disease: a review. 2018 , 16, 379-386	6

1155	Essential Elements of Early Post Discharge Care of Patients with Heart Failure. 2018 , 15, 181-190	4
1154	When more is less and less is more: Is there an additional value of NT-proBNP in risk stratification in heart failure?. 2018 , 25, 885-888	3
1153	[Cardio-renal axis : Relationship of heart failure and renal insufficiency as comorbidities]. 2018 , 59, 420-427	1
1152	Short-term outcomes of heart failure patients with reduced and preserved ejection fraction after acute decompensation according to the final destination after emergency department care. 2018 , 107, 698-710	12
1151	Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction. 2018 , 24, 365-374	19
1150	Incidence and predictors of 6 months mortality after an acute heart failure event in rural Uganda: The Mbarara Heart Failure Registry (MAHFER). 2018 , 264, 113-117	7
1149	Body composition in acute heart failure patients: Relationship with gender and left ventricular ejection fraction. 2018 , 151, 291-292	
1148	[Digoxin in reduced heart failure and sinus rhythm. When should it be indicated in 2018?]. 2018 , 53, 119-120	2
1147	Outcomes of Heart Transplant Recipients With Preexisting Malignancies. 2018 , 50, 2738-2741	0
1146	RESONANCIA MAGNÉTICA CARDÍACA: NUEVOS DESARROLLOS Y PERSPECTIVAS FUTURAS. 2018 , 29, 44-53	
1145	[Management of heart failure in cardiology and primary care (MICCAP) program: Improving the management of patients with heart failure]. 2018 , 44, 572-578	4
1144	In-depth haemodynamic phenotyping of pulmonary hypertension due to left heart disease. 2018 , 51,	11
1143	Role of NT-proANP and NT-proBNP in patients with atrial fibrillation: Association with atrial fibrillation progression phenotypes. 2018 , 15, 1132-1137	30
1142	Outcome of clinical management in relatives of sudden cardiac death victims. 2018 , 262, 45-50	8
1141	Identifying novel phenotypes of acute heart failure using cluster analysis of clinical variables. 2018 , 262, 57-63	33
1140	Impact of catheter ablation of atrial fibrillation on long-term clinical outcomes in patients with heart failure. 2018 , 72, 240-246	27
1139	Sources of Variability in the Detection of B-Lines, Using Lung Ultrasound. 2018 , 44, 1212-1216	17
1138	A rabbit model of progressive chronic right ventricular pressure overload. 2018 , 26, 673-680	3

1137	Expanded algorithm for managing patients with acute decompensated heart failure. 2018 , 23, 597-607	4
1136	Heart Failure with Recovered EF and Heart Failure with Mid-Range EF: Current Recommendations and Controversies. 2018 , 20, 35	7
1135	Addition of Digoxin Improves Cardiac Function in Children With the Dilated Cardiomyopathy With Ataxia Syndrome: A Mitochondrial Cardiomyopathy. 2018 , 34, 972-977	7
1134	A single-center observational study on the efficacy of percutaneous coronary intervention for ischemic heart failure: A cohort study. 2018 , 97, e0238	
1133	Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events. 2018 , 24, 3803-3812	28
1132	Combination Therapy of Renin Angiotensin System Inhibitors and β Blockers in Patients with Heart Failure. 2018 , 1067, 17-30	6
1131	Effects of glycemic control on in-hospital mortality among acute heart failure patients with reduced, mid-range, and preserved ejection fraction. 2018 , 33, 1022-1028	1
1130	Heart failure in sub-Saharan Africa: A contemporaneous systematic review and meta-analysis. 2018 , 257, 207-215	54
1129	Resultados a largo plazo del tratamiento precoz con ivabradina más bloqueadores beta en pacientes hospitalizados por insuficiencia cardiaca sistólica. 2018 , 71, 1086-1088	3
1128	Strain for Relaxation in the Operating Room?. 2018 , 32, 1305-1307	1
1127	Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation. 2018 , 20, 32	16
1126	Implanted Pacemakers Indications and Novel Programming. 2018 , 77-86	1
1125	Recent major advances in cardiovascular pharmacotherapy. 2018 , 74, 853-862	3
1124	An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER). 2018 , 32, 183-190	4
1123	Can Nuclear Imaging Techniques Predict Patient Outcome and Guide Medical Management in Hereditary Transthyretin Cardiac Amyloidosis?. 2018 , 20, 33	4
1122	Ablation of the stress protease OMA1 protects against heart failure in mice. 2018 , 10,	41
1121	Cardiac resynchronization therapy in the Czech Republic - Data from the EHRA CRT Survey II multicenter registry. 2018 , 60, e622-e630	
1120	Determinantes e impacto pronóstico de la insuficiencia cardiaca y la fracción de eyección del ventrículo izquierdo en el síndrome coronario agudo. 2018 , 71, 820-828	8

1119	Atrial fibrillation, a difficulty in the heart failure screening with natriuretic peptides. 2018 , 104, 1236-1237	
1118	[Chronic heart failure and depression]. 2018 , 59, 445-452	7
1117	Dyspnoe bei Diabetes und Herzinsuffizienz. 2018 , 14, 36-43	1
1116	Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. 2018 , 24, 281-302	160
1115	Natriuretic peptide B plasma concentration increases in the first 12 h of pulmonary edema recovery. 2018 , 53, 52-56	1
1114	Reduction of systemic inflammation after cardiac resynchronization therapy: A new form of response?. 2018 , 37, 115-116	
1113	Systolic pulmonary artery pressure assessed during routine exercise Doppler echocardiography: insights of a real-world setting in patients with elevated pulmonary pressures. 2018 , 34, 1215-1225	1
1112	Current Management and Future Directions of Heart Failure With Preserved Ejection Fraction: a Contemporary Review. 2018 , 20, 28	11
1111	Effects on short term outcome of non-invasive ventilation use in the emergency department to treat patients with acute heart failure: A propensity score-based analysis of the EAHFE Registry. 2018 , 53, 45-51	9
1110	Surfactant proteins changes after acute hemodynamic improvement in patients with advanced chronic heart failure treated with Levosimendan. 2018 , 252-253, 47-51	7
1109	Opportunistic screening for heart failure with natriuretic peptides in patients with atrial fibrillation: a meta-analysis of individual participant data of four screening studies. 2018 , 104, 1236-1237	10
1108	Cardiac magnetic resonance imaging and primary prevention implantable cardioverter defibrillator therapy: current recommendations and future directions. 2018 , 19, 223-228	4
1107	Inferential characterization of the dose-response relationships of neurohormonal antagonists in chronic heart failure: A novel approach based on large-scale trials with active comparators. 2018 , 261, 130-133	4
1106	Attractor landscape analysis of the cardiac signaling network reveals mechanism-based therapeutic strategies for heart failure. 2018 , 10, 180-194	6
1105	N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure. 2018 , 25, 889-895	11
1104	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. 2018 , 24, 313-320	33
1103	Characteristics and outcome for heart failure patients with mid-range ejection fraction. 2018 , 19, 297-303	9
1102	Decreased blood glucose at admission has a prognostic impact in patients with severely decompensated acute heart failure complicated with diabetes mellitus. 2018 , 33, 1008-1021	3

1101	Resynchronization therapy in heart failure: the 'nonresponder'. 2018 , 19 Suppl 1, e112-e115	3
1100	Ablation for persistent atrial fibrillation in patients with heart failure: is it underutilized?. 2018 , 19 Suppl 1, e99-e102	
1099	Bradyarrhythmias and pacemakers. 2018 , 360, k642	2
1098	Wet is bad: Residual congestion predicts worse prognosis in acute heart failure. 2018 , 258, 201-202	4
1097	Hyponatremia as a surrogate marker for optimal diuretic selection in acute heart failure. 2018 , 71, 547-549	3
1096	Reply to Regarding the 2016 European guidelines for heart failure 2018 , 218, 157-158	
1095	Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction. 2018 , 272, 137-144	22
1094	European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRs) and Latin American Heart Rhythm Society (LAHRS). 2018 , 20, 895-896	13
1093	Cardiac unloading by LVAD support differentially influences components of the cGMP-PKG signaling pathway in ischemic and dilated cardiomyopathy. 2018 , 33, 948-957	4
1092	Relation of Testosterone Levels to Mortality in Men With Heart Failure. 2018 , 121, 1321-1327	15
1091	Arrhythmic Risk Stratification in Patients With Idiopathic Dilated Cardiomyopathy. 2018 , 121, 1601-1609	21
1090	"Primary" dilated hearts. 2018 , 257, 366-370	3
1089	Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis. 2018 , 23, 547-553	4
1088	The association between plasma big endothelin-1 levels at admission and long-term outcomes in patients with atrial fibrillation. 2018 , 272, 1-7	10
1087	Alcohol puts the heart under pressure: Acetaldehyde activates a localized renin angiotensin aldosterone system within the myocardium in alcoholic cardiomyopathy. 2018 , 257, 220-221	5
1086	Social determinants are crucial factors in the long-term prognosis of severely decompensated acute heart failure in patients over 75 years of age. 2018 , 72, 140-148	10
1085	Diagnostic and therapeutic approach to the hypertensive crisis. 2018 , 150, 317-322	
1084	Evolution of secondary mitral regurgitation. 2018 , 19, 622-629	26

1083	New Innovations in Treatment and Monitoring of Heart Failure With Guidelines on the Use of Sacubitril/Valsartan and Ivabradine. 2018 , 25, e92-e103		
1082	Myocardial I-MIBG scintigraphy in relation to markers of inflammation and long-term clinical outcome in patients with stable chronic heart failure. 2018 , 25, 845-853		5
1081	Novel electrocardiographic dyssynchrony criteria improve patient selection for cardiac resynchronization therapy. 2018 , 20, 97-103		15
1080	Polymorphism of SLC6A2 gene does not influence outcome of myocardial I-MIBG scintigraphy in patients with chronic heart failure. 2018 , 25, 900-906		1
1079	Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. <i>European Heart Journal</i> , 2018 , 39, 2793-2799	9.5	19
1078	Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study. 2018 , 4, 82-92		7
1077	Assessment of early treatment response by rapid cardiothoracic ultrasound in acute heart failure: Cardiac filling pressures, pulmonary congestion and mortality. 2018 , 7, 311-320		21
1076	Imaging of cardiac sympathetic activity in heart failure: Not out of the woods yet. 2018 , 25, 1172-1177		2
1075	Specifics of fetuin-A levels in distinct types of chronic heart failure. 2018 , 32,		8
1074	Plasma volume status predicts prognosis in patients with acute heart failure syndromes. 2018 , 7, 330-338		28
1073	Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. <i>European Heart Journal</i> , 2018 , 39, 503-507	9.5	67
1072	The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: insight from Danish nationwide registers. 2018 , 20, 301-307		4
1071	Strategies to address the shortcomings of commonly used advanced chronic heart failure descriptors to improve recruitment in palliative care research: A parallel mixed-methods feasibility study. 2018 , 32, 517-524		3
1070	Isolated Right Ventricular Mechanical Support: Outcomes and Prognosis. 2018 , 64, e20-e27		6
1069	High sensitivity troponin T and I reflect left atrial function being assessed by cardiac magnetic resonance imaging. 2018 , 55, 264-275		2
1068	Validation of echocardiographic criteria for the clinical diagnosis of heart failure in chronic kidney disease. 2018 , 33, 653-660		6
1067	Opioids for the treatment of dyspnoea in patients with chronic heart failure. 2018 , 60, e89-e93		1
1066	Health Literacy and Health Outcomes in Very Old Patients With Heart Failure. 2018 , 71, 178-184		7

1065	Effects of a mindfulness-based intervention on symptoms and signs in chronic heart failure: A feasibility study. 2018 , 17, 54-65		15
1064	Baseline serum bicarbonate levels independently predict short-term mortality in critically ill patients with ischaemic cardiogenic shock. 2018 , 7, 45-52		18
1063	A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort. 2018 , 5, 19-26		7
1062	Short-term reconsultation, hospitalisation, and death rates after discharge from the emergency department in patients with acute heart failure and analysis of the associated factors. The ALTUR-ICA Study. 2018 , 150, 167-177		1
1061	Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. <i>European Heart Journal</i> , 2018 , 39, 39-46	9.5	156
1060	EBlockers on Discharge From Acute Atrial Fibrillation Are Associated With Decreased Mortality and Lower Cerebrovascular Accidents in Patients With Heart Failure and Reduced Ejection Fraction. 2018 , 69, 316-322		1
1059	[Current developments in telemedicine : Expectations, disappointments and hopes]. 2018 , 43, 364-366		
1058	Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and N-terminal pro-brain natriuretic peptide. 2018 , 32,		4
1057	Challenges in Destination LVAD Therapy, Management of Mediastinitis and Device Infection, a Case Report. 2018 , 27, e7-e10		2
1056	Anomalous left coronary artery from the pulmonary artery: A rare case diagnosed in an adult. 2018 , 60, e412-e417		0
1055	Brain Natriuretic Peptide mediates the prognostic role of renal function toward 10-year cardiovascular mortality in patients with Acute Coronary Syndrome: the HHF study (2006-2016). 2018 , 59, 110-118		3
1054	Patterns of self-care and clinical events in a cohort of adults with heart failure: 1 year follow-up. 2018 , 47, 40-46		63
1053	Use of 'ideal' alveolar air equations and corrected end-tidal PCO to estimate arterial PCO and physiological dead space during exercise in patients with heart failure. 2018 , 250, 176-182		8
1052	De novo implantation vs. upgrade cardiac resynchronization therapy: a systematic review and meta-analysis. 2018 , 23, 15-26		19
1051	Automatic initialization and quality control of large-scale cardiac MRI segmentations. 2018 , 43, 129-141		35
1050	Atrial fibrillation and cardiac resynchronization therapy. 2018 , 33, 1-6		3
1049	Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. 2018 , 15, 14-23		11
1048	Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. 2018 , 250, 195-200		17

1047	2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. 2018 , 53, 5-33		183
1046	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2018 , 39, 119-177	9.5	4237
1045	Fructose metabolism, cardiometabolic risk, and the epidemic of coronary artery disease. <i>European Heart Journal</i> , 2018 , 39, 2497-2505	9.5	38
1044	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. <i>European Heart Journal</i> , 2018 , 39, 26-35	9.5	245
1043	Home-based telerehabilitation in older patients with chronic obstructive pulmonary disease and heart failure: a randomised controlled trial. 2018 , 47, 82-88		61
1042	Milrinone Dosing and a Culture of Caution in Clinical Practice. 2018 , 26, 35-42		16
1041	Usefulness of lung ultrasound in the management of patients with heart failure. 2018 , 13, 11-12		
1040	Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide. 2018 , 121, 107-112		16
1039	Implantable cardioverter-defibrillator-computed respiratory disturbance index accurately identifies severe sleep apnea: The DASAP-HF study. 2018 , 15, 211-217		12
1038	A systematic review of heart failure dyadic self-care interventions focusing on intervention components, contexts, and outcomes. 2018 , 77, 232-242		42
1037	Getting to the Heart of the Matter: What is the Landscape of Exercise Rehabilitation for People With Heart Failure in Australia?. 2018 , 27, 1350-1356		5
1036	Heart failure management with ambulatory pulmonary artery pressure monitoring. 2018 , 28, 212-219		6
1035	Reactive oxygen species signalling in the diabetic heart: emerging prospect for therapeutic targeting. 2018 , 104, 293-299		80
1034	Focused echocardiography and lung ultrasound protocol for guiding treatment in acute heart failure. 2018 , 5, 120-128		34
1033	Prognostic value of selected echocardiographic, impedance cardiographic, and hemodynamic parameters determined during right heart catheterization in patients qualified for heart transplantation. 2018 , 33, 180-190		2
1032	Geriatric Medicine. 2018 ,		
1031	Epidemiology of Left Ventricular Systolic Dysfunction and Heart Failure in the Framingham Study: An Echocardiographic Study Over 3 Decades. 2018 , 11, 1-11		95
1030	Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. 2018 , 137, 1320-1330		76

1029	Prevalence and characteristics of coronary artery disease in heart failure with preserved and mid-range ejection fractions: A systematic angiography approach. 2018 , 111, 109-118	13	
1028	Routes to diagnosis of heart failure: observational study using linked data in England. 2018 , 104, 600-605	29	
1027	High validity of cardiomyopathy diagnoses in western Sweden (1989-2009). 2018 , 5, 233-240	8	
1026	Coronary angiography in heart failure: when and why? Uncertainty reigns. 2018 , 104, 548-549	1	
1025	Practical management of concomitant acute heart failure and worsening renal function in the emergency department. 2018 , 25, 229-236	6	
1024	Outcomes of de novo and acute decompensated heart failure patients according to ejection fraction. 2018 , 104, 525-532	26	
1023	Mechanical dispersion is associated with poor outcome in heart failure with a severely depressed left ventricular function and bundle branch blocks. 2018 , 50, 128-138	6	
1022	Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Diagnosing and Ranking Its Causes Using Personalized O Pathway Analysis. 2018 , 137, 148-161	95	
1021	The Utility of a Wireless Implantable Hemodynamic Monitoring System in Patients Requiring Mechanical Circulatory Support. 2018 , 64, 301-308	19	
1020	Prognostic benefit of maintaining the hemoglobin level during the acute phase in patients with severely decompensated acute heart failure. 2018 , 33, 264-278	3	
1019	Therapeutic drug monitoring of digoxin-20 years of experience. 2018 , 70, 184-189	15	
1018	Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. 2018 , 20, 295-303	41	
1017	Design of a nationwide survey on palliative care for end-stage heart failure in Japan. 2018 , 71, 202-211	8	
1016	Serial Assessment of Natriuretic Peptides in Patients Undergoing Interventional Closure of the Left Atrial Appendage. 2018 , 27, 828-834	7	
1015	Empagliflozin across the stages of diabetic heart disease. <i>European Heart Journal</i> , 2018 , 39, 371-373	9.5	6
1014	Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application. 2018 , 23, 89-97	3	
1013	Psychometric Properties of the 9-item European Heart Failure Self-care Behavior Scale Using Confirmatory Factor Analysis and Rasch Analysis Among Iranian Patients. 2018 , 33, 281-288	25	
1012	Transcatheter aortic valve implantation in lower-risk patients: what is the perspective?. <i>European Heart Journal</i> , 2018 , 39, 658-666	9.5	42

1011	New echocardiographic parameters in the diagnosis of heart failure with preserved ejection fraction. 2018 , 34, 229-235	3
1010	[Cardiovascular rehabilitation and prevention guideline update]. 2018 , 168, 2-6	
1009	Early decrease of oxidative stress by non-invasive ventilation in patients with acute respiratory failure. 2018 , 13, 183-190	5
1008	Renal function monitoring in heart failure - what is the optimal frequency? A narrative review. 2018 , 84, 5-17	8
1007	Clinical practices and attitudes regarding the diagnosis and management of heart failure: findings from the CORE Needs Assessment Survey. 2018 , 5, 172-183	8
1006	Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. 2018 , 107, 76-86	10
1005	Electrophysiology Catheter-Facilitated coronary sinus cannulation and implantation of cardiac resynchronization therapy systems. 2018 , 59, 26-33	5
1004	Influence of atrial fibrillation on the mortality of patients with heart failure with preserved ejection fraction. 2018 , 150, 376-382	6
1003	Development and validation of a scoring system for the identification of pleural exudates of cardiac origin. 2018 , 50, 60-64	8
1002	Trends and predictors of non-cardiovascular death in patients hospitalized for acute heart failure. 2018 , 250, 164-170	10
1001	Multidisciplinary team approach to heart failure management. 2018 , 104, 1376-1382	22
1000	Noncardiovascular death after acute heart failure. Do not lose the war while fighting for the failing heart. 2018 , 250, 231-232	0
999	A Database Cohort Study to Assess the Risk of Angioedema Among Patients with Heart Failure Initiating Angiotensin-Converting Enzyme Inhibitors in the USA. 2018 , 18, 205-211	10
998	Acute Dyspnea and Decompensated Heart Failure. 2018 , 36, 63-72	8
997	Cardiovascular Anatomy and Pharmacology. 2018 , 195-228	
996	N-Terminal B-type Natriuretic Peptide in Heart Failure. 2018 , 14, 27-39	30
995	Predictors and outcomes of heart failure with mid-range ejection fraction. 2018 , 20, 651-659	46
994	Exercise testing in heart failure: a contemporary discussion in an era of novel diagnostic techniques and biomarkers. 2018 , 33, 217-224	1

993	Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction. 2018 , 121, 621-627	7
992	Prognostic Value of Strain by Tissue Tracking Cardiac Magnetic Resonance After ST-Segment Elevation Myocardial Infarction. 2018 , 11, 1448-1457	60
991	[Left Ventricular Assist Device Therapy - Ways to Improve the Ambulatory Care]. 2018 , 143, 349-353	1
990	Early warning systems for the management of chronic heart failure: a systematic literature review of cost-effectiveness models. 2018 , 18, 161-175	3
989	Circulatory Support with Extracorporeal Membrane Oxygenation and/or Impella for Cardiogenic Shock During Myocardial Infarction. 2018 , 64, 708-714	24
988	NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?). 2018 , 137, 1671-1683	70
987	Exercise and heart failure: an update. 2018 , 5, 222-232	71
986	Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan. 2018 , 5, 327-336	30
985	Measuring Fear of Physical Activity in Patients with Heart Failure. 2018 , 25, 294-303	10
984	Galectin-3 in Heart Failure: An Update of the Last 3 Years. 2018 , 14, 75-92	55
983	The effects of Baduanjin exercise on fatigue and quality of life in patients with heart failure: A randomized controlled trial. 2018 , 17, 456-466	29
982	A New Face of Cardiac Emergencies: Human Immunodeficiency Virus-Related Cardiac Disease. 2018 , 36, 161-170	3
981	Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study. 2018 , 93, 952-960	21
980	Update on the management of acute heart failure. 2018 , 33, 225-231	4
979	Adjuvant therapy in acute heart failure. 2018 , 44, 900-903	1
978	Modern iron replacement therapy: clinical and pathophysiological insights. 2018 , 107, 16-30	91
977	Challenges in clarifying goals of care in patients with advanced heart failure. 2018 , 12, 32-37	1
976	How to deliver optimal cardiac resynchronisation therapy. 2018 , 104, 1300-1307	3

975	[Cardiac Rehabilitation]. 2018 , 57, 117-126	2
974	Regulation of circulating chromogranin B levels in heart failure. 2018 , 23, 78-87	3
973	Association Between Global Longitudinal Strain and Cardiovascular Events in Patients With Left Bundle Branch Block Assessed Using Two-Dimensional Speckle-Tracking Echocardiography. 2018 , 31, 52-63.e6	14
972	Anesthesia in High-Risk Patients. 2018 ,	
971	Use of implantable cardioverter defibrillator in nonischemic cardiomyopathy: a U-turn?. 2018 , 19 Suppl 1, e63-e67	
970	The Patient with Advanced Chronic Heart Failure. 2018 , 19-38	
969	Update on revascularization in patients with heart failure and coronary artery disease. 2018 , 33, 232-236	2
968	Low- and High-renin Heart Failure Phenotypes with Clinical Implications. 2018 , 64, 597-608	27
967	Point-of-care B-type natriuretic peptide and portable echocardiography for assessment of patients with suspected heart failure in primary care: rationale and design of the three-part Handheld-BNP program and results of the training study. 2018 , 107, 95-107	11
966	Shared heart failure knowledge and self-care outcomes in patient-caregiver dyads. 2018 , 47, 32-39	15
965	Magnetic resonance imaging in heart failure, including coronary imaging: numbers, facts, and challenges. 2018 , 5, 3-8	3
964	Prognostic value of fibrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events. 2018 , 63, 160-166	11
963	Renin-Angiotensin System Blockers and Statins Are Associated With Lower In-Hospital Mortality in Very Elderly Hypertensives. 2018 , 19, 342-347	15
962	Anemia in Heart Failure: Still Relevant?. 2018 , 6, 201-208	43
961	Real-Life Use of Neurohormonal Antagonists and Loop Diuretics in Chronic Heart Failure: Analysis of Serial Biomarker Measurements and Clinical Outcome. 2018 , 104, 346-355	2
960	The prognostic impact of malnutrition in patients with severely decompensated acute heart failure, as assessed using the Prognostic Nutritional Index (PNI) and Controlling Nutritional Status (CONUT) score. 2018 , 33, 134-144	78
959	Lung ultrasound in internal medicine efficiently drives the management of patients with heart failure and speeds up the discharge time. 2018 , 13, 27-33	35
958	Comprehensive Echocardiographic and Cardiac Magnetic Resonance Evaluation Differentiates Among Heart Failure With Preserved Ejection Fraction Patients, Hypertensive Patients, and Healthy Control Subjects. 2018 , 11, 577-585	55

957	Pharmacological strategies in heart failure with preserved ejection fraction: time for an individualised treatment strategy?. 2018 , 104, 365-366	3
956	Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. 2018 , 104, 407-415	75
955	Interval training early after heart failure decompensation is safe and improves exercise tolerance and quality of life in selected patients. 2018 , 25, 9-18	13
954	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. 2018 , 104, 606-613	9
953	Are defibrillators less useful in patients with non-ischemic heart disease?. 2018 , 37, 835-841	
952	Cardiac arrest in a patient diagnosed with acute myeloid leukemia after the first dose of idarubicin. 2018 , 151, 506-507	
951	Cardiac Resynchronization Therapy. 2018 , 475-488	
950	Optimising Heart Failure Therapies in the Acute Setting. 2018 , 4, 38-42	16
949	Feasibility of left ventricular endocardial lead pacing for cardiac resynchronization therapy. 2018 , 6, 53-55	
948	Natural history of cardiac function in Duchenne and Becker muscular dystrophies on home mechanical ventilation. 2018 , 97, e11381	11
947	Interventions: Endomyocardial Biopsy. 2018 , 119-125	
946	Novel biochemical predictors of unfavorable prognosis for stable coronary disease. 2018 , 97, e12372	2
945	Exercise-Based Cardiac Rehabilitation with and Without Neuromuscular Electrical Stimulation and its Effect on Exercise Tolerance and Life Quality of Persons with Chronic Heart Failure. 2018 , 65, 151-164	2
944	Feasibility and acceptability of a self-measurement using a portable bioelectrical impedance analysis, by the patient with chronic heart failure, in acute decompensated heart failure. 2018 , 16, 145-154	1
943	Ronda clínica y epidemiológica: club de revistas. 2018 , 31, 205-215	
942	Nursing clinical competence in area medica. 2018 , 1-83	
941	Ödemstauung und Herzinsuffizienz Wann sind Kompression und Manuelle Lymphdrainage gegenangezeigt?. 2018 , 47, 115-119	2
940	The role of ACE inhibitors in cardiovascular disease. 2018 , 13, 600-608	1

939 Update: kardiovaskuläre Schlafmedizin. **2018**, 14, 271-283

938 Ejection Fraction: Do You Know Your Number?. **2018**, 32, 63-64

937 Stato dell'arte dei peptidi natriuretici cardiaci (PNC) in Italia. La IV indagine del GDS MM SIPMeL. **2018**, 14, 234-240 1

936 Biomaterials and heart recovery: cardiac repair, regeneration and healing in the MCS era: a state of the "heart". **2018**, 10, S2346-S2362 10

935 Cardiovascular adverse events in multiple myeloma patients. **2018**, 10, S4296-S4305 12

934 Diagnosing the Obstructive Sleep APNEA from Multi Parameter Values. **2018**, 1 1

933 Guideline-Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient-Pooled Analysis From the Kor HF and Kor AHF Registries. **2018**, 7, e009806 17

932 Improving medical care and prevention in adults with congenital heart disease-reflections on a global problem-part I: development of congenital cardiology, epidemiology, clinical aspects, heart failure, cardiac arrhythmia. **2018**, 8, 705-715 19

931 Catheter Ablation for Atrial Fibrillation in Systolic Heart Failure Patients: Stone by Stone, a CASTLE. **2018**, 7, 265-272 3

930 Familiäre Kardiomyopathien - von der Phänomenologie zur zielgerichteten Therapie. **2018**, 7, 211-219

929 "Valve in valve" through femoral approach to allow the later implantation of long-term left ventricle assist device: a case report. **2018**, 10, E447-E449 2

928 Female gender and left ventricular dysfunction in myocardial surgical revascularization: the strange couple. **2018**, 10, S2160-S2164

927 Comparison of the Efficacy of Neuromuscular Electrostimulation and Interval Exercise Training in Early Rehabilitation of Patients Hospitalized with Decompensation of Chronic Heart Failure. **2018**, 44, 663-672 5

926 Improving patient outcomes through palliative care integration in other specialised health services: what we have learned so far and how can we improve?. **2018**, 7, S219-S230 10

925 Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. **2018**, 10, S4282-S4295 39

924 EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION. **2018**, 14, 210-216 2

923 Heart Failure as a Risk Factor for Stroke. **2018**, 20, 33-45 36

922 Anemia in heart failure - from guidelines to controversies and challenges. **2018**, 20, 52-59 12

921	Stellenwert der diagnostischen Koronarangiographie. 2018 , 32, 361-371	
920	Advanced heart failure: Where do we stand?. 2018 , 59, 303-305	1
919	Left ventricular assist device may improve glycemic control in diabetes mellitus patients but the reverse is not true. 2018 , 10, S4093-S4095	0
918	Circulating biomarkers in heart failure: diagnostic and prognostic importance. 2018 , 3, 36-36	5
917	Clinical Significance of Get With the Guidelines-Heart Failure Risk Score in Patients With Chronic Heart Failure After Hospitalization. 2018 , 7, e008316	27
916	Cardiac Prevention and Rehabilitation "3.0": From acute to chronic phase. Position Paper of the Italian Association for Cardiovascular Prevention and Rehabilitation (GICR-IACPR). 2018 , 88, 1004	7
915	Perceptions of heart failure symptoms, disease severity, treatment decision-making, and side effects by patients and cardiologists: a multinational survey in a cardiology setting. 2018 , 14, 2265-2272	10
914	Validation of heart failure quality of life tool and usage to predict all-cause mortality in acute heart failure in Uganda: the Mbarara heart failure registry (MAHFER). 2018 , 18, 232	3
913	Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers. 2018 , 64, 745-754	9
912	The impact of gender in cardiovascular medicine: Lessons from the gender/sex-issue in heart failure. 2018 , 88, 988	12
911	Trends of socioeconomic equality in mortality amenable to healthcare and health policy in 1992-2013 in Finland: a population-based register study. 2018 , 8, e023680	6
910	4 Bridges to transplant. 2018 ,	
909	6 Mechanical circulatory support programme at chiba university hospital, japan. 2018 ,	
908	5 mechanical circulatory support programme: experience in hong kong. 2018 ,	
907	47 Rehabilitation enablement in chronic heart failure (reach-HF) a multicentre randomised controlled trial of facilitated self-care rehabilitation intervention in heart failure with reduced ejection fraction. 2018 ,	
906	Transfemoral aortic valve implantation with new-generation devices: the repositionable Lotus vs. the balloon-expandable Edwards Sapien 3 valve. 2018 , 19, 655-663	16
905	sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction. 2018 , 2018, 3952526	13
904	49 Reduced myocardial perfusion reserve in systolic heart failure a therapeutic target?. 2018 ,	

- 903 Therapie von Non-Respondern einer kardialen Resynchronisation. **2018**, 7, 470-475
- 902 OBSOLETE: Biomarkers in Ischemic Heart Disease. **2018**,
- 901 Untreated Obstructive Sleep Apnea Is Associated With Myocardial Injury Independent of Blood Pressure Control in Hypertension. **2018**, 14, 1841-1847 3
- 900 Cardiac Dyssynchrony as a Pathophysiologic Factor of Functional Mitral Regurgitation: Role of Cardiac Resynchronization Therapy. **2018**,
- 899 Evaluation of the effects of different treatment modalities on angiogenesis in heart failure patients with reduced/mid-range ejection fraction via VEGF and sVEGFR-1. **2018**, 39, 1028-1034 1
- 898 Exercise-based cardiac rehabilitation for people with implantable ventricular assist devices. **2018**, 9, CD012223
- 897 Efficacy and safety of levosimendan in Chinese elderly patients with Takotsubo syndrome. **2018**, 6, 438 7
- 896 Advances in Imaging and Heart Failure: Where are we Heading?. **2018**, 4, 73-77 2
- 895 Hartfalen, diagnostiek in de tweede lijn. **2018**, 34, 436-447
- 894 Doações e transplantes cardíacos no estado do Paraná **2018**, 39,
- 893 Hartfalen en COPD. **2018**, 34, 448-455
- 892 Method Comparison and Validation of the Determination of Ejection Duration from Oscillometric Measurements. **2018**, 51, 343-348 0
- 891 Ten Years of 2D Longitudinal Strain for Early Myocardial Dysfunction Detection: A Clinical Overview. **2018**, 2018, 8979407 29
- 890 OBSOLETE: Stage A Heart Failure: Identification and Management of Heart Failure Risk Factors. **2018**,
- 889 OBSOLETE: Practical Guide to Evidence-Based Management of Heart Failure in the Outpatient Setting. **2018**,
- 888 OBSOLETE: Myocarditis in Heart Failure. **2018**,
- 887 OBSOLETE: Biomarkers: Heart Failure. **2018**,
- 886 OBSOLETE: Interventions: Endomyocardial Biopsy. **2018**,

885	OBSOLETE: Remission and Recovery in Heart Failure. 2018,		
884	OBSOLETE: Alcoholic Cardiomyopathy. 2018,		
883	Einsatz des tragbaren Kardioverter-Defibrillators nach kardiochirurgischen Eingriffen. 2018, 32, 286-299		1
882	6 PBM im nicht chirurgischen Bereich. 2018,		
881	Fuling Sini decoction for patients with chronic heart failure: A protocol for a systematic review and meta-analysis. 2018, 97, e13692		3
880	Results of new-generation intrapericardial continuous flow left ventricular assist devices as a bridge-to-transplant. 2018, 19, 739-747		6
879	Samen zorgen voor de patiënt met hartfalen: regionale afspraken. 2018, 34, 488-495		
878	Eindstadium hartfalen in de huisartsenpraktijk. 2018, 34, 505-515		
877	Herzinsuffizienz und Diabetes. 2018, 16, 148-155		
876	Gender differences in cardiology: is it time for new guidelines?. 2018, 19, 685-688		16
875	[Percutaneous treatment of mitral regurgitation by Mitraclip in the elderly]. 2018, 67, 474-481		
874	Clinical Phenotype and Genotype Associations With Improvement in Left Ventricular Function in Dilated Cardiomyopathy. 2018, 11, e005220		25
873	Imaging of Valvular Heart Disease in Heart Failure. 2018, 4, 78-86		5
872	Heart failure and its causes: high blood pressure, atrial fibrillation, radiotherapy, and chemotherapy. <i>European Heart Journal</i> , 2018, 39, 3827-3831	9.5	1
871	Effect of beta-blocker therapy on clinical outcomes, safety, health-related quality of life and functional capacity in patients with chronic obstructive pulmonary disease (COPD): a protocol for a systematic literature review and meta-analysis with multiple treatment comparison. 2018, 8, e024736		1
870	In-hospital mortality is associated with high NT-proBNP level. 2018, 13, e0207118		3
869	Alcoholic Cardiomyopathy. 2018, 58-65		
868	Congestive Heart Failure Risk Assessment Monitoring through Internet of things and mobile Personal Health Systems. 2018, 2018, 2925-2928		6

867	The effect of angiotensin-converting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial. 2018 , 12, 351-359	4
866	Selective Blockade of HCN1/HCN2 Channels as a Potential Pharmacological Strategy Against Pain. 2018 , 9, 1252	26
865	The evolving field of nonpharmacological therapies to improve functional capacity in chronic heart failure. 2018 , 59, 321-322	2
864	Myocardial performance versus exercise tolerance: What matters the most in patients with heart failure?. 2018 , 59, 336-337	3
863	Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. 2018 , 14, 1273-1285	4
862	Artificial Intelligence to Prevent Mobile Heart Failure Patients Decompensation in Real Time: Monitoring-Based Predictive Model. 2018 , 2018, 1-11	9
861	[Wearable defibrillator : Current evidence]. 2018 , 29, 362-368	1
860	Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?. 2018 , 17, 145	11
859	Temporal Frame of Immune Cell Infiltration during Heart Failure Establishment: Lessons from Animal Models. 2018 , 19,	9
858	Focus on extracorporeal life support. 2018 , 44, 2251-2253	3
857	Body composition in acute heart failure patients: Relationship with gender and left ventricular ejection fraction. 2018 , 151, 291-292	
856	Echocardiographic Predictors of Mortality in Women With Heart Failure With Reduced Ejection Fraction. 2018 , 11, e008031	11
855	Heart Failure. 2018 , 169, 737-738	
854	Heart Failure. 2018 , 169, 738	2
853	Left Atrial Function in Heart Failure With Reduced Ejection Fraction. 2018 , 11, e008427	6
852	Expert opinion on managing chronic HCV in patients with cardiovascular disease. 2018 , 23, 35-46	5
851	Defining, Estimating, and Communicating Overdiagnosis in Cancer Screening. 2018 , 169, 738-739	
850	Defining, Estimating, and Communicating Overdiagnosis in Cancer Screening. 2018 , 169, 739	3

849 Firearms and Dementia. **2018**, 169, 739-740

848 Firearms and Dementia. **2018**, 169, 740

3

847 ST2 and Prognosis in Chronic Heart Failure. **2018**, 72, 2321-2323

6

846 sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. **2018**, 72, 2309-2320

73

845 [Leadless endocardial ultrasound based left ventricular stimulation : WISE CRT System: alternative to conventional methods]. **2018**, 29, 340-348

3

844 [New directions in cardiology over the past 10 years]. **2018**, 160, 30-34

843 Biomarkers: a window into the pathophysiology of atrial fibrillation in heart failure with reduced vs. preserved ejection fraction. *European Heart Journal*, **2018**, 39, 3876-3878

9.5 1

842 Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. **2018**, 9, 1514

80

841 Risk factors for incident heart failure with preserved or reduced ejection fraction, and valvular heart failure, in a community-based cohort. **2018**, 5, e000782

28

840 Prognostic Implications of QRS Duration in Third-Degree Atrioventricular Block Patients with Heart Failure Treated with Cardiac Resynchronization Therapy. **2018**, 59, 1320-1326

2

839 Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application. **2018**, 32, 617-624

30

838 Cardiovascular and Metabolic Comorbidities in Rheumatoid Arthritis. **2018**, 20, 81

23

837 Letter by Fung et al Regarding Article, "Frailty and Clinical Outcomes in Heart Failure: A Systematic Review and Meta-analysis". **2018**, 19, 1143-1146

836 Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs. **2018**, 21, 80-86

2

835 Coronary Microcirculation in Heart Failure with Preserved Systolic Function. **2018**, 24, 2960-2966

4

834 The interplay between metabolic alterations, diastolic strain rate and exercise capacity in mild heart failure with preserved ejection fraction: a cardiovascular magnetic resonance study. **2018**, 20, 88

33

833 Association of Interleukin-10 -1082A>G (rs1800896) Polymorphism with Predisposition to Breast Cancer: a Meta-Analysis based on 17 Case-Control Studies. **2018**, 64, 756-764

3

832 Profiles of hospitalized patients with valvular heart disease: Experience of a tertiary center. **2018**, 37, 991-998

1

831	Is B-type natriuretic peptide (BNP) similarly associated with mortality in patients with and without heart failure?. 2018 , 6, S9	1
830	Diagnosing heart failure with NT-proBNP point-of-care testing: lower costs and better outcomes. A decision analytic study. 2018 , 2, bjgpopen18X101596	7
829	Urapidil, compared to nitroglycerin, has better clinical safety in the treatment of hypertensive patients with acute heart failure: a meta-analysis. 2019 , 13, 161-172	1
828	Cardiac resynchronization therapy outcomes in patients under nonoptimal medical therapy. 2018 , 34, 548-555	2
827	Registro Español de Marcapasos. XV Informe Oficial de la Sección de Estimulación Cardíaca de la Sociedad Española de Cardiología (2017). 2018 , 71, 1059-1068	15
826	Mental health interventions during ventricular assist device therapy: a scoping review. 2018 , 27, 958-964	2
825	Moving From Heart Failure Guidelines to Clinical Practice: Gaps Contributing to Readmissions in Patients With Multiple Comorbidities and Older Age. 2018 , 12, 1179546818809358	13
824	SIGN offers guidance for managing chronic heart failure. 2018 , 13, 114-115	1
823	[Atrial fibrillation in acute heart failure: Clinical features and prognosis]. 2018 , 44, e98-e100	1
822	Does nitric oxide mediate the effects of ivabradine in patients with heart failure?. 2018 , 20, 273-274	
821	[Mortality rate in patients with heart failure at the Libreville University Hospital and associated factors]. 2018 , 31, 27	2
820	Heart diseases and echocardiography in rural Tanzania: Occurrence, characteristics, and etiologies of underappreciated cardiac pathologies. 2018 , 13, e0208931	12
819	Association of Alcohol Consumption After Development of Heart Failure With Survival Among Older Adults in the Cardiovascular Health Study. 2018 , 1, e186383	5
818	Profiles of hospitalized patients with valvular heart disease: Experience of a tertiary center. 2018 , 37, 991-998	6
817	Increased Cardiac Uptake of Ketone Bodies and Free Fatty Acids in Human Heart Failure and Hypertrophic Left Ventricular Remodeling. 2018 , 11, e004953	49
816	Effect of Hospital-based Cardiac Rehabilitation on Quality of Life and Physical Capacity in Acute Myocardial Infarction Patients: 2 Years Follow Up. 2018 , 09,	0
815	Effect of Sympatholytic Therapy on Circadian Cardiac Autonomic Activity in Non-Diabetic Chronic Kidney Disease. 2018 , 59, 1352-1358	4
814	Personalized approaches to heart failure: age, acute presentation, and comorbidities. <i>European Heart Journal</i> , 2018 , 39, 4223-4226	9.5 0

813	Innovative Strategies in Heart Failure: Present and Future. 2018 , 49, 558-567	2
812	Therapie von Vorhofflimmern bei Herzinsuffizienz – Sind die Leitlinien noch aktuell?. 2018 , 7, 476-480	
811	Linking cross-bridge cycling kinetics to response to cardiac resynchronization therapy: a multiscale modelling study. 2018 , 20, iii87-iii93	2
810	Seasonality of the Cardiac Biomarker Troponin in the Eastern Croatian Population. 2018 , 7,	2
809	Size Matters: Normalization of QRS Duration to Left Ventricular Dimension Improves Prediction of Long-Term Cardiac Resynchronization Therapy Outcome. 2018 , 11, e006767	18
808	The Influence of Mutuality on Self-Care in Heart Failure Patients and Caregivers: A Dyadic Analysis. 2018 , 24, 563-584	19
807	Current Research and New Perspectives of Telemedicine in Chronic Heart Failure: Narrative Review and Points of Interest for the Clinician. 2018 , 7,	20
806	Specialty-Related Differences in the Acute-Phase Treatment and Prognosis in Patients With Acute Heart Failure - Insights From REALITY-AHF. 2018 , 83, 174-181	6
805	Cardiac Index by Transthoracic Echocardiography (CITE) study. 2018 , 13, e0207269	0
804	Overview of the 82 Annual Scientific Meeting of the Japanese Circulation Society - Futurability: Pioneering the Future of Circulatory Medicine. 2018 , 82, 1985-1990	
803	Renal Functions and Prognosis Stratification in Chronic Heart Failure Patients and the Importance of Neutrophil Gelatinase-Associated Lipocalin. 2018 , 43, 1865-1877	4
802	Adenosine Plasma Level and A2A Receptor Expression in Patients With Cardiogenic Shock. 2018 , 46, e874-e880	6
801	Skeletal muscle wasting in chronic heart failure. 2018 , 5, 1099-1107	51
800	Reasons for Guideline Nonadherence at Heart Failure Discharge. 2018 , 7, e008789	19
799	Regulation of Red Blood Cell Volume with Exercise Training. 2018 , 9, 149-164	32
798	The association among biomarkers of renal and heart function in patients with heart failure: the role of NGAL. 2018 , 12, 1323-1330	6
797	B-type natriuretic peptide in patients with asymptomatic severe aortic stenosis. 2019 , 105, 384-390	17
796	Resistant Hypertension From Renal Artery Stenosis Leading to Heart Failure With Preserved Ejection Fraction. 2018 , 6, 2324709618816501	1

795	Iron deficiency anaemia in chronic kidney disease: an overview. 2018 , 3, S3-S8	0
794	Bromocriptine for the Treatment of Peripartum Cardiomyopathy. 2018 , 4, 46-49	9
793	The Role of Renal Vascular Reactivity in the Development of Renal Dysfunction in Compensated and Decompensated Congestive Heart Failure. 2018 , 43, 1730-1741	8
792	Disability-free survival after coronary artery bypass grafting in women and men with heart failure. 2018 , 5, e000911	19
791	Echocardiography in Heart Failure. 2018 , 619-642	1
790	Gut Microbiome and Plasma Microbiome-Related Metabolites in Patients With Decompensated and Compensated Heart Failure. 2018 , 83, 182-192	50
789	The Inflammatory Response to Ventricular Assist Devices. 2018 , 9, 2651	22
788	Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. 2018 , 320, 2231-2241	44
787	Prevalence, risk factors, and significance of iron deficiency and anemia in nonischemic heart failure patients with reduced ejection fraction from a Himachal Pradesh heart failure registry. 2018 , 70 Suppl 3, S182-S188	4
786	Real-world presentation with heart failure in primary care: do patients selected to follow diagnostic and management guidelines have better outcomes?. 2018 , 5, e000935	4
785	Exercise training in pulmonary arterial hypertension. 2018 , 10, 508-521	18
784	Therapeutic Targets for Treatment of Heart Failure: Focus on GRKs and Arrestins Affecting AR Signaling. 2018 , 9, 1336	15
783	Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. 2018 , 72, 3158-3176	555
782	Triple lead cephalic versus subclavian vein approach in cardiac resynchronization therapy device implantation. 2018 , 8, 17709	4
781	Sucrosomial Iron: A New Generation Iron for Improving Oral Supplementation. 2018 , 11,	37
780	Shear Wave Elastography of Peripheral Muscle Weakness in Patients with Chronic Congestive Heart Failure. 2018 , 44, 2531-2539	6
779	End-of-life situations in cardiology: a qualitative study of physicians' and nurses' experience in a large university hospital. 2018 , 17, 112	9
778	Heart Failure Differentially Modulates the Effects of Ivabradine on the Electrical Activity of the Sinoatrial Node and Pulmonary Veins. 2018 , 24, 763-772	4

777	First Hospitalization for Heart Failure in Outpatients With Stable Coronary Artery Disease: Determinants, Role of Incident Myocardial Infarction, and Prognosis. 2018 , 24, 815-822		10
776	Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study. 2018 , 17, 1063-1069		4
775	Upregulation of Myocardial and Vascular Phosphodiesterase 9A in A Model of Atherosclerotic Cardiovascular Disease. 2018 , 19,		6
774	[Hemodynamic target variables in the intensive care unit]. 2018 , 67, 797-808		2
773	Imaging and Management of Heart Failure and Preserved Ejection Fraction. 2018 , 20, 90		8
772	How to Manage Heart Failure: New Guidelines 2018. 2018 , 27, 1267-1269		
771	Differential Clinical Implications of Current Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. 2018 , 31, 1203-1208		39
770	Association between loop diuretic dose administered in first 24 hours of heart failure admissions and length of hospital stay. 2018 , 8, 195-199		
769	Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. <i>European Heart Journal</i> , 2018 , 39, 3766-3776	9.5	65
768	Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis. 2018 , 19, 597-605		7
767	Secular trends in first-time hospitalization for heart failure with following one-year readmission and mortality rates in the 3.8 million adult population of Silesia, Poland between 2010 and 2016. The SILCARD database. 2018 , 271, 146-151		6
766	2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. 2018 , 36, 1053-2011		1262
765	Novel biomarkers in heart failure. What they add in daily clinical practice?. 2018 , 59, 193-195		4
764	Continuity and utilization of health and community care in elderly patients with heart failure before and after hospitalization. 2018 , 18, 177		6
763	Circulating monocyte subsets and heart failure prognosis. 2018 , 13, e0204074		2
762	[Cardiac contractility modulation]. 2018 , 59, 1021-1027		
761	Stage A Heart Failure: Identification and Management of Heart Failure Risk Factors. 2018 , 446-455		
760	Osteoprotegerin and Myocardial Fibrosis in Patients with Aortic Stenosis. 2018 , 8, 14550		4

759	Biopsy-Negative Rejection: a Rare but Difficult Issue in Heart Transplantation. 2018 , 5, 231-234		1
758	Glucagon secretion determined by the RIA method is lower in patients with low left ventricular ejection fraction: The new glass study. 2018 , 144, 260-269		1
757	Intravenous sildenafil acutely improves hemodynamic response to exercise in patients with connective tissue disease. 2018 , 13, e0203947		1
756	Left ventricular assist devices: let's move toward better quality of extended life, away from hospital. <i>European Heart Journal</i> , 2018 , 39, 3461-3463	9.5	1
755	Caring for Pediatric Heart Failure Patients With Long-Term Mechanical Circulatory Support. 2018 , 38, 44-56		1
754	Treatment of heart failure with preserved ejection fraction. 2018 , 88, 951		
753	Nutrients restriction upregulates adiponectin in epicardial or subcutaneous adipose tissue: impact in heart failure patients. 2018 , 15, 417-424		6
752	Absence of Myocardial Fibrosis Predicts Favorable Long-Term Survival in New-Onset Heart Failure. 2018 , 11, e007722		25
751	Cardiovascular disease and COPD: dangerous liaisons?. 2018 , 27,		87
750	Management of advanced heart failure: a review. 2018 , 16, 775-794		5
749	Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis protocol. 2018 , 7, 151		6
748	9-Year Trend in the Management of Acute Heart Failure in Japan: A Report From the National Consortium of Acute Heart Failure Registries. 2018 , 7, e008687		71
747	Upregulation of the aging related LMNA splice variant progerin in dilated cardiomyopathy. 2018 , 13, e0196739		13
746	Leadless pacing. 2018 , 43, 605-611		
745	Neuromodulation for Refractory Angina and Heart Failure. 2018 , 1279-1291		
744	Diuretics in the Management of Cardiorenal Syndrome. 2018 , 25, 425-433		7
743	The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients. 2018 , 72, e13274		5
742	Dynamics of high-sensitivity cardiac troponin T during therapy with balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. 2018 , 13, e0204683		9

741	Best practice in psychological activities in cardiovascular prevention and rehabilitation: Position Paper. 2018 , 88, 966	21
740	Prise en charge de l'infarctus du myocarde, nouveautés des Recommandation ESC 2017. 2018 , 30, 20-27	
739	Benzodiazepine Use and Long-Term Mortality in Real-Life Chronic Heart Failure Outpatients: A Cohort Analysis. 2018 , 87, 372-374	2
738	Should heart failure patients be left to fate? Temporary implementation of veno-arterial extracorporeal membrane oxygenation for haemodynamic support during excision of rectal carcinoma in an end-stage biventricular heart failure patient. 2018 , 6, 2050313X18789217	
737	Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. 2018 , 17, 132	93
736	Preface. 2018 , 14, xiii-xiv	
735	B-type natriuretic peptides in pregnant women with normal heart or cardiac disorders. 2018 , 121, 149-151	5
734	Safety and Effectiveness of Intravenous Iron Therapy in Patients Supported by Durable Left Ventricular Assist Devices. 2022 , 11, 3900	
733	Prognostic significance of diastolic dysfunction in patients with systolic dysfunction undergoing atrial fibrillation ablation. 2022 , 41, 101079	
732	Circulating cardiac biomarkers improve risk stratification for incident cardiovascular disease in community dwelling populations. 2022 , 82, 104170	1
731	Tratamiento farmacológico de la insuficiencia cardíaca según la fracción de eyección ventricular en atención primaria. 2022 , 54, 102362	
730	Clinical impact of blood urea nitrogen, regardless of renal function, in heart failure with preserved ejection fraction. 2022 , 363, 94-101	
729	The importance of pharmacokinetics, pharmacodynamic and repetitive use of levosimendan. 2022 , 153, 113391	0
728	Métodos de valoración de la fracción de eyección del ventrículo izquierdo. 2018 , 1, 1-6	
727	DIAGNOSIS AND TREATMENT OF MYOCARDITIDES. 2019 , 4-33	1
726	The relationship of coronary artery disease and indirect inflammatory markers.	
725	Heart failure with mildly reduced ejection fraction: from diagnosis to treatment. Gaps and dilemmas in current clinical practice.	1
724	Relaxin-2, pathophysiological insights and outcomes in heart failure with preserved ejection fraction: Findings from the NETDiamond cohort. 2022 ,	

- 723 Evaluation of the effect of intravenous nitroglycerine on short-term survival of patients with acute heart failure according to congestion and perfusion status at emergency department arrival. Publish Ahead of Print, ○
- 722 Cardiogenic Shock Does Not Portend Poor Long-Term Survival in Patients Undergoing Primary Percutaneous Coronary Intervention. **2022**, 12, 1193
- 721 Initiating ivabradine during hospitalization in patients with acute heart failure: A real-world experience in China. 1
- 720 Data-driven versus a domain-led approach to k-means clustering on an open heart failure dataset. ○
- 719 Role of the Electrocardiogram in Differentiating Genetically Determined Dilated Cardiomyopathy from Athlete's Heart. ○
- 718 Unfolding the genotype-to-phenotype black box of cardiovascular diseases through cross-scale modeling. **2022**, 104790 ○
- 717 Diagnostic Values of Blood Urea Nitrogen (BUN), Creatinine (Cr), and the Ratio of BUN to Cr for Distinguishing Heart Failure from Asthma and Chronic Obstructive Pulmonary Disease. **2022**, 2022, 1-7
- 716 Factors associated with left ventricular diastolic dysfunction in patients with septic shock. **2022**, 27,
- 715 Diuretic resistance in patients with chronic heart failure: mechanisms, prevention, and treatment. **2022**, 21, 152-167
- 714 Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through β Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical Trial. **2022**, 15, 1
- 713 Identification of Differential Expression Genes between Volume and Pressure Overloaded Hearts Based on Bioinformatics Analysis. **2022**, 13, 1276
- 712 Pentraxin 3 in Circulating Microvesicles: a Potential Biomarker for Acute Heart Failure After Cardiac Surgery with Cardiopulmonary Bypass.
- 711 Dystrophinopathy phenotypes and modifying factors in DMD exon 45's deletion. ○
- 710 Nurse-Provided Lung and Inferior Vena Cava Assessment in Patients With Heart Failure. **2022**, 80, 513-523 ○
- 709 Quality of life and medication adherence in patients with chronic heart failure associated with arterial hypertension and chronic kidney disease. **2021**, 40-48
- 708 Tablet-Based Assessment of Cognitive Function Among Heart Failure Patients. **2022**, 21, 147-152
- 707 Factors associated with the intermediate probability of heart failure with preserved ejection fraction on the H&sub>2&sub>FPEF score in asymptomatic patients in rotation work conditions in the Arctic. **2022**, 21, 3167
- 706 Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm. **2022**, ○

- 705 Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with heart failure and preserved, mildly reduced, and reduced ejection fraction: A systemic review and meta-analysis. **9,**
- 704 Cost-of-disease of Heart Failure in Turkey: A Delphi Panel-based Analysis of Direct and Indirect Costs. **2022, 39, 282-289** ○
- 703 Peri-event plasma PCSK9 and hsCRP after an acute myocardial infarction correlate with early deterioration of left ventricular ejection fraction: a cohort study. **2022, 21,** ○
- 702 Prediction of rehospitalization in patients with acute heart failure using point-of-care lung ultrasound. **2022, 22,**
- 701 Effect of Qishen granules on isoproterenol-induced chronic heart failure in rats evaluated by comprehensive metabolomics.
- 700 Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality. **2022, 17, 1139-1149**
- 699 Association of Repetitive Dosing of Levosimendan with Reduction of NYHA Class and NT-proBNP Levels in Decompensated Heart Failure: A Retrospective Cohort Study. **2022, 9, 529-537**
- 698 The relationship of family functioning and family health with hospital readmission in patients with heart failure: insights from an international cross-sectional study.
- 697 Do adrenergic alpha-antagonists increase the risk of poor cardiovascular outcomes? A systematic review and meta-analysis.
- 696 Extracellular volume fraction improves risk-stratification for ventricular arrhythmias and sudden death in non-ischaemic cardiomyopathy. ○
- 695 Acute Heart Failure. **2022, 44, 178-189**
- 694 Opini3 sobre la gu3a ESC 2021 sobre insuficiencia cardiaca. Una encuesta a 387 m3dicos. **2022,** ○
- 693 Electrocardiographic signs of impaired depolarization (fragmented QRS, early ventricular repolarization, etc.) as markers of left ventricular systolic dysfunction. **2022, 27, 5113**
- 692 Healthcare costs of a telemonitoring programme for heart failure: indirect deterministic data linkage analysis.
- 691 Prognostic value of combined coronary angiography-derived IMR and myocardial perfusion imaging by CZT SPECT in INOCA. ○
- 690 A method using deep learning to discover new predictors from left-ventricular mechanical dyssynchrony for CRT response. ○
- 689 Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure. **2022, 80, 584-594** ○
- 688 Carvedilol versus Metoprolol in Patients with Ventricular Tachyarrhythmias. **2022, 9, 274**

- 687 Albumin infusion in hospitalized patients with acute heart failure: a retrospective cohort study. **2022**, 22,
- 686 Performance of current risk stratification models for predicting mortality in patients with heart failure: a systematic review and meta-analysis. 1
- 685 Utilization of Partial Carbon Dioxide and Serum Total Carbon Dioxide Gradients in the Emergency Care of Acute Decompensated Heart Failure. **2022**, 4,
- 684 HF?EF: The Mysterious Relationship Between Heart Failure and Ejection Fraction Continues. **2022**, 146, 519-522 3
- 683 Elevated Fasting Blood Glucose Levels Are Associated with Worse Clinical Outcomes in COVID-19 Patients Than in Pneumonia Patients with Bacterial Infections. **2022**, 11, 902
- 682 Left Atrial Long Axis Shortening Allows Effective Quantification of Atrial Function and Optimized Risk Prediction Following Acute Myocardial Infarction. 0
- 681 Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care. 1
- 680 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. 15
- 679 Age and sex hormones modulate left ventricle regional response to Angiotensin II in male and female mice.
- 678 Elevated NT-proBNP as a cardiovascular disease risk equivalent: Evidence from the Atherosclerosis Risk in Communities (ARIC) Study. **2022**,
- 677 Incidence of ventricular arrhythmias after biventricular defibrillator replacement: impact on safety of downgrading from CRT-D to CRT-P. **2022**, 70,
- 676 Utility of P-wave abnormalities for distinguishing embolic stroke from non-embolic stroke. **2022**,
- 675 Postmenopausal Women with Breast, Endometrial, and Ovarian Cancers Have an Increased Risk for Cardiovascular Conditions prior to Active Endocrine Therapy. **2022**, 2022, 1-10
- 674 Neglected Comorbidity of Chronic Heart Failure: Iron Deficiency. **2022**, 14, 3214 1
- 673 Cardiology Research Institute, Tomsk National Research Medical Center. **2022**, 27, 4753
- 672 Sympathomodulation in Heart Failure with High vs. Normal Ejection Fraction. **2022**, 100073
- 671 Impact du programme d'aide au retour ^ domicile-insuffisance cardiaque (PRADO-IC) sur la mortalit^et la r'hospitalisation ^ un an dans une population de patients insuffisants cardiaques. **2022**,
- 670 Myocardial work: the analytical methodology and clinical utilities. **2022**, 0

- 669 Clinical profile and 90 day outcomes of 10 851 heart failure patients across India: National Heart Failure Registry. ○
- 668 Combination of White Blood Cell Count to Mean Platelet Volume Ratio and Neutrophil-to-Platelet Ratio Predicts Long-Term Adverse Events in Patients with MINOCA. **2022**, 2022, 1-11
- 667 Clinical course and decision-making in heart failure by preload stress echocardiography: a preliminary study. ○
- 666 Hospitalization following an emergency-department visit for worsening heart failure: The role of left ventricular ejection fraction. **2022**, 159, 157-163
- 665 A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates.
- 664 Rehabilitation in patients with chronic thromboembolic pulmonary hypertension. **2022**, 94, 903-907
- 663 Efficacy and safety of different modes of exercise-based cardiac rehabilitation delivery for patients with heart failure: a protocol for a systematic review and network meta-analysis. **2022**, 12, e062152
- 662 The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland. ○
- 661 Management of heart failure with reduced ejection fraction. heartjnl-2020-318811 ○
- 660 Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?. **2022**, 23, 8631 ○
- 659 Sex differences and adherence of patients treated with wearable cardioverter-defibrillator: insights from an international multicenter register. ○
- 658 Electrocardiographic Patterns of Depolarization Abnormalities Help to Identify Reduced Left Ventricular Ejection Fraction. **2022**, 12, 2020
- 657 A novel echocardiographic right ventricular dysfunction score can identify hemodynamic severity profiles in left ventricular dysfunction. **2022**, 20, ○
- 656 Cardiopulmonary exercise test: A 20-year (2002-2021) bibliometric analysis. 9, 1
- 655 Early initiation of slow continuous ultrafiltration (SCUF) in a case of pregnancy induced hypertension (PIH) with acute decompensated heart failure (ADHF) refractory to standard medical therapy: A case report. **2022**, 9, 402-404
- 654 Serum Osmolarity and Vasopressin Concentration in Acute Heart Failure Influence on Clinical Course and Outcome. **2022**, 10, 2034 1
- 653 Acute heart failure outcome and predictors of outcome among patients admitted to Jimma University Medical Center, Southwest Ethiopia.
- 652 The Efficacy of Various Pharmacological Agents on Long-Term Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Randomized Control Trials. **2022**,

- 651 Heart failure and atrial fibrillation: updates and perspectives. **2022**, 27, 5018 1
- 650 Management of Iron Deficiency in Heart Failure: A Review of Evidence. **2022**, Publish Ahead of Print,
- 649 Analyzing the Complicated Connection Between Intestinal Microbiota and Cardiovascular Diseases. **2022**, 0
- 648 Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66). **2022**,
- 647 A Review of Cardiac amyloidosis: Presentation, Diagnosis, and Treatment. **2022**, 101366 1
- 646 Quels schémas vaccinaux contre les infections respiratoires chez l'insuffisant cardiaque?. **2022**,
- 645 The role of iron in chronic inflammatory diseases - from mechanisms to treatment options in Anemia of Inflammation. 2
- 644 Beta blocker versus ivabradine for cardiovascular outcomes among patients with atrial fibrillation. *postgradmedj-2022*
- 643 A Device Strategy-Matched Comparison Analysis among Different Intermacs Profiles: A Single Center Experience. **2022**, 11, 4901 0
- 642 Association between proteinuria trajectories and outcomes in critically ill patients with sepsis or shock. **2022**, 17, e0272835
- 641 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. 37
- 640 ⁶⁸Ga-FAPI PET visualize heart failure: from mechanism to clinic.
- 639 Treatment of cardiac resynchronization therapy non-responders: current approaches and new frontiers.
- 638 Biomarkers and the quadriceps femoris muscle architecture assessed by ultrasound in older adults with heart failure with preserved ejection fraction: a cross-sectional study. 0
- 637 Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial.
- 636 Social determinants of health and cardiovascular outcomes in patients with heart failure. 0
- 635 Intraventricular pressure gradient: A novel tool to assess the post-infarction chronic congestive heart failure. 9,
- 634 Candidate microRNAs as prognostic biomarkers in heart failure: A systematic review. **2022**,

633	EvaLuation of early CRRT and beta-blocker InTervention in patients with ECMO (ELITE) trial: study protocol for a 2 × 2 partial factorial randomized controlled trial. 2022 , 23,	1
632	Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.	1
631	Contractile Reserve in Heart Failure with Preserved Ejection Fraction. 2022 , 9, 248	
630	Perceived barriers and enablers influencing physical activity in heart failure: A qualitative one-to-one interview study. 2022 , 17, e0271743	1
629	The Role of Cardiac Resynchronization Therapy for the Management of Functional Mitral Regurgitation. 2022 , 11, 2407	0
628	Cardiovascular complications and predictors of mortality in hospitalized patients with COVID-19: a cross-sectional study from the Indian subcontinent. 2022 , 50,	0
627	Cardiomyopathies in the Clinical Practice An Overview. 2022 , 111, 623-631	
626	Predictive factors of heart failure in acute coronary syndrome: Institutional cross-sectional study. 2022 , 81, 104332	0
625	Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. 2022 , 42, 101103	0
624	Expression of the β ₁ -adrenergic receptor (ADRB1) gene in the myocardium and β ₁ -adrenergic reactivity of the body in patients with a history of myocardium infraction. 2022 , 844, 146820	
623	Left Ventricular Unloading in Acute on Chronic Heart Failure: From Statements to Clinical Practice. 2022 , 12, 1463	0
622	Facteurs associés à l'inclusion des patients dans le programme PRADO d'Insuffisance Cardiaque : Étude cas-témoin au Centre Hospitalier de Troyes en 2017-2018. 2022 ,	0
621	DELIVERing Progress in Heart Failure with Preserved Ejection Fraction. 2022 , 387, 1138-1140	0
620	Moderate continuous or high intensity interval exercise in heart failure with reduced ejection fraction: Differences between ischemic and non-ischemic etiology. 2022 , 22, 100202	0
619	Citri Reticulatae Pericarpium (Chenpi): A multi-efficacy pericarp in treating cardiovascular diseases. 2022 , 154, 113626	0
618	Bioactive lipids in cardiovascular disease. 2023 , 77-99	0
617	Automatic diagnosis of newly emerged heart failure from serial electrocardiography by repeated structuring & learning procedure. 2023 , 79, 104185	0
616	Ekokardiografi pada Gagal Jantung. 2020 , 33, 43-47	1

- 615 Evaluation of systolic time intervals in patients of ischemic heart disease with clinical heart failure. **2022**, 8, 84 0
- 614 Herztransplantation. **2022**, 299-313 0
- 613 Ventricular Assist Devices. **2022**, 1-14 0
- 612 Acquired von Willebrand syndrome and hemocompatibility-related adverse events in patients with left ventricular assist device. **2022**, 36, 12-22 0
- 611 Sex Differences in Pharmacotherapy and Long-Term Outcomes in Patients with Ischaemic Heart Disease and Comorbid Left Ventricular Dysfunction. 0
- 610 A digital self-care intervention for Ugandan patients with heart failure and their clinicians: User-centred design and usability study. **2022**, 8, 205520762211290 0
- 609 Hypochlorous acid-activated two-photon fluorescent probe for evaluation of anticancer drugs-induced cardiotoxicity and screening of antioxidant drugs. 0
- 608 Effects of Empagliflozin on Diuretics Reduction in Outpatient Heart Failure Patients. 4, 2
- 607 Comparison of 1-year healthcare resource utilization and related costs for patients with heart failure in the Chagas and non-Chagas matched cohorts. **2022**, 9, 204993612211142 0
- 606 The Pathogenesis and Treatment Progress of Heart Failure with Preserved Ejection Fraction and Atrial Fibrillation. **2022**, 12, 7552-7558 0
- 605 AI-Enabled Assessment of Cardiac Systolic and Diastolic Function from Echocardiography. **2022**, 75-85 1
- 604 Clinical Implication of N-Terminal Pro-B Type Natriuretic Peptide to Predict Mortality in Patients with Acute Type A Aortic Dissection: A Prospective Cohort Study. 0
- 603 Left Ventricular Diastolic Dysfunction Screening by a Smartphone-Case Based on Single Lead ECG. **2022**, 16, 117954682211200 0
- 602 The age, NT-proBNP, and Ejection Fraction Score as a Novel Predictor of Clinical Outcomes in CAD Patients After PCI. **2022**, 28, 107602962211133 0
- 601 Hypertensive crisis: Diagnosis and treatment. **2022**, 1, 42-47 0
- 600 Advances in Research on Heart Failure with Preserved Ejection Fraction. **2022**, 12, 7613-7620 0
- 599 End-of-Life Care for End-stage Heart Failure Patients. **2022**, 52, 659 1
- 598 Management of Patients with Cardiac Toxicity: The Point of View of the Cardiologist. **2022**, 73-89 0

- 597 Echocardiographic Evaluation of Right Ventricular Function in Patients Presenting with Acute ST-Elevation Myocardial Infarction. **2022**, 6, 108 ○
- 596 Cardiovascular-derived therapeutic peptidomimetics in cardiovascular disease. **2022**, 579-614 ○
- 595 Narrative review on effects of physical training on risk of cardiometabolic diseases. **2022**, 16, 4 ○
- 594 Machine learning-based medical decision support system for diagnosing HFpEF and HFrEF using PPG. **2023**, 79, 104164 1
- 593 Anxiety in heart failure patients and its association with socio-demographic and clinical characteristics: a cross-sectional study. **2022**, 7, e177 ○
- 592 Effectiveness of home-based telerehabilitation programs on functional capacity and cardiac function in elderly heart failure patients: A prospective longitudinal study. **2022**, 101, e29799 ○
- 591 Inhibition of peripheral chemoreceptors improves ventilatory efficiency during exercise in heart failure with preserved ejection fraction: A role of tonic activity and acute reflex response. 13, ○
- 590 A review on aptamers selection and application in heart diseases diagnosis. **2022**, 22, ○
- 589 Heart failure and the risk of left atrial thrombus formation in patients with atrial fibrillation or atrial flutter. 1
- 588 Normal weight is really not normal in chronic disease. ○
- 587 Leucine and perindopril to improve physical performance in people over 70 years with sarcopenia: the LACE factorial RCT. **2022**, 9, 1-82 ○
- 586 Impact of remote monitoring in heart failure patients with cardiac implantable electronic devices during COVID-19 pandemic: a single center experience. **2022**, 17, ○
- 585 STEMI Patients in the First and Second Waves of the COVID-19 Pandemic in Northeast Slovenia: A Retrospective, Single-Center Observational Study. **2022**, 2, 1232-1243 ○
- 584 Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure. ○
- 583 Sphingolipid metabolism and signaling in cardiovascular diseases. 9, ○
- 582 Clinical characteristics of heart failure patients with mid-range ejection fraction. 1-8 1
- 581 Medikamentöse Therapie der HFrEF: Früher Nutzen von Synergien und individuelle Konzepte. **2022**, 11, 308-313 ○
- 580 Impact of congestion and perfusion status in the emergency department on severity of decompensation and short-term prognosis in patients with acute heart failure. ○

579	Trends in Ischemic Evaluation in New-Onset Heart Failure Without Known Coronary Artery Disease. 2022,	0
578	PRE-OPERative ECHOCardiography for prevention of cardiovascular events after non-cardiac surgery in intermediate- and high-risk patients: protocol for a low-interventional, mixed-cohort prospective study design (PREOP-ECHO). 2022, 23,	0
577	Cardiovascular disease and COVID-19, a deadly combination: A review about direct and indirect impact of a pandemic. 2022, 10, 9556-9572	1
576	Pregnancy-induced Physiological Hypertrophic Preconditioning Attenuates Pathological Myocardial Hypertrophy by Mnemonic Activation of FoxO3a/GSK3 β Pathway.	0
575	Effectiveness of eHealth Self-management Interventions in Patients With Heart Failure: Systematic Review and Meta-analysis. 2022, 24, e38697	1
574	Edema formation in congestive heart failure and the underlying mechanisms. 9,	1
573	Correlation between serum levels of microRNA-21 and inflammatory factors in patients with chronic heart failure. 2022, 101, e30596	1
572	Noninvasive Hemodynamic Monitoring in Advanced Heart Failure Patients: New Approach for Target Treatments. 2022, 10, 2407	0
571	Increased Body Mass Index and Risk of Left Atrial Thrombus in Nonvalvular Atrial Fibrillation Patients Data from the Left Atrial Thrombus on Transesophageal Echocardiography (LATTEE) Registry. 2022, 14, 3652	0
570	Determining Holistic Factors Related to Depressive Symptoms in Patients With Heart Failure. 105477382211214	1
569	Digoxin and Outcomes in Patients with Heart Failure and Preserved Ejection Fraction [HFpEF] Patients: A Systematic Review and Meta-analysis. 2022, 23,	1
568	Differential Impact of Systolic and Diastolic Heart Failure on In-Hospital Treatment, Outcomes, and Cost of Patients Admitted for Pneumonia. 2022, 100025	0
567	Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure and Preserved Ejection Fraction. 2022, 15,	0
566	N-Terminal of the Prohormone Brain Natriuretic Peptide Predicts Postoperative Cardiogenic Shock Requiring Extracorporeal Membrane Oxygenation. 2022, 11, 5493	0
565	Protocol of bedside ultrasound examination for heart failure (ConCORd [CONgestion, Cardiac and multiORGan Dysfunction]). 2022, 42-49	0
564	Nebivolol for the Treatment of Arrhythmias: a Narrative Review.	0
563	Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure.	0
562	Clinical Characteristics of Patients Undergoing Right Heart Catheterizations in Community Hospitals. 2022, 11,	1

561	The Prevalence of Cognitive Frailty and Its Association with Sleep duration and Depression Among Older Adults with Heart Failure. 1-10	1
560	Death without Previous Hospital Readmission in Patients with Heart Failure with Reduced Ejection Fraction—A New Endpoint from Old Clinical Trials. 2022 , 11, 5518	0
559	Association of Carotid Plaque and Flow Velocity With White Matter Integrity in a Middle-aged to Elderly Population. 10.1212/WNL.0000000000201297	0
558	Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients. 1-10	0
557	Effects of hyperventilation length on muscle sympathetic nerve activity in healthy humans simulating periodic breathing. 13,	0
556	Additional prognostic value of stress cardiovascular magnetic resonance for cardiovascular risk stratification after a cryptogenic ischemic stroke. 9,	0
555	Estimation of Left Ventricular Ejection Fraction Using Cardiovascular Hemodynamic Parameters and Pulse Morphological Characteristics with Machine Learning Algorithms. 2022 , 14, 4051	0
554	Acute Heart Failure—Should We Abandon the Term Altogether?.	0
553	Predicting 90-day readmission for patients with heart failure: a machine learning approach using XGBoost.	0
552	Prognostic impact of incident left ventricular systolic dysfunction after myocardial infarction. 9,	0
551	Benzoylaconine improves mitochondrial function in oxygen-glucose deprivation and reperfusion-induced cardiomyocyte injury by activation of the AMPK/PGC-1 axis. 2022 , 26, 325-333	0
550	Prevalence and predictors of sleep-disordered breathing in chronic heart failure: the SchlaHF-XT registry.	2
549	Impact of SGLT2 inhibitors on old age patients with heart failure and chronic kidney disease. 2022 ,	1
548	Elevated plasma WIF-1 levels are associated with worse prognosis in heart failure with pulmonary hypertension.	0
547	Prevalence of constipation and associated factors among patients with heart disease: A cross-sectional survey. 2022 , 12, 1-13	0
546	Efficacy of Implantable Cardioverter Defibrillator in Nonischemic Systolic Heart Failure According to Sex: Extended Follow-Up Study of the DANISH Trial. 2022 , 15,	0
545	Prognostic Value of NT-pro BNP in Extracorporeal Membrane Oxygenation Assisted Cardiogenic Shock Patients: A 5-Year Single-Center Retrospective Analysis.	0
544	Predicting obstructive coronary artery disease in heart failure with reduced ejection fraction: A practical clinical score. 2022 ,	0

543	Effect of metformin on left ventricular mass and functional parameters in non-diabetic patients: a meta-analysis of randomized clinical trials. 2022 , 22,	1
542	Association between periodontitis and heart failure in the general population.	0
541	Sex differences in the impact of frailty in elderly outpatients with heart failure. 9,	1
540	Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study Of 5400 asian patients.	1
539	Motives, frequency, predictors and outcomes of MRA discontinuation in a real-world heart failure population. 2022 , 9, e002022	0
538	4-Fluoroamphetamine (4-FA) intoxication results in exaggerated blood pressure effects compared to MDMA and amphetamine: A retrospective analysis. 2022 , 3,	0
537	Emerging Roles of Micrnas in Veterinary Cardiology. 2022 , 9, 533	1
536	Impact of long-term optimizing atrioventricular delay using device-based algorithms on cardiac resynchronization therapy.	0
535	Erwachsene mit angeborenen Herzfehlern: Prognose durch Arrhythmien und Herzinsuffizienz definiert.	0
534	Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV. 2022 , 22,	0
533	Cumulative Complexity: A qualitative analysis of patients' experiences of living with heart failure with preserved ejection fraction.	0
532	Guía práctica sobre el diagnóstico y tratamiento de la hipertensión arterial en España, 2022. Sociedad Española de Hipertensión - Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA). 2022 ,	1
531	Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP. 2022 , 22,	0
530	Characteristics, Treatment Patterns, and Clinical Outcomes After Heart Failure Hospitalizations in COVID-19 Pandemic, March to October 2020. 2022 ,	0
529	Exercise for Primary and Secondary Prevention of Cardiovascular Disease. 2022 , 80, 1091-1106	1
528	Factors influencing prescribing by critical care physicians to heart failure patients in Egypt: a cross-sectional survey. 2022 , 8,	0
527	Cardiac function modifies the impact of heart base dose on survival: A voxel-wise analysis of lung cancer patients from the PET-Plan trial. 2022 ,	0
526	Trends in Outcomes of Heart Transplants Utilizing Extended Criteria Donors: A UNOS Database Analysis. 2022 ,	0

- 525 Heart failure with recovered ejection fraction: Current understanding and future prospects. **2022**, 0
- 524 Higher body mass index and disease duration are associated with increased risk of left ventricular diastolic dysfunction in women with systemic lupus erythematosus. 096120332211284 0
- 523 Treatment of Patients with Myocardial Infarction in Modern Conditions of a Regional Vascular Center. **2022**, 11, 324-331 1
- 522 A Solution Trick: Implantation of Coronary Sinus Lead Without Delivery System, A Case Series Study. **2022**, 64, 374-379 0
- 521 Successful treatment of doxorubicin-induced cardiomyopathy with low-dose sacubitril/valsartan 1a case report. 0
- 520 The synergistic compatibility mechanisms of fuzi against chronic heart failure in animals: A systematic review and meta-analysis. 13, 0
- 519 STUDIES BASED ON THE HEALTH BELIEF MODEL IN HEART FAILURE: A SYSTEMATIC REVIEW. 0
- 518 Circulating long non-coding RNA Coromarker expression correlated with inflammation, coronary artery stenosis, and plaque vulnerability in patients with coronary artery disease. 0
- 517 Frailty and Hospitalization Burden in Patients With Chronic Heart Failure. **2022**, 0
- 516 B-type natriuretic peptide as prognostic marker in primary care patients with and without heart failure. **2022**, 0
- 515 Factors associated with hospitalisations of patients with chronic heart failure approaching the end of life: A systematic review. 026921632211234 0
- 514 Association of Systemic Trimethyllysine with Heart Failure with Preserved Ejection Fraction and Cardiovascular Events. 0
- 513 Transcatheter and surgical treatment of tricuspid regurgitation: Predicting right ventricular decompensation and favorable responders. 9, 0
- 512 Extent of Ejection Fraction Improvement After Revascularization Associated with Outcomes Among Patients with Ischemic Left Ventricular Dysfunction. Volume 15, 7219-7228 0
- 511 Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease. **2022**, 11, 1
- 510 Long-term Outcomes of Papillary Muscle Relocation Anteriorly for Functional Mitral Regurgitation. 0
- 509 Effectiveness and Safety of Thyroid Hormone Therapy in Patients with Dilated Cardiomyopathy: A Systematic Review and Meta-analysis of RCTs. 0
- 508 The myocardial flow reserve in patients with heart failure with preserved ejection fraction. 0

- 507 Role of Cardiac Contractility Modulation in Heart Failure with a Higher Ejection Fraction. **2022**, 0
- 506 Effects of multifaceted optimization management for chronic heart failure: a multicentre, randomized controlled study. 0
- 505 Assessment of Kidney Dysfunction in Patients with Chronic Heart Failure. **2022**, 10, 2093-2097 0
- 504 Clinical outcome and risk factors for acute fulminant myocarditis supported by venoarterial extracorporeal membrane oxygenation: An analysis of nationwide CSECLS database in China. **2022**, 1 1
- 503 Prognostic value of cardiac troponin in dialysis patients with paroxysmal supraventricular tachycardia. **2022**, 101, e30513 0
- 502 The effect of SGLT-2i administration on red blood cell distribution width in patients with heart failure and type 2 diabetes mellitus: A randomized study. 9, 0
- 501 The Conundrum of HFpEF Definition: Non-Invasive Assessment Uncertainties and Alternative Diagnostic Strategies. **2022**, 101433 0
- 500 Variables Associated with In-hospital and Post-Discharge Outcomes after Post-Cardiotomy Extracorporeal Membrane Oxygenation: Netherlands Heart Registration Cohort. **2022**, 0
- 499 Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction. 0
- 498 Guillaume et René LaenneImpact of procedural success on clinical outcome after MitraClip: Results from the MITRA-FR trial. **2022**, 0
- 497 Anthropometric parameters-derived estimation of muscle mass predicts all-cause mortality in heart failure patients. 0
- 496 QT and Tpeak-Tend interval variability: Predictive electrical markers of hospital stay length and mortality in acute decompensated heart failure. Preliminary data. 0
- 495 Current Status of Dapagliflozin in Congestive Heart Failure. **2022**, 0
- 494 Kardiyak Resenkronizasyon Tedavisinin Ventrikler Repolarizasyon Parametreleri ve Ventrikler Aritmiler Üzerindeki Etkisi. 0
- 493 Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST-CHF study. 0
- 492 Post-mortem examination of high mortality in patients with heart failure and atrial fibrillation. **2022**, 20, 0
- 491 Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension. Publish Ahead of Print, 0
- 490 Repetitive Therapie mit Levosimendan reduziert NT-proBNP und verbessert NYHA-Klasse. **2022**, 11, 484-489 0

- 489 The MAGGIC risk score in the prediction of death or hospitalization in patients with heart failure: Comparison with natriuretic peptides. **2022,** ○
- 488 SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction. **2022, 18, 561-577** ○
- 487 Sex-specific responses to slow progressive pressure overload in a large animal model of HFpEF. **2022, 323, H797-H817** ○
- 486 Extracorporeal life support in cardiotoxicant poisoning - a narrative review. ○
- 485 Clinical outcomes of opioid administration in acute and chronic heart failure: A meta-analysis. **2022, 102636** ○
- 484 Five-year prognosis of life in patients with peripartum cardiomyopathy. **2022, 17, 58** ○
- 483 The effect of COVID-19 infection on heart rate variability: A cross-sectional study. **2022, 8, 61** ○
- 482 Research Progress of Desflurane on Perioperative Myocardial Protection. **2022, 12, 9070-9080** ○
- 481 A New Medical Decision Support System for Diagnosing HFrEF and HFpEF Using ECG and Machine Learning Techniques. **2022, 10, 107283-107292** ○
- 480 Farmacología de los simpaticomiméticos: indicaciones terapéuticas en reanimación. **2022, 48, 1-16** ○
- 479 Integrated palliative care in the management of advanced heart failure. **2022, 9, 95-96** ○
- 478 Farmacologia dei simpaticomimetici: indicazioni terapeutiche in terapia intensiva. **2022, 27, 1-15** ○
- 477 ?????????, ????? ? ??? ????????? ?????????? ?????????? ??????? ?????????????????? ??????????? ?????????????? ○
- 476 Systemic Biomarkers and Unique Pathways in Different Phenotypes of Heart Failure with Preserved Ejection Fraction. **2022, 12, 1419** 1
- 475 Cardiovascular magnetic resonance phenotyping of heart failure with mildly reduced ejection fraction. ○
- 474 Systemic immune-inflammation index as a prognostic marker for advanced chronic heart failure with renal dysfunction. ○
- 473 Association of the medical therapy with beta-blockers or inhibitors of renin-angiotensin system with clinical outcomes in patients with mildly reduced left ventricular ejection fraction after acute myocardial infarction. **2022, 101, e30846** ○
- 472 The role of Qishen Yiqi dripping pills in treating chronic heart failure: An overview of systematic reviews and meta-analyses. 9, ○

- 471 The Electrocardiogram in the Diagnosis and Management of Patients With Left Ventricular Non-Compaction. ○
- 470 Risk factors for left atrial thrombus in younger patients (aged < 65 years) with atrial fibrillation or atrial flutter: Data from the multicenter left atrial thrombus on transesophageal echocardiography (LATTEE) registry. 9, ○
- 469 The Role of Gut Microbiota in Heart Failure: When Friends Become Enemies. **2022**, 10, 2712 ○
- 468 Burden of atrial fibrillation among adults with heart failure in sub-Saharan Africa: a systematic review and meta-analysis. **2022**, 12, e061618 ○
- 467 Excessive Adventitial and Perivascular Vascularisation Correlates with Vascular Inflammation and Intimal Hyperplasia. **2022**, 23, 12156 1
- 466 Risk factors of early death in pediatric hemophagocytic lymphohistocytosis: Retrospective cohort study. 10, ○
- 465 Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction. ○
- 464 Clinical performance and quality measures for heart failure management in China: the China-Heart Failure registry study. ○
- 463 Application Value of Systemic Inflammatory Indexes in the Clinical Evaluation of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF). **2022**, 58, 1473 ○
- 462 Analysis of rotary ventricular assist devices using CFD technique. Review. 095440892211283 ○
- 461 New principles for the treatment of chronic heart failure: the phenomenon of sodium-glucose cotransporter type 2 inhibitors. **2022**, 44-51 ○
- 460 Serum Uric Acid Is Associated with the Progression of Left Ventricular Diastolic Dysfunction in Apparently Healthy Subjects. **2022**, 2022, 1-12 1
- 459 Data-driven identification of heart failure disease states and progression pathways using electronic health records. **2022**, 12, ○
- 458 Pulmonary Capillary Wedge Pressure during Exercise Is Prognostic for Long-Term Survival in Patients with Symptomatic Heart Failure. **2022**, 11, 5901 ○
- 457 Association between tricuspid annular systolic velocity and poor short-term prognosis in patients with acute decompensated heart failure. **2022**, 54, 2898-2908 ○
- 456 Comprehensive Evaluation of Left Ventricle Dysfunction by a New Computed Tomography Scanner. **2022**, ○
- 455 Increased Soluble Epoxide Hydrolase Activity Positively Correlates with Mortality in Heart Failure Patients with Preserved Ejection Fraction: Evidence from Metabolomics. ○
- 454 Clusters of Comorbidities in the Short-Term Prognosis of Acute Heart Failure among Elderly Patients: A Retrospective Cohort Study. **2022**, 58, 1394 ○

- 453 Noninvasive evaluation of the hemodynamic status in patients after heart transplantation or left ventricular assist device implantation. **2022**, 17, e0275977 ○
- 452 Incidence and predictors of heart failure after acute coronary syndrome: The CORALYS registry. **2022**, ○
- 451 A multi-criteria decision model for assessing health and self-care ability. ○
- 450 Diversities in the Gut Microbial Patterns in Patients with Atherosclerotic Cardiovascular Diseases and Certain Heart Failure Phenotypes. **2022**, 10, 2762 ○
- 449 Angiotensin, vascular endothelial growth factors and secretory phospholipase A2 in heart failure patients with preserved ejection fraction. **2022**, ○
- 448 The SOCE Machinery: An Unbalanced Knowledge between Left and Right Ventricular Pathophysiology. **2022**, 11, 3282 ○
- 447 EFFECT OF TORASEMIDE AND INDAPAMIDE ON MAGNESIUM, POTASSIUM, CALCIUM AND SODIUM EXCRETION IN POST-MENOPAUSAL WOMEN WITH HYPERTENSION AND CHRONIC HEART FAILURE DEPENDING ON MAGNESIUM DEFICIENCY. **2022**, 24, 33-40 ○
- 446 Comparison of Patients with Reduced and Mildly Reduced Left Ventricular Ejection Fraction: Intermediate Data from the FAR NHL Registry. **2022**, 12, 10827 ○
- 445 Metabolomics implicate eicosanoids in severe functional mitral regurgitation. ○
- 444 Iron Deficiency in Heart Failure: What Do We Know So Far?. **2022**, ○
- 443 Comparison of six frailty instruments in adults with heart failure: a prospective cohort pilot study. ○
- 442 Iron Deficiency in Patients with Advanced Heart Failure. **2022**, 58, 1569 ○
- 441 Patient-Reported Quality of Life, Depression, Anxiety, and Physical Activity in Patients Receiving an Implantable Cardioverter-Defibrillator for Primary versus Secondary Prevention: A Single-Centre, Prospective, Observational Cohort Study. **2022**, 19, 12830 1
- 440 Funktionelle Charakterisierung von Patienten mit isoliert postkapillärer oder kombiniert post- und präkapillärer pulmonaler Hypertonie. **2022**, 76, 689-696 ○
- 439 Development and validation of a diagnostic prediction model reminiscent of systemic inflammation and organ interaction in heart failure preserved ejection fraction (HFpEF) patients. ○
- 438 Prognostic Nutritional Index and Major Cardiovascular Events in Patients Undergoing Invasive Coronary Angiography: A Clinical Retrospective Study. **2022**, 12, 1679 ○
- 437 Long-Term Ambulatory Intravenous Milrinone Therapy in Advanced Heart Failure. **2022**, ○
- 436 Prevalence of Chronic Kidney Disease After Heart Transplant: A Single Center Experience. **2022**, ○

- 435 Cardiac and Cancer-Associated Cachexia: Role of Exercise Training, Non-coding RNAs, and Future Perspectives. ○
- 434 Symptom Burden among Hospitalised Older Patients with Heart Failure in Hanoi, Vietnam. **2022**, 19, 13593 ○
- 433 Iron metabolism and cardiovascular disease: Basic to translational purviews and therapeutical approach. **2022**, ○
- 432 Real-time automatic quantification of left ventricular function by hand-held ultrasound devices in patients with suspected heart failure: a feasibility study of a diagnostic test with data from general practitioners, nurses and cardiologists. **2022**, 12, e063793 ○
- 431 Role of percutaneous pulmonary artery cannulation in extracorporeal life support for acute cardiac failure: A single-center case series. ○
- 430 Impact of Inpatient Initiation of Sodium-Glucose Cotransporter-2 Inhibitors on Prescription Rates in Patients With Heart Failure With Reduced Ejection Fraction. **2022**, ○
- 429 Gender Differences in Anxiety, Depression, Insomnia, and Quality of Life in Heart Failure With Preserved Ejection Fraction: A Multicenter, Cross-sectional Study. Publish Ahead of Print, ○
- 428 Prognostic impact of guideline-directed medical therapy in patients with heart failure on regular hemodialysis. **2022**, ○
- 427 Galectin-3 is Associated with Heart Failure Incidence: A Meta-Analysis. ○
- 426 Characterization of Plasma SDS-Protein Aggregation Profile of Patients with Heart Failure with Preserved Ejection Fraction. ○
- 425 Predictors of Clinical Success After Transcatheter Paravalvular Leak Closure: An International Prospective Multicenter Registry. **2022**, 15, ○
- 424 Clinical presentation and outcomes of acute heart failure in the critically ill patient: A prospective, observational, multicentre study. **2022**, ○
- 423 ⁶⁸Ga-FAPI PET visualize heart failure: from mechanism to clinic. ○
- 422 Drug-based MSC mobilisation improves cardiac function post myocardial infarction. ○
- 421 User experience and image quality influence on performance of automated real-time quantification of left ventricular function by handheld ultrasound devices: a diagnostic accuracy study with data from general practitioners, nurses and cardiologists. **2022**, 9, e002083 ○
- 420 Lßliche Guanylatzyklase(sGC)-Stimulation mit Vericiguat. ○
- 419 Impact of left ventricular ejection fraction on outcomes after left main revascularization: g-LM Registry. Publish Ahead of Print, ○
- 418 Prognostic value of right ventricular strain and peak oxygen consumption in heart failure with reduced ejection fraction. ○

417	Machine Learning Approach to Understand Worsening Renal Function in Acute Heart Failure. 2022 , 12, 1616	1
416	Left atrial phasic volumes and functions changes in asymptomatic patients with sarcoidosis: evaluation by three-dimensional echocardiography. 1-9	1
415	Remote Dielectric Sensing to detect acute heart failure in patients with dyspnoea in a prospective observational study in the emergency department.	1
414	Morphological, functional, and biomechanical progression of LV remodelling in a porcine model of HFpEF. 2022 , 144, 111348	0
413	Performance of the heart failure risk scores in predicting 1 year mortality and short-term readmission of patients.	0
412	Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study. 9,	0
411	Liver stiffness assessed by magnetic resonance elastography predicts clinical outcomes in patients with heart failure and without chronic liver disease.	0
410	Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective. 13,	0
409	Characteristics and Perioperative Outcomes of Fracture in Elderly patients with Chronic Heart Failure: A Cross-Sectional Study.	0
408	Clinician Adoption of an Artificial Intelligence Algorithm to Detect Left Ventricular Systolic Dysfunction in Primary Care.. 2022 , 97, 2076-2085	0
407	Left atrial strain correlates with severity of cardiac involvement in Anderson-Fabry disease.	0
406	Association of Selenium and Cadmium with Heart Failure and Mortality Based on the National Health and Nutrition Examination Survey.	0
405	Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. 2022 , 102, 990-999	1
404	Physical performance and maximum tongue pressure associated with oral intake independence: a retrospective study on hospitalized patients with heart failure. 2022 , 12,	0
403	Long-term outcomes following catheter ablation versus medical therapy in patients with persistent atrial fibrillation and heart failure with reduced ejection fraction.	1
402	Impact of clinical ultrasound in patients with heart failure treated in home. 2022 , 159, 420-425	0
401	Cardiac MRI Risk Stratification for Dilated Cardiomyopathy with Left Ventricular Ejection Fraction of 35% or Higher.	0
400	Relationship of Circulating Vegetable Omega-3 to Prognosis in Patients With Heart Failure. 2022 , 80, 1751-1758	0

- 399 Identification of predictive factors interacting with heart rate reduction for potential beneficial clinical outcomes in chronic heart failure: A systematic literature review and meta-analysis. **2022**, 43, 101141 0
- 398 Recomendaciones para la evaluación de la función diastólica del ventrículo izquierdo: enfoque actualizado. **2017**, 65-69 0
- 397 Effects of obesity on arrhythmic events and survival in patients with an implantable cardioverter defibrillator. **2022**, 62, 56-65 0
- 396 Atrial Fibrillation Risk Assessment after Embolic Stroke of Undetermined Source. 0
- 395 Combination Prophylaxis in CMV high risk heart transplant recipients in a single centre experience. 0
- 394 Upgrading right ventricular pacemakers to biventricular pacing or conduction system pacing: a systematic review and meta-analysis. 0
- 393 Design and rationale of the inferior vena CAVA and Lung UltraSound-guided therapy in Acute Heart Failure (CAVAL US-AHF Study): a randomised controlled trial. **2022**, 9, e002105 0
- 392 Advanced glycation end-products, cardiac function and heart failure in the general population: The Rotterdam Study. 2
- 391 Right ventricular free wall longitudinal strain is independently associated with mortality in mechanically ventilated patients with COVID-19. **2022**, 12, 0
- 390 Factors Associated With Depression and Anxiety for Community-Dwelling Patients With Heart Failure. Publish Ahead of Print, 0
- 389 A New Chapter in the Treatment of Patients with Heart Failure. The Role of Sodium-Glucose Co-transporter Type 2 Inhibitors. **2022**, 18, 606-613 0
- 388 Contemporary Data on the Status and Medical Management of Acute Heart Failure. 1
- 387 Outpatient treatment of worsening heart failure with intravenous diuretics: first results from a multicentre 2-year experience. 0
- 386 Management of circulatory failure after Fontan surgery. 10, 0
- 385 Vagal nerve stimulation preserves right ventricular function in a rat model of right ventricular pressure overload. 0
- 384 Predictive value of the TyG index and rheumatoid factor for cardiovascular disease risk in a rheumatoid arthritis population: data from a survey of 418 patients. **2022**, 21, 0
- 383 Validation of Algorithms to Identify Acute Myocardial Infarction, Stroke, and Cardiovascular Death in German Health Insurance Data. Volume 14, 1351-1361 0
- 382 The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial. **2022**, 21, 5

- 381 Clinical trajectories and outcomes of patients with heart failure with preserved ejection fraction with normal or indeterminate diastolic function. ○
- 380 Metabolic pathways enriched according to ERG status are associated with biochemical recurrence in Hispanic/Latino patients with prostate cancer. ○
- 379 Analysis of pathogenesis and drug treatment of chronic obstructive pulmonary disease complicated with cardiovascular disease. 9, ○
- 378 Case report: challenges in monitoring and treatment of anthracycline induced cardiotoxicity in young adults with osteosarcoma. **2022**, 8, ○
- 377 Fluid overload and mortality in critically ill patients with severe heart failure and cardiogenic shock. An observational cohort study. 9, ○
- 376 Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms. **2022**, 4, 442-454 ○
- 375 Cardiac resynchronization therapy in an orthotopic heart transplant recipient. **2022**, ○
- 374 Speckle-tracking echocardiography for predicting improvement of myocardial contractile function after revascularization: a meta-analysis of prospective trials. ○
- 373 Renal function during hospitalization and outcome in Chinese patients with acute decompensated heart failure: A retrospective study and literature review. ○
- 372 Use of vasodilators in patients with acute heart failure: contra. ○
- 371 Treatment response in recent-onset heart failure with reduced ejection fraction: non-ischaemic vs. ischaemic aetiology. ○
- 370 METTL14 is required for exercise-induced cardiac hypertrophy and protects against myocardial ischemia-reperfusion injury. **2022**, 13, ○
- 369 Genome-wide association and multi-trait analyses characterize the common genetic architecture of heart failure. **2022**, 13, ○
- 368 Successful conservative management of left ventricular assist device candidates. ○
- 367 Unveiling Human Proteome Signatures of Heart Failure with Preserved Ejection Fraction. **2022**, 10, 2943 ○
- 366 Challenges in the Differential Diagnosis of COVID-19 Pneumonia: A Pictorial Review. **2022**, 12, 2823 1
- 365 Adversarial reinforcement learning for dynamic treatment regimes. **2022**, 104244 ○
- 364 Stress hyperglycemia ratio and neutrophil to lymphocyte ratio are reliable predictors of new-onset atrial fibrillation in patients with acute myocardial infarction. 9, ○

- 363 A formal validation of a deep learning-based automated workflow for the interpretation of the echocardiogram. **2022**, 13, 0
- 362 The Landscape of Outpatient Palliative Care in Germany: Results from a Retrospective Analysis of 14,792 Patients. **2022**, 19, 14885 1
- 361 Multifactorial Effects of Outpatient Cardiac Rehabilitation in Patients with Heart Failure: A Nationwide Retrospective Cohort Study. 0
- 360 Neurometabolism and Ventricular Dyssynchrony in Patients With Heart Failure and Reduced Ejection Fraction. **2022**, 80, 1884-1896 0
- 359 Correlation between the prognostic nutritional index and outcomes in older patients aged ≥ 60 years with chronic heart failure. 1
- 358 Update on gut microbiota in cardiovascular diseases. 12, 2
- 357 Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF. 9, 0
- 356 Neutrophilic granulocyte percentage is associated with anxiety in Chinese hospitalized heart failure patients. **2022**, 22, 0
- 355 Meta-Analysis on the Safety and Efficacy of Sodium Glucose Cotransporters 2 Inhibitors in Patients With Heart Failure With and Without Diabetes. **2023**, 187, 93-99 0
- 354 Pulmonary hypertension associated with left-sided heart disease. **2017**, 147, w14395 0
- 353 Sinais e sintomas de pacientes com insuficiência cardíaca em cuidados paliativos: revisão de escopo. 26, 0
- 352 The relationship between caregiver contributions to self-care and quality of life in heart failure patients in Ardabil hospitals in Ardebil-Iran. **2023**, 18, 100511 0
- 351 Diagnosis of heart failure from imbalance datasets using multi-level classification. **2023**, 81, 104538 0
- 350 Fall 43 Die Ösophagusresektion. **2022**, 39-63 0
- 349 Malnutrition management of hospitalized patients with diabetes/hyperglycemia and heart failure. **2022**, 0
- 348 Risk Factors with 30-Day Readmission and the Impact of Length of Hospital Stay on It in Patients with Heart Failure: A Retrospective Observational Study Using a Japanese National Database. **2022**, 0
- 347 Other Important Clinical Pictures and Interventions in Cardiology. **2022**, 129-199 0
- 346 Introduction of specialized heart failure nurses in primary care and its impact on readmissions. **2022**, 23, 0

345	Le patient atteint de maladies cardiovasculaires. 2022 , 99-122	○
344	Telemedicine to Support Heart Failure Patients during Social Distancing: A Systematic Review. 2022 , 17,	○
343	Prescription patterns of evidence-based heart failure medications in a Tertiary Hospital in North-Western Nigeria: A retrospective study. 2022 , 19, 151	○
342	Relevance of Machine Learning to Cardiovascular Imaging. 2022 , 589-605	○
341	Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction.	○
340	Impact of a heart failure nurse practitioner service on rehospitalizations, emergency presentations, and survival in patients hospitalized with acute heart failure.	○
339	Early administration of ivabradine in patients admitted for acute decompensated heart failure. 9,	○
338	Reduced left atrial contractile strain with speckle tracking analysis predicts abnormal plasma NTproBNP in an asymptomatic community population. 2022 , 20,	○
337	Multimarker Analysis of Serially Measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, Creatinine, and Prognosis in Acute Heart Failure.	○
336	Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry.	1
335	Cardiopulmonary exercise testing excludes significant disease in patients recovering from COVID-19. e002193	○
334	Left Ventricle Wall Motion Analysis with Real-Time MRI Feature Tracking in Heart Failure Patients: A Pilot Study. 2022 , 12, 2946	○
333	Cardiac Rehabilitation for Older Women with Heart Failure. 2022 , 12, 1980	○
332	Trends in contemporary advanced heart failure management: an in-depth review over 30 years of heart transplant service in Hong Kong. 2022 ,	○
331	Early predicting improvement of severe systolic heart failure by left atrial volume.	○
330	Septal myocardial scar burden predicts the response to cardiac contractility modulation in patients with heart failure. 2022 , 12,	○
329	Machine learning models in heart failure with mildly reduced ejection fraction patients. 9,	○
328	The Role of Modifiable and Non-Modifiable Factors in the Development of Right and Left Ventricular Myocardial Dysfunction in High-Risk Patients. 2022 , 62, 26-32	○

- 327 Severity of and Recovery From Anemia After Transcatheter Aortic Valve Replacement: An Analysis of the PARTNER Trials and Registries. **2022**, 100531 ○
- 326 The relationship between myocardial microstructure and strain in chronic infarction using cardiovascular magnetic resonance diffusion tensor imaging and feature tracking. **2022**, 24, ○
- 325 Management of ventricular arrhythmias in heart failure: current perspectives. **2022**, 21, 139-149 ○
- 324 Atrial cardiomyopathy markers predict ischemic cerebrovascular events independent of atrial fibrillation in patients with acute myocardial infarction. 9, ○
- 323 Central role of laboratory medicine in public health and patient care. **2022**, ○
- 322 Beta-blockers and mechanical dyssynchrony in heart failure assessed by radionuclide ventriculography. ○
- 321 Machine learning predicting atrial fibrillation as an adverse event in the Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial (Preprint). ○
- 320 Risk Factors of Sudden Cardiac Arrest during the Postoperative Period in Patient Undergoing Heart Valve Surgery. **2022**, 11, 7098 ○
- 319 Influence of Atrial Fibrillation on Two-Year Survival of Patients with Implanted Cardioverter Defibrillator. **2022**, ○
- 318 Coefficient of R-R interval variations under deep breathing load in patients with wild-type transthyretin amyloid cardiomyopathy: A case-control study. **2023**, 6, ○
- 317 Dynamic aspects of ventricular interaction during exercise in HFpEF and in pre-capillary pulmonary hypertension. ○
- 316 HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity. **2022**, ○
- 315 Magnetic resonance elastography from fundamental soft-tissue mechanics to diagnostic imaging. ○
- 314 Cardiac contractility modulation in heart failure with reduced ejection fraction treatment. **2022**, 62, 71-78 ○
- 313 The Association of Protein Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. ○
- 312 Prise en charge de la carence martiale au cours de la maladie rhale chronique : mise au point et proposition d'un algorithme. **2022**, 18, 658-665 ○
- 311 Predicting diagnostic immune-related gene biomarkers in the development of heart failure after acute myocardial infarction: Bioinformatics based approaches. ○
- 310 Inter-American Society of Cardiology (CIFACAH-ELECTROSIAC) and Latin-American Heart Rhythm Society (LAHRS): multidisciplinary review on the appropriate use of implantable cardioverter defibrillator in heart failure with reduced ejection fraction. ○

- 309 Physical Activity Readiness in Patients with Heart Failure. **2022**, 19, 16332 ○
- 308 Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors. **2022**, 21, ○
- 307 Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study. **2023**, 26, 51-60 1
- 306 Carbohydrate antigen 125 combined with N-terminal pro-B-type natriuretic peptide in the prediction of acute heart failure following ST-elevation myocardial infarction. **2022**, 101, e32129 ○
- 305 The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients. **2022**, ○
- 304 Comparing clinical characteristics of systemic sclerosis with or without interstitial lung disease: A cross-sectional study from a single center of the Chinese Rheumatism Data Center. 9, ○
- 303 Cardiovascular predictors of mortality and exacerbations in patients with COPD. **2022**, 12, ○
- 302 Diagnostic utility of total NT-proBNP testing by immunoassay based on antibodies targeting glycosylation-free regions of NT-proBNP. **2022**, ○
- 301 Higher Work of Breathing during Exercise in Heart Failure with Preserved Ejection Fraction. **2022**, ○
- 300 Systems Biology in Chronic Heart Failure Identification of Potential miRNA Regulators. **2022**, 23, 15226 1
- 299 Brain natriuretic peptide levels and short physical performance battery scores independently influence short-term readmission rates in older patients with heart failure. ○
- 298 Heart failure with preserved left ventricular ejection fraction amidst diabetes mellitus: from general mechanisms to possible therapy tactics. **2022**, 13, 115-123 ○
- 297 Applicability of new proposed criteria for iron deficiency in Japanese patients with heart failure. ○
- 296 Prognostic Implications of Mechanical Phenotypes in Heart Failure Characterized by 3-Chamber Strain Echocardiography. **2022**, 11, ○
- 295 Left-ventricular volumes and ejection fraction from cardiac ECG-gated 15O-water positron emission tomography compared to cardiac magnetic resonance imaging using simultaneous hybrid PET/MR. ○
- 294 Overexpression of GRK2 in vascular smooth muscle leads to inappropriate hypertension and acute heart failure as in Clinical Scenario 1. ○
- 293 Hyperkalemia: Prevalence, Predictors and Emerging Treatments. ○
- 292 Pragmatic screening for heart failure in the general population using an electrocardiogram-based neural network. ○

291	Relationship between quadriceps femoris muscle architecture and muscle strength and physical function in older adults with heart failure with preserved ejection fraction. 2022 , 12,	0
290	Association of genetically-predicted lipid traits and lipid-modifying targets with heart failure.	0
289	Diagnostic signature for heart failure with preserved ejection fraction (HFpEF): a machine learning approach using multi-modality electronic health record data. 2022 , 22,	0
288	Preoperative clinical diagnostic accuracy of heart failure among patients undergoing major noncardiac surgery: a single-centre prospective observational analysis. 2022 , 4, 100113	0
287	A Self-Sustaining Antioxidant Strategy for Effective Treatment of Myocardial Infarction. 2204999	1
286	The Role of the N-Terminal of the Prohormone Brain Natriuretic Peptide in Predicting Postoperative Multiple Organ Dysfunction Syndrome. 2022 , 11, 7217	2
285	SECURE, ADVOR and REVIVED: Clinical Trials Presented at ESC 2022.	0
284	Left Bundle Branch Area Pacing versus Biventricular Pacing for Cardiac Resynchronization Therapy on Morbidity and Mortality.	0
283	Primary Healthcare Nurses' Views on Digital Healthcare Communication and Continuity of Care: A Deductive and Inductive Content Analysis. 2022 , 12, 945-957	1
282	Mechanotransduction regulates inflammation responses of epicardial adipocytes in cardiovascular diseases. 13,	0
281	Experimental heart failure models in small animals.	0
280	Right ventricular echocardiographic parameters and prediction of stroke volume in ischemic cardiogenic shock: A retrospective study. 2022 , 154219	0
279	Prevalence of sarcopenia in heart failure: A systematic review. 2022 ,	0
278	The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus.	1
277	Hyperpolypharmacy is a predictor of mortality after left ventricular assist device (LVAD) implantation. 2022 , 24, 100233	0
276	Fetal NT-proBNP levels and their course in severe anemia during intrauterine treatment.	0
275	Pathogenic roles of neutrophil-derived alarmins (S100A8/A9) in heart failure: From molecular mechanisms to therapeutic insights.	0
274	Associations between serum electrolyte and short-term outcomes in patients with acute decompensated heart failure. 2023 , 55, 155-167	0

273	The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients. 2022,	0
272	Exercise Capacity, Iron Status, Body Composition, and Mediterranean Diet in Patients with Chronic Heart Failure. 2023, 15, 36	0
271	Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction. 2023, 12, 42	1
270	Hepatic Steatosis and Advanced Hepatic Fibrosis are Independent Predictors of Long-Term Mortality in Acute Myocardial Infarction.	0
269	Quantitative evaluation of hemodynamic parameters by echocardiography in patients with post-cardiotomy cardiac shock supported by extracorporeal membrane oxygenation. 2023, 18,	0
268	A Novel Reperfusion Strategy for Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction: A Prospective Case Series. 2023, 12, 433	0
267	The evolution of digital health technologies in cardiovascular disease research. 2023, 6,	0
266	Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure. 9,	1
265	Point-of-Care Diagnostic Testing in Urgent Cardiac Care. 2022, 155-171	0
264	Comparison of telemonitoring combined with intensive patient support with standard care in patients with chronic cardiovascular disease - a randomized clinical trial. 2023, 28,	0
263	Aspects of transthoracic echocardiography protocol in obese patients. 2023, 27, 5243	0
262	Prevalence of Cardio-Embolic Brain Complications in Permanent and Paroxysmal Atrial Fibrillation Patients. 2023, 11, 175	0
261	Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update.	1
260	Relevance of subclinical right ventricular dysfunction measured by feature-tracking cardiac magnetic resonance in non-ischemic dilated cardiomyopathy. 2023, 23,	0
259	Predictors of in-hospital heart failure in patients with acute anterior wall ST-segment elevation myocardial infarction. 2023,	0
258	Frailty phenotype in heart failure: A condition that transcends age. 2023,	0
257	Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study). 2023, 12, 699	0
256	Acute heart failure after non-cardiac surgery: incidence, phenotypes, determinants and outcomes.	1

- 255 Cognitive impairment in patients with heart failure: molecular mechanism and therapy. ○
- 254 Valvular Heart Disease in the Elderly: Clinical and Multi-Modality Imaging Perspectives. **2023**, 277-302 ○
- 253 Prognostic value of coronary CT angiography in heart failure patients with preserved ejection fraction. ○
- 252 Longer-Term Effects of Remote Patient Management Following Hospital Discharge After Acute Systolic Heart Failure. **2023**, ○
- 251 Sex and age differences in sST2 in cardiovascular disease. 9, ○
- 250 The optimum anticoagulation time after endovascular thrombectomy for atrial fibrillation-related large vessel occlusion stroke: a real-world study. ○
- 249 Rasch analysis of the Short Physical Performance Battery in older inpatients with heart failure. 1-6 ○
- 248 Comparisons of Drug-Eluting Balloon versus Drug-Eluting Stent in the Treatment of Young Patients with Acute Myocardial Infarction. **2023**, 10, 29 ○
- 247 Risk scores in cardiac resynchronization therapy: A review of the literature. 9, ○
- 246 Diabetic microvascular complications predicts non-heart failure with reduced ejection fraction in type 2 diabetes. ○
- 245 The prognostic role of the echocardiographic tricuspid annular plane systolic excursion/systolic pulmonary arterial pressure (TAPSE/sPAP) ratio and its relationship with NT-proANP plasma level in systemic sclerosis. 9, ○
- 244 Association between glucocorticoid use and all-cause mortality in critically ill patients with heart failure: A cohort study based on the MIMIC-III database. 14, ○
- 243 The scale of scientific evidence behind the current ESC clinical guidelines. **2023**, 101175 ○
- 242 Outcomes of inflammatory cardiomyopathy following cardiac rehabilitation. **2023**, 24, 59-61 ○
- 241 Heart Failure-Smart Life: a randomized controlled trial of a mobile app for self-management in patients with heart failure. **2023**, 23, ○
- 240 Analysis of Function Role and Long Noncoding RNA Expression in Chronic Heart Failure Rats Treated with Hui Yang Jiu Ji Decoction. **2023**, 2023, 1-15 ○
- 239 Effectiveness of Spironolactone in Terms of Galectin-3 Levels in Patients with Heart Failure with a Reduced Ejection Fraction in the Vietnamese Population. **2023**, 11, 253 ○
- 238 Age affects the diagnostic accuracy of serum N-terminal pro-B-type natriuretic peptide for heart failure in patients with pleural effusion. **2023**, ○

- 237 Iron therapy and severe arrhythmias in HFREF: rationale, study design, and baseline results of the RESAFE-HF trial. ○
- 236 Circular RNAs at the intersection of cancer and heart disease: potential therapeutic targets in cardio-oncology. ○
- 235 Involvement of Vasopressin in Tissue Hypoperfusion during Cardiogenic Shock Complicating Acute Myocardial Infarction in Rats. **2023**, 24, 1325 ○
- 234 N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia. **2023**, 98, 290-299 ○
- 233 ROX index versus HACOR scale in predicting success and failure of high-flow nasal cannula in the emergency department for patients with acute hypoxemic respiratory failure: a prospective observational study. **2023**, 16, ○
- 232 Evaluation of sodium-glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics. ○
- 231 Role of Iron Deficiency in Heart Failure Clinical and Treatment Approach: An Overview. **2023**, 13, 304 1
- 230 Characteristics and Outcomes of Early vs Late Initiation of Mechanical Circulatory Support in Non-Acute Myocardial Infarction related Cardiogenic Shock: An Analysis of the National Inpatient Sample Database. **2023**, 101584 ○
- 229 Genetically determined serum bilirubin level and the risk of heart failure: A mendelian randomization study. 14, ○
- 228 Efficacy and Safety of Shenfu Injection on Acute Heart Failure: A Systematic Review and Meta-Analysis. **2023**, 110, 154641 ○
- 227 Lung ultrasound in diagnosis of acute heart failure: A protocol for systematic review and meta-analysis. **2022**, 101, e32257 ○
- 226 Investigating the Association Between Telemedicine Use and Timely Follow-Up Care After Acute Cardiovascular Hospital Encounters. **2022**, 1, 100156 ○
- 225 Anakinra in Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. **2023**, 11, 4 ○
- 224 Advanced heart failure: parenteral diuretics for breathlessness and peripheral oedema Systematic review. spcare-2022-003863 ○
- 223 Elevated Plasma Immunoglobulin Levels Prior to Heart Transplantation Are Associated with Poor Post-Transplantation Survival. **2023**, 12, 61 ○
- 222 Prognostic significance of pulmonary arterial wedge pressure estimated by deep learning in acute heart failure. ○
- 221 Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials. **2022**, 101, e32489 ○
- 220 Diagnostic Accuracy of Global Longitudinal Strain for Detecting Exercise Intolerance in Patients with Ischemic Heart Disease. **2023**, 10, 10 ○

- 219 Cardiac dysfunction and high-sensitive C-reactive protein are associated with troponin T elevation in ischemic stroke: insights from the SICFAIL study. **2022**, 22, ○
- 218 Kinematic Parameters That Can Discriminate in Levels of Functionality in the Six-Minute Walk Test in Patients with Heart Failure with a Preserved Ejection Fraction. **2023**, 12, 241 ○
- 217 Impact of tolvaptan add-on treatment on patients with heart failure requiring long-term congestion management: A retrospective cohort study using a medical claim database in Japan. **2022**, ○
- 216 Inflammation on Endomyocardial Biopsy Predicts Risk of MACE in Undefined Left Ventricular Arrhythmogenic Cardiomyopathy. **2023**, ○
- 215 Acute Heart Failure: Diagnostic Therapeutic Pathways and Preventive Strategies A Real-World Clinician Guide. **2023**, 12, 846 1
- 214 Heart failure with preserved ejection fraction: the role of microvascular dysfunction. **2023**, 21, 88-97 ○
- 213 Practical role of preoperative echocardiography in low-risk non-cardiac surgery. 10, ○
- 212 Interatrial septal aneurysm associated with patent foramen ovale in a dog - case report. **2023**, 75, 98-106 ○
- 211 Xin-Li-Fang efficacy and safety for patients with chronic heart failure: A study protocol for a randomized, double-blind, and placebo-controlled trial. 10, ○
- 210 Long-term outcomes of perioperative myocardial infarction/injury after non-cardiac surgery. ○
- 209 Suture-based vs. pure plug-based vascular closure devices for VA-ECMO decannulation A retrospective observational study. 10, ○
- 208 Left ventricle segmentation and quantification using deep learning. **2023**, 113-147 ○
- 207 Prognostic Role of Sonographic Decongestion in Patients with Acute Heart Failure with Reduced and Preserved Ejection Fraction: A Multicentre Study. **2023**, 12, 773 ○
- 206 Right ventricular free wall strain and effect of defibrillator implantation in patients with non-ischemic systolic heart failure.. **2023**, ○
- 205 Bloquants: interdits chez les asthmatiques?. **2023**, ○
- 204 Diretriz Brasileira de Dispositivos Cardíacos Eletrônicos Implantáveis 2023. **2023**, 120, ○
- 203 EVIDENCE FOR ANGIOTENSIN II AS A NATURALLY EXISTING SUPPRESSOR FOR THE NATRIURETIC PEPTIDE SYSTEM. ○
- 202 Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis. 18, ○

201	Prediction and Analysis of Heart Failure Decompensation Events Based on Telemonitored Data and Artificial Intelligence Methods. 2023 , 10, 48	1
200	Differences in the clinical outcome of Ischemic and Non-Ischemic Cardiomyopathy in Heart Failure with concomitant Opioid Use Disorder. 2023 , 101609	0
199	Effects of phytosterols supplementation on lipid profiles in patients with hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials.	0
198	Management of Heart Failure with Reduced Ejection Fraction. 2023 , 101596	0
197	Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction. 2023 , 23,	1
196	Cardiovascular Disease Causes Proinflammatory Microvascular Changes in the Human Right Atrium.	0
195	Validation of the Meta-Analysis Global Group in Chronic Heart Failure risk score for the prediction of 1-year mortality in a Chinese cohort. 2022 , 135, 2829-2835	0
194	Bioinformatics Study on Renin Angiotensin in Lung, and Liver Cancer Using Plant-Based Extracts. 2023 , 155-177	0
193	Use of Electronic Messages in the Follow-Up of Patients With Heart Failure: Randomized Pilot Study. 2023 , 16, 117863292311546	0
192	Body posture determination for Heart Failure patients from ankle orientation measurements. 2023 , 1-1	0
191	Ambulatory Care Management in Low Blood Pressure Patient with HFrEF.	0
190	Maternal Outcomes Among Pregnant Women With Congenital Heart Disease Associated Pulmonary Hypertension. 2023 , 147, 549-561	0
189	Prognostic utility of pulse pressure in patients with heart failure with preserved ejection fraction: The RICA Registry. 2023 , 223, 231-239	0
188	Comparison of classical Fabry and its p.D313Y and p.A143T variants by cardiac T1 mapping, LGE and feature tracking myocardial strain. 2023 , 13,	0
187	Disparities in prevalence of heart failure between the genders in relation to age, multimorbidity and socioeconomic status in southern Sweden: a cross-sectional study. 1-10	0
186	Machine learning-based in-hospital mortality risk prediction tool for intensive care unit patients with heart failure. 10,	0
185	Heart failure and diabetes: Clinical significance and epidemiology of this two-way association.	0
184	Heart Failure with Preserved vs. Reduced Ejection Fraction: Patient Characteristics, In-hospital Treatment and Mortality DanAHF, a Nationwide Prospective Study.	0

- 183 Diabetes mellitus and hemodynamics in advanced heart failure. **2023**, 379, 60-65 ○
- 182 Prognostic impact of cardiovascular polypharmacy on octogenarians with heart failure with preserved ejection fraction. **2023**, 378, 55-63 ○
- 181 Failure of Guidelines and Consensus Statements to Recommend Follow-up for Chronic Cardiovascular Conditions. **2023**, 59, 128-138 ○
- 180 Salivary lipid mediators: Key indexes of inflammation regulation in heart failure disease. **2023**, 201, 55-65 ○
- 179 Left ventricular strain-volume loops and diastolic dysfunction in suspected heart failure with preserved ejection fraction. **2023**, 378, 144-150 ○
- 178 Cardiovascular magnetic resonance rest and exercise-stress left atrioventricular coupling index to detect diastolic dysfunction. **2023**, 324, H686-H695 ○
- 177 Long-term exposure to air pollution and increased risk of atrial fibrillation prevalence in China. **2023**, 378, 130-137 ○
- 176 Iron chelation alleviates multiple pathophysiological pathways in a rat model of cardiac pressure overload. **2023**, 200, 1-10 ○
- 175 Fifth decennium after the arterial switch operation for transposition of the great arteries. **2023**, 12, 100451 ○
- 174 Predictors of physical activity behavior change among patients with heart failure enrolled in home-based cardiac rehabilitation intervention. **2023**, 61, 16-21 ○
- 173 Features of drug pharmacotherapy in patients with heart failure after pacemaker implantation. **2020**, 88, 21-26 ○
- 172 Machine Learning-Based Prediction of Digoxin Toxicity in Heart Failure: A Multicenter Retrospective Study. **2023**, 46, 614-620 ○
- 171 Renal Denervation Helps Preserve the Ejection Fraction by Preserving Endocardial-Endothelial Function during Heart Failure. **2023**, 24, 7302 ○
- 170 Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results. **2023**, ○
- 169 Screening for Biomarkers Associated with Left Ventricular Function During Follow-up After Acute Coronary Syndrome. **2023**, 16, 244-254 ○
- 168 Heart Failure Outcomes and Management. **2022**, 111-115 ○
- 167 Educational inequalities in heart failure mortality and the cycles of the internal armed conflict in Colombia: An observational panel study of ecological data, 1999-2017. **2023**, 9, e13050 ○
- 166 Cardiac Rehabilitation for Patients with Left Ventricular Assist Device and Heart Transplantation. **2022**, 2, 52-61 ○

- 165 Prediction of one-year adverse clinical outcomes by macrophage migration inhibitory factor in stemi patients. **2022**, 19-29 ○
- 164 Comparison of the Recent Updates to the ACC/AHA and ESC Guidelines for the Management of Valvular Heart Disease: Similarities and Differences. **2023**, 25, 147-156 ○
- 163 Investigating Occupation, Ejection Fraction, and Comorbidity Factors with Quality of Life in Heart Failure Patients: A Cross-Sectional Study in Indonesia. **2023**, In Press, ○
- 162 Comparison of Hemodynamic Response between Patients with Systolic Heart Failure Differing in Serum Aldosterone Concentrations during and after a 6-Minute Walk Test. **2023**, 12, 1007 ○
- 161 Features of post-infarction chronic heart failure in patients with a new coronavirus infection COVID-19. **2023**, 104, 20-29 ○
- 160 Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction: Technique Principles, Current Evidence, and Future Perspectives. Publish Ahead of Print, ○
- 159 Citalopram in the treatment of elderly chronic heart failure combined with depression: A systematic review and meta-analysis. 10, ○
- 158 The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure. **2023**, 10, 1314-1325 ○
- 157 Innovations in medical therapy of heart failure with reduced ejection fraction. **2023**, 24, e47-e54 ○
- 156 Efficacy of CRT upgrade in pacemaker-induced cardiomyopathy in an outpatient clinic [Results of a prospective registry. **2023**, 377, 60-65 ○
- 155 Chronic Kidney Disease as a Comorbidity in Heart Failure. **2023**, 24, 2988 ○
- 154 Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction. **2023**, 10, 1358-1371 ○
- 153 The Efficacy and Safety of a Qiliqiangxin Capsule Combined with Sacubitril/Valsartan in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis. **2023**, 2023, 1-15 ○
- 152 Efficacy of peritoneal dialysis in patients with refractory congestive heart failure: a systematic review and meta-analysis. ○
- 151 Persistent Hypochloremia Is Associated with Adverse Prognosis in Patients Repeatedly Hospitalized for Heart Failure. **2023**, 12, 1257 ○
- 150 Hypocapnia is an independent predictor of in-hospital mortality in acute heart failure. **2023**, 10, 1385-1400 ○
- 149 Global historical retrospect and future prospects on biomarkers of heart failure: A bibliometric analysis and science mapping. **2023**, 9, e13509 ○
- 148 A Pharmacological Review of Tanshinones, Naturally Occurring Monomers from *Salvia miltiorrhiza* for the Treatment of Cardiovascular Diseases. **2023**, 2023, 1-24 ○

- 147 Morbidity and Mortality Following Heart Failure Rehabilitation: The Effect of Programme Completion and 6-min Walk Test Distance. 026921552311541 ○
- 146 Continuous Infusion Versus Bolus Injection of Loop Diuretics for Patients With Congestive Heart Failure: A Meta-Analysis. **2023**, ○
- 145 Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Disease: A Real-World Experience. **2023**, 12, 1334 ○
- 144 Distinct Associations Between Postdischarge Cognitive Change Patterns and 1-year Outcomes in Patients Hospitalized for Heart Failure. **2023**, ○
- 143 I. General: Read Treatment Algorithm for Heart Failure in the Guideline Focused Update; 2. Heart Failure with Preserved Ejection Fraction (HFpEF). **2022**, 111, 213-220 ○
- 142 Prognostic Implications of OSA in Acute Coronary Syndrome by Obesity Status. **2023**, ○
- 141 Effectiveness and Safety of Mitral Valve Plasty in Patients with an Anomalous Origin of the Coronary Artery from the Pulmonary Artery. **2023**, 10, 75 ○
- 140 The Charlson comorbidity index and short-term readmission in patients with heart failure: A retrospective cohort study. **2023**, 102, e32953 ○
- 139 Cardioprotective effect of thiotriazoline in cancer patients. **2023**, 28, 5304 ○
- 138 Effects of Individualised High Positive End-Expiratory Pressure and Crystalloid Administration on Postoperative Pulmonary Function in Patients Undergoing Robotic-Assisted Radical Prostatectomy: A Prospective Randomised Single-Blinded Pilot Study. **2023**, 12, 1460 ○
- 137 Diagnostic value of left atrial strain in heart failure with a preserved ejection fraction. ○
- 136 Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group. **2023**, 24, e108-e120 ○
- 135 Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis. 1-10 ○
- 134 Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction. ○
- 133 Omega-3 fatty acids in heart disease: Why accurately measured levels matter. ○
- 132 Long-term outcome of cardiac resynchronization therapy patients in the elderly. ○
- 131 The platelet to lymphocyte ratio in heart failure: a comprehensive review. **2023**, ○
- 130 Accuracy and Performance of Heart Failure Prediction System by Using Backpropagation Network (BPN). **2023**, 67-90 ○

- 129 FK506-Binding Protein like (FKBPL) Has an Important Role in Heart Failure with Preserved Ejection Fraction Pathogenesis with Potential Diagnostic Utility. **2023**, 13, 395 ○
- 128 Causes of Moderate and Severe Anaemia in a High-HIV and TB-Prevalent Adult Population in the Eastern Cape Province, South Africa. **2023**, 20, 3584 ○
- 127 Seguimiento de los pacientes con cardiopatía isquémica en Atención Primaria durante la pandemia por COVID-19. ○
- 126 Emergency department direct discharge compared to short-stay unit admission for selected patients with acute heart failure: analysis of short-term outcomes. ○
- 125 Effects of different exercise modalities on inhibiting left ventricular pathological remodeling in patients with heart failure with reduced ejection fraction: A systematic review and network meta-analysis. **2023**, 319, 121511 ○
- 124 Molecular Mechanisms and Therapeutic Implications of Endothelial Dysfunction in Patients with Heart Failure. **2023**, 24, 4321 ○
- 123 Acute kidney injury patterns in acute heart failure: The prognostic value of worsening renal function and its timing. **2023**, ○
- 122 EDTA plasma in glass and polyethylene terephthalate tubes is suitable for measurement of B-type natriuretic peptide on the Mindray CL-6000i. 000456322311622 ○
- 121 The association between serum albumin and long length of stay of patients with acute heart failure: A retrospective study based on the MIMIC-IV database. **2023**, 18, e0282289 ○
- 120 Low Prognostic Nutritional Index Predicts Adverse Outcomes in Patients With Heart Failure: A Systematic Review and Meta-analysis. 000331972311596 ○
- 119 Diagnosing Lung Abnormalities Related to Heart Failure in Chest Radiogram, Lung Ultrasound and Thoracic Computed Tomography. **2023**, 91, 103-122 ○
- 118 Pulse amplitude ratio under noninvasive ventilation as a new method in the diagnosis of left heart failure in patients with acute exacerbation of chronic obstructive pulmonary disease. **2023**, 23, ○
- 117 Pulmonary Congestion on Lung Ultrasound Predicts Increased Risk of 30-Day Readmission in Heart Failure Patients. ○
- 116 Heart failure treatment in patients with and without obesity with an ejection fraction below 50%. ○
- 115 Bundle branch block in cardiac arrest survivors without ischemic heart disease. **2023**, 45, 101188 ○
- 114 Validity and reliability of SCREEN II (Seniors in the Community: Risk Evaluation for Eating and Nutrition) search on elder people in Turkish society. **2023**, ○
- 113 Heart Diseases in Geriatric Patients. **2023**, 109-135 ○
- 112 Association between Iron Deficiency and Survival in Older Patients with Cancer. **2023**, 15, 1533 ○

- 111 Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction. **2023**, 147, 1147-1161 1
- 110 Prognosis after discontinuing renin angiotensin aldosterone system inhibitor for heart failure with restored ejection fraction after acute myocardial infarction. **2023**, 13, 0
- 109 Efficacy of disease management program used among patients with chronic heart failure: protocol for a systematic review and network meta-analysis. **2023**, 12, 0
- 108 Naples Prognostic Score and Prediction of Left Ventricular Ejection Fraction in STEMI Patients. 000331972311619 0
- 107 Ivabradine monotherapy in pediatric patients with focal atrial tachycardia: a single-center study. 0
- 106 Not all Shock States Are Created Equal. **2023**, 41, 1-25 0
- 105 High-urgency-Kriterien für die Herzallokation nach den neuen Richtlinien der Bundesärztekammer zur Herz- und Herz-Lungen-Transplantation. 0
- 104 Geriatric Nutritional Risk Index at Hospital Admission or Discharge in Patients with Acute Decompensated Heart Failure. **2023**, 12, 1891 0
- 103 Sacubitril/valsartan as a component of therapy for chronic heart failure. **2023**, 20, 407-413 0
- 102 Implantable Cardioverter-Defibrillator for Primary Prevention in Asia. **2023**, 0
- 101 One-year mortality after hospitalization for acute heart failure: Predicting factors (PRECIC study subanalysis). **2023**, 0
- 100 In Vitro Investigation of the Effect of the Timing of Left Ventricular Assist Device Speed Modulation on Intraventricular Flow Patterns. Publish Ahead of Print, 0
- 99 Prevalence and Correlates of Elevated NT-proBNP in Pregnant Women in the General U.S. Population. **2023**, 2, 100265 0
- 98 Intensivtherapie im Rahmen der Transplantation solider Organe. **2023**, 1-40 0
- 97 Dyssynchrony and Response to Cardiac Resynchronization Therapy in Heart Failure Patients With Unfavorable Electrical Characteristics. **2023**, 0
- 96 Recent Advances in Cardiovascular Disease Biosensors and Monitoring Technologies. **2023**, 8, 956-973 0
- 95 Impact of pharmacist-led interventions on heart failure medication adherence: a prospective cohort study. 0
- 94 A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure. **2023**, 24, 0

- 93 microRNAs as Biomarkers of Endothelial Dysfunction and Therapeutic Target in the Pathogenesis of Atrial Fibrillation. **2023**, 24, 5307 ○
- 92 Infection as an under-recognized precipitant of acute heart failure: prognostic and therapeutic implications. ○
- 91 Cardio4Health study. A cardiac telerehabilitation pilot program aimed at patients after an ischemic event: evaluation of its feasibility, safety, and results in improving functional capacity, adherence to a healthy lifestyle, and quality of life. (Preprint). ○
- 90 The influence of comorbidities on the prognosis after an acute heart failure decompensation and differences according to ejection fraction: Results from the EAHFE and RICA registries. **2023**, 111, 97-104 ○
- 89 Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction. **2023**, 23, ○
- 88 Ultrasound-Driven Injectable and Fully Biodegradable Triboelectric Nanogenerators. 2201350 ○
- 87 Assessment of the Desire and Readiness of Taif Residents for Heart Donation After Death. **2023**, ○
- 86 From Bioimpedance to Volume Estimation: A Model for Edema Calculus in Human Legs. **2023**, 12, 1383 ○
- 85 Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study). Volume 16, 73-82 ○
- 84 Peripartum cardiomyopathy: risk factors and predictors of outcome. **2023**, 38, 223-232 ○
- 83 Relationship Between Medical Therapy, Long-Term Care Insurance, and Comorbidity in Elderly Patients With Heart Failure With Systolic Dysfunction. **2023**, ○
- 82 Life expectancy in patients with chronic heart failure, atrial fibrillation and implantable cardiac contractility modulation devices. **2023**, 18, 38 ○
- 81 WGCNA combined with machine learning algorithms for analyzing key genes and immune cell infiltration in heart failure due to ischemic cardiomyopathy. 10, ○
- 80 Comparison of Efficacy and Safety of Angiotensin Receptor-Nepriylsin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis. **2023**, ○
- 79 Assessing fluid volume and determining outcomes of acute heart failure using plasma human atrial natriuretic peptide. ○
- 78 Cardiac contractility modulation and subcutaneous defibrillator (S-ICD): First experience with simultaneous implantation. ○
- 77 Controlling nutritional status score predicts 2-year outcomes in elderly patients admitted for acute heart failure. ○
- 76 Digital Health Technologies for Post-Discharge Care after Heart Failure Hospitalisation to Relieve Symptoms and Improve Clinical Outcomes. **2023**, 12, 2373 ○

- 75 Leucine-Rich Alpha-2-Glycoprotein: A Novel Predictor of Diastolic Dysfunction. **2023**, 11, 944 ○
- 74 Viabilidade do Implante de Eletrodo Ventricular Esquerdo na Terapia de Ressincronizaçã Cardâca Guiada por Gated SPECT e Remodelamento Ventricular. **2023**, 120, ○
- 73 Lidocaine-induced central nervous system toxicity during implantable cardioverter defibrillator placement [A case report and literature review. **2023**, ○
- 72 Factors influencing self-care behaviour in patients with heart failure: Grit as a behavioural support factor. ○
- 71 Utilidad pronóstica de la presiã de pulso en pacientes con insuficiencia cardiaca con fracciã de eyecciã preservada: Registro RICA. **2023**, 223, 231-239 ○
- 70 Evaluation of large animal models for preclinical studies of heart failure with preserved ejection fraction using clinical score systems. 10, ○
- 69 Afterload reduction after non-invasive vagus nerve stimulation in acute heart failure. 17, ○
- 68 Digoxin and Standard-of-Care Therapy for Heart Failure Patients with COVID-19: Analysis of Data from the US Military Health System (MHS) Data Repository. ○
- 67 Pathophysiology, emerging techniques for the assessment and novel treatment of aortic stenosis. **2023**, 10, e002244 ○
- 66 Intrarenal Doppler ultrasonography in patients with HFrEF and acute decompensated heart failure undergoing recompensation. ○
- 65 Fetal NT-proBNP levels and their course in severe anemia during intrauterine treatment. ○
- 64 Arterial stiffness and its associations with left ventricular diastolic function according to heart failure types. **2023**, 29, ○
- 63 Primary careAdherenceToHeartFailure guidelinesIN Diagnosis,Evaluation andRoutine management (PATHFINDER): a randomised controlled trial protocol. **2023**, 13, e063656 ○
- 62 Clinical Usefulness of Right VentriclePulmonary Artery Coupling in Cardiovascular Disease. **2023**, 12, 2526 ○
- 61 The history and mystery of sacubitril/valsartan: From clinical trial to the real world. 10, ○
- 60 EFFECTIVENESS OF DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC HEART FAILURE. **2023**, ○
- 59 Medications to Avoid When Treating Heart Failure. **2023**, 285-306 ○
- 58 Acute Coronary Syndromes: Epidemiological, Clinical and Management Aspects in Thies (Senegal). **2023**, 13, 114-123 ○

- 57 Current and future trial design in refractory cardiogenic shock. ○
- 56 Pathophysiology of Heart Failure. **2023**, 3-11 ○
- 55 Heart Failure with Preserved Ejection Fraction. **2023**, 89-106 ○
- 54 Management of Heart Failure with Reduced Ejection Fraction Globally and in Lebanon: Where Do SGLT-2is Stand?. **2023**, 13, 138-169 ○
- 53 Low Occurrence of Infections and Death in a Real-World Cohort of Patients with Cardiac Implantable Electronic Devices. **2023**, 12, 2599 ○
- 52 Insuficiencia Cardíaca Aguda Asociada a Pancreatitis Aguda: Reporte de Caso. **2023**, 3, e161 ○
- 51 Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: the VICTORIA echocardiographic substudy. ○
- 50 Interchangeability in left ventricular ejection fraction measured by echocardiography and cardiovascular magnetic resonance: not a perfect match in the real world. **2023**, 101721 ○
- 49 Prevalence and Prognostic Implication of Atrial Fibrillation in Heart Failure Subtypes: Systematic Review and Meta-Analysis. **2023**, ○
- 48 Four-dimensional speckle tracking echocardiography and fragmented QRS in detection of early left ventricular systolic dysfunction in patients with subclinical hyperthyroidism. ○
- 47 Serum biomarkers and left ventricular mechanics in the diagnosis of diastolic dysfunction in patients with epicardial obesity. **2023**, 12, 6-15 ○
- 46 Prognostic implications of left ventricular systolic dysfunction in patients with spontaneous coronary artery dissection. ○
- 45 The impact of vascular access location on pulmonary arterial pressure in chronic kidney disease patients undergoing hemodialysis. ○
- 44 Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure. ○
- 43 Guidelines on the Use of Therapeutic Apheresis in Clinical Practice [Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. **2023**, 38, 77-278 ○
- 42 The Usefulness of Bioelectrical Impedance as a Marker of Fluid Status in Patients With Congestive Heart Failure: A Systematic Review and Meta-Analysis. **2023**, ○
- 41 Aspects of chronic heart failure in patients with type 2 diabetes mellitus after implantation of a permanent pacemaker, depending on body weight. **2020**, 89, 35-41 ○
- 40 Benefits of sacubitril/valsartan use in patients with chronic heart failure after cardiac valve surgery: a single-center retrospective study. **2023**, 18, ○

- 39 Combination of cardiac color Doppler ultrasound, serum MR-ProANP and NT-ProBNP forecasted hypertensive LVH and LFH. 1-15 ○
- 38 Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis. 53, ○
- 37 Effect of sacubitril/valsartan on heart rate variability parameters in patients with heart failure with reduced ejection fraction. **2023**, 18, 144-144 ○
- 36 Cardiac Resynchronization Therapy and Left Atrial Remodeling: A Novel Insight?. **2023**, 11, 1156 ○
- 35 Analysis of factors associated with 6MWD among older patients with chronic heart failure. **2023**, 51, 030006052311662 ○
- 34 Sodium-glucose cotransporter type 2 inhibitors in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. **2023**, 13, 198-205 ○
- 33 Soluble ST2 predicts continuous renal replacement therapy in patients receiving venoarterial extracorporeal membrane oxygenation. 026765912311694 ○
- 32 Heart Failure. **2023**, 169-189 ○
- 31 Multidisciplinary Approach to Treatment of Ischaemic Heart Disease: The Role of the Heart Team. **2023**, 335-344 ○
- 30 Association between Cardiovascular Response and Inflammatory Cytokines in Non-Small Cell Lung Cancer Patients. **2023**, 10, 173 ○
- 29 The role of the pregnancy heart team in clinical practice. 10, ○
- 28 Cost-effectiveness of an inpatient nurse practitioner in heart failure. ○
- 27 Hypertensive response to exercise, hypertension and heart failure with preserved ejection fraction (HFpEF) – continuum of disease?. ○
- 26 Management of Heart Failure in Patients With Diabetes Mellitus in the UAE: A Call to Action. **2023**, 28, 107424842311622 ○
- 25 Association between vasoactive/inotropic score, morbidity and mortality after heart transplantation. **2023**, 36, ○
- 24 Effect of Acetazolamide as Add-On Diuretic Therapy in Patients With Heart Failure: A Meta-Analysis. **2023**, ○
- 23 Emerging Modalities for Temporary Mechanical Circulatory Support in Cardiogenic Shock. Publish Ahead of Print, ○
- 22 Clinical Impact of ACE-I/ARB for Conservatively Treated Patients with Moderate to Severe Mitral Regurgitation: A Single Center Observational Study. **2023**, 10, 177 ○

- 21 Practical guidelines for exercise prescription in patients with chronic heart failure. ○
- 20 Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis. 5, ○
- 19 Cardiac Microvascular Endothelial Cells and Pressure Overload-Induced Cardiac Fibrosis. **2023**, 229-264 ○
- 18 A Systematic Approach for the Interpretation of Cardiopulmonary Exercise Testing in Children with Focus on Cardiovascular Diseases. **2023**, 10, 178 ○
- 17 Factors associated with lipid control in outpatients with heart failure. 10, ○
- 16 Non-alcoholic fatty liver disease is associated with a worse prognosis in patients with heart failure: A pool analysis. 14, ○
- 15 The Prognostic Value and Treatment Strategies of Nutritional Status in Heart Failure Patients. **2023**, 101742 ○
- 14 Pharmacotherapy of heart failure with reduced ejection fraction: heart failure basic therapy and an episode of decompensation. **2023**, 63, 66-76 ○
- 13 Depressive symptomatology and NT-proBNP and Health status in Heart Failure. ○
- 12 Profiles of cognitive impairment in chronic heart failure: A cluster analytic approach. 17, ○
- 11 Heart failure therapy: the fifth card. **2023**, 25, B140-B143 ○
- 10 Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction. **2023**, 12, 3028 ○
- 9 Long-term dietary n3 fatty acid prevents aging-related cardiac diastolic and vascular dysfunction. **2023**, 150, 107175 ○
- 8 Lung cancer surgery for patients with reduced left ventricular ejection fraction: clinical outcomes and long-term survival. **2023**, 63, ○
- 7 Druggable proteins influencing cardiac structure and function: Implications for heart failure therapies and cancer cardiotoxicity. **2023**, 9, ○
- 6 Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz (Update 2023). **2023**, 135, 201-206 ○
- 5 The impact of right ventricular hemodynamics on the performance of a left ventricular assist device in a numerical simulation model. **2023**, ○
- 4 Relationship between diffuse fibrosis assessed by CMR and depressed myocardial strain in different stages of heart failure. **2023**, 164, 110848 ○

- 3 An evidence map of systematic reviews on models of outpatient care for patients with chronic heart diseases. **2023**, 12, ○
- 2 Comparative analysis of level of evidence and class of recommendation for 50 clinical practice guidelines released by the European Society of Cardiology from 2011 to 2022. **2023**, ○
- 1 Comparison of linear and non-linear machine learning models for time-dependent readmission or mortality prediction among hospitalized heart failure patients. **2023**, 9, e16068 ○